



(12) **EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:  
**07.06.2006 Bulletin 2006/23**

(21) Application number: **04772194.9**

(22) Date of filing: **19.08.2004**

(51) Int Cl.:  
**C12N 15/09** <sup>(1990.01)</sup> **C07K 14/47** <sup>(1995.01)</sup>  
**C12N 5/08** <sup>(1990.01)</sup> **A61K 35/26** <sup>(1985.01)</sup>  
**A61P 35/00** <sup>(2000.01)</sup> **A61P 37/04** <sup>(2000.01)</sup>

(86) International application number:  
**PCT/JP2004/012238**

(87) International publication number:  
**WO 2005/019450 (03.03.2005 Gazette 2005/09)**

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IT LI LU MC NL PL PT RO SE SI SK TR**

(30) Priority: **22.08.2003 JP 2003298208**  
**05.01.2004 JP 2004000699**  
**09.04.2004 JP 2004115648**  
**29.07.2004 JP 2004222441**

(71) Applicant: **TAKARA BIO INC.**  
**Otsu-shi,**  
**Shiga 520-2193 (JP)**

(72) Inventors:  
• **IDENO, Mitsuko**  
**Kyoto-shi,**  
**Kyoto 616-8176 (JP)**  
• **MURAKI, Nobuko**  
**Koka-shi,**  
**Shiga 529-1851 (JP)**

- **OGAWA, Kinuko**  
**Otsu-shi,**  
**Shiga 520-2134 (JP)**
- **KISHIMOTO, Masayuki**  
**Otsu-shi,**  
**Shiga 520-2133 (JP)**
- **ENOKI, Tatsuji**  
**Kyotanabe-shi,**  
**Kyoto 610-0313 (JP)**
- **SAGAWA, Hiroaki**  
**Kusatsu-shi,**  
**Shiga 525-0025 (JP)**
- **KATO, Ikunoshin**  
**Koka-shi,**  
**Shiga 529-1851 (JP)**

(74) Representative: **Vossius & Partner**  
**Siebertstrasse 4**  
**81675 München (DE)**

(54) **PROCESS FOR PRODUCING CYTOTOXIC LYMPHOCYTES**

(57) The present invention provides a method for preparing a cytotoxic lymphocyte **characterized in that** the method comprises the step of carrying out at least one step selected from induction, maintenance and expansion of a cytotoxic lymphocyte using a medium containing

serum and plasma at a total concentration of 0% by volume or more and less than 5% by volume, in the presence of fibronectin, a fragment thereof or a mixture thereof.

**Description**TECHNICAL FIELD

5 **[0001]** The present invention relates to a method for preparing a cytotoxic lymphocyte, which is useful in the medical field.

BACKGROUND ART

10 **[0002]** A living body is protected from foreign substances mainly by an immune response, and an immune system has been established by various cells and the soluble factors produced thereby. Among them, leukocytes, especially lymphocytes, play a key role. The lymphocytes are classified in two major types, B lymphocyte (which may be hereinafter referred to as B cell) and T lymphocyte (which may be hereinafter referred to as T cell), both of which specifically recognize an antigen and act on the antigen to protect the living body.

15 **[0003]** T cell is subclassified to helper T cell having CD (Cluster of Differentiation)4 marker (hereinafter referred to as  $T_H$ ), mainly involved in assisting in antibody production and induction of various immune responses, and cytotoxic T cell having CD8 marker ( $T_C$ : cytotoxic T lymphocyte, also referred to as killer T cell, which may be hereinafter referred to as CTL), mainly exhibiting a cytotoxic activity. CTL, which plays the most important role in recognizing, destroying and eliminating tumor cell, virus-infected cell or the like, does not produce an antibody specifically reacting with an antigen  
20 like B cell, but directly recognizes and acts on antigens (antigenic peptide) from a target cell which is associated with major histocompatibility complex [MHC, which may be also referred to as human leukocyte antigen (HLA) in human] Class I molecules existing on the surface of the target cell membrane. At this time, T cell receptor (hereinafter referred to as TCR) existing on the surface of the CTL membrane specifically recognizes the above-mentioned antigenic peptides and MHC Class I molecules, and determines whether the antigenic peptide is autologous or nonautologous. Target cell  
25 which has been determined to be nonautologous is then specifically destroyed and eliminated by CTL.

**[0004]** Recent years, a therapy which would cause a heavy physical burden on a patient, such as pharmacotherapy and radiotherapy, has been reconsidered, and an interest has increased in an immunotherapy with a light physical burden on a patient. Especially, there has been remarked an effectiveness of adoptive immunotherapy in which CTL capable of specifically reacting with an antigen of interest is induced *ex vivo* from lymphocyte derived from a human  
30 having normal immune function, or the lymphocyte is expanded without induction, and then transferred to a patient. For instance, it has been suggested that in an animal model adoptive immunotherapy is an effective therapy for virus infection and tumor (for example, authored by Greenberg, P. D., published in 1992, *Advances in Immunology* and Reusser P. and three others, *Blood*, 1991, **78(5)**, 1373-1380). In this therapy, it is important to maintain or increase the cell number in a state in which the antigen-specific cytotoxic activity of the CTL is maintained or enhanced.

35 **[0005]** In the adoptive immunotherapy as described above, it is necessary to administer cytotoxic lymphocytes in the number of cells of a given amount or larger in order to obtain a therapeutic effect. In other words, it can be said that it is the greatest problem to obtain the above number of cells *ex vivo* in a short period of time.

**[0006]** In order to maintain and enhance an antigen-specific cytotoxic activity of CTL, there has been generally employed a method of repeating stimulation with an antigen of interest when a specific response to an antigen for CTL is  
40 induced. However, in this method, the number of CTL finally obtained may usually be decreased, so that a sufficient number of cells cannot be obtained.

**[0007]** As a method for preparing T cell which is effective for the treatment of a disease, there has been known, for instance, adoptive immunotherapy using a lymphokine-activated killer cell (LAK cell) (for example, Rosenberg S. A. et al., *N. Engl. J. Med.* 1987, **316(15)**, 889-897) and adoptive immunotherapy using a tumor-infiltrating lymphocyte (TIL) induced with interleukin-2 (IL-2) in a high concentration (for example, Rosenberg S. A. et al., *N. Engl. J. Med.*, 1988, **319(25)**, 1676-1680 and Ho M. and nine others, *Blood*, 1993, **81(8)**, 2093-2101).

**[0008]** Next, regarding the preparation of the antigen-specific CTL, there has been reported a method for isolating and expanding a CMV-specific CTL clone using autologous CMV infected fibroblast and IL-2 (for example, Riddell S. A. and four others, *J. Immunol.*, 1991, **146(8)**, 2795-2804) or using anti-CD3 monoclonal antibody (anti-CD3 mAb) and IL-2 (for example, Greenberg, P. D. and one other, *J. Immunol. Methods*, 1990, **128(2)**, 189-201).

**[0009]** Furthermore, WO 96/06929 discloses an REM method (rapid expansion method). This REM method is a method for expanding a primary T cell population containing antigen-specific CTL and  $T_H$  in a short period of time. In other words, this method is characterized in that a large amount of T cell can be provided by proliferating individual T cell clones, and that the number of antigen-specific CTL is increased using an anti-CD3 antibody, IL-2, and PBMC (peripheral blood mononuclear cell) made deficient in an ability for proliferation by irradiation, and Epstein-Barr virus (hereinafter simply  
55 referred to as EBV)-infected cells.

**[0010]** In addition, WO 97/32970 discloses a modified REM method, wherein the method is a method using as a feeder cell a nondividing mammal cell strain expressing a T-cell stimulating component which is distinguishable from PBMC to

reduce an amount of PBMC used.

**[0011]** The lymphokine-activated killer cell (LAK cell) is a functional cell population having a cytotoxic activity, which is obtained by adding IL-2 to peripheral blood (peripheral blood leukocyte), umbilical cord blood, tissue fluid or the like containing lymphocytes, and culturing the cells *in vitro* for several days. During the culture, proliferation of the LAK cell is further accelerated by adding an anti-CD3 antibody thereto and culturing the cell. The LAK cell thus obtained has a cytotoxic activity non-specifically to various cancer cells and other targets. The LAK cell is also used in the adoptive immunotherapy in the same manner as the above-mentioned CTL.

**[0012]** As described above, utilization of IL-2 is essential in the step of obtaining a cytotoxic lymphocyte, for instance, CTL, LAK cell, TIL or the like. The cell is further activated by binding of IL-2 to interleukin-2 receptor (IL-2R) on a cell surface. In addition, IL-2R has been known as an activation marker for a lymphocyte. From these viewpoints, it is important to improve IL-2R expression on the cell surface. In addition, in the induction of CTL, it is important to improve an efficiency for inducing a precursor cell of CTL subjected to stimulation by an antigen as CTL, i.e., to improve a proportion (ratio) of the CD8-positive cell in a group of cells after the induction.

**[0013]** Usually, serum or plasma is also added thereto in a ratio of 5% by volume to 20% by volume, when these lymphocytes are expanded *ex vivo*. This serum or plasma is a component required when a cell such as a lymphocyte is cultured *ex vivo*. However, risk of various virus infections and the like cannot be excluded, since serum or plasma is derived from blood of a nonautologous animal (human, bovid or the like). In addition, it is impossible to completely deny the presence of a virus or a pathogenic microorganism undetectable with current detection technique.

**[0014]** In this regard, in recent years, more and more serum or plasma derived from a patient (autologous serum or plasma) is used. However, it may lead to significant risk for the patient to take a large amount of blood from the patient for obtaining serum or plasma in an amount required for culture, since it causes a heavy physical burden on the patient. In order to avoid this risk, a small amount of serum or plasma is used to expand for obtaining lymphocytes required for treatment, which is to be consequently culture with low concentration of serum or plasma. Generally, growth of cells such as lymphocytes is unstable in the culture under low-serum or low-plasma conditions; thereby cells cannot be obtained in an amount required for the treatment. Furthermore, serum-free culture is strongly required for avoiding the physical burden and the risk of infection as mentioned above. However, most cells cannot grow under such culture conditions.

**[0015]** Therefore, a method for expanding a lymphocyte with low-serum or serum-free (low-plasma or plasma-free) is strongly required.

**[0016]** If a method for expanding a lymphocyte under serum-free (plasma-free) conditions is established, difference in serum or plasma among lots can be eliminated, and negative elements resulting from the serum or plasma from a patient (such as immunosuppressive components) can be excluded, whereby the advantage obtained by the establishment of such system is inestimable.

**[0017]** Fibronectin is a gigantic glycoprotein having a molecular weight of 250 thousands, which exists in an animal blood, on the surface of a cultured cell, or in an extracellular matrix of a tissue, and has been known to have various functions. A domain structure thereof is divided into seven portions (hereinafter refer to Figure 1), wherein three kinds of similar sequences are contained in an amino acid sequence thereof, repetitions of each of these sequences constituting the entire sequence. Three kinds of the similar sequences are referred to as type I, type II and type III. Among them, the type III is constituted by 71 to 96 amino acid residues, wherein a coincidence ratio of these amino acid residues is 17 to 40%. In fibronectin, there are fourteen type III sequences, among which the 8th, 9th or 10th sequence (each being hereinafter referred to as III-8, III-9 or III-10) is contained in a cell binding domain, and the 12th, 13th or 14th sequence (each being hereinafter referred to as III-12, III-13 or III-14) is contained in a heparin binding domain. In addition, a VLA (very late activation antigen)-5 binding region is contained in III-10, and its core sequence is RGDS. In addition, a region referred to as IIICS exists at a C-terminal side of the heparin binding domain. A region referred to as CS-1 consisting of 25 amino acids and having a binding activity to VLA-4 exists in IIICS (for example, authored by Deane F. Momer, published in 1988, *FIBRONECTIN*, ACADEMIC PRESS INC., P1-8, Kimizuka F. and eight others, *J. Biochem.*, 1991, **110(2)**, 284-291 and Hanenberg H. and five others, *Human Gene Therapy*, 1997, **8(18)**, 2193-2206).

#### DISCLOSURE OF INVENTION

**[0018]** An object of the present invention is to provide a method for preparing a cytotoxic lymphocyte having a cytotoxic activity at a high level, which is highly secure and suitably used in the medical field.

**[0019]** Summarizing the present invention, a first embodiment of the present invention relates to a method for preparing a cytotoxic lymphocyte characterized in that the method comprises a step of carrying out at least one step selected from induction, maintenance and expansion of a cytotoxic lymphocyte using a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 5% by volume of the medium, in the presence of fibronectin, a fragment thereof or a mixture thereof. The cytotoxic lymphocyte prepared in the first embodiment of the present invention is exemplified by a cytotoxic lymphocyte which highly expresses an interleukin-2 receptor as compared to a

cytotoxic lymphocyte prepared in the absence of fibronectin, a fragment thereof or a mixture thereof. In addition, the cytotoxic lymphocyte prepared in the first embodiment of the present invention is exemplified by a cytotoxic lymphocyte which contains CD8-positive cell in a higher ratio as compared to a cytotoxic lymphocyte prepared in the absence of fibronectin, a fragment thereof or a mixture thereof. Furthermore, the cytotoxic lymphocyte prepared in the first embodiment of the present invention is exemplified by a cytotoxic lymphocyte of which expansion fold is higher as compared to that of a cytotoxic lymphocyte prepared by the method for preparing a cytotoxic lymphocyte in the absence of fibronectin, a fragment thereof or a mixture thereof. Also, the cytotoxic lymphocyte prepared in the first embodiment of the present invention is exemplified by a cytotoxic lymphocyte which has a cytotoxic activity enhanced or highly maintained as compared to that of a cytotoxic lymphocyte prepared in the absence of fibronectin, a fragment thereof or a mixture thereof.

**[0020]** In the first embodiment of the present invention, use of fibronectin, a fragment thereof or a mixture thereof is exemplified by use wherein these are immobilized on a solid phase. Here, the solid phase is exemplified by a cell culture equipment or a cell culture carrier. The cell culture equipment is exemplified by a petri dish, a flask or a bag, and the cell culture carrier is exemplified by beads, a membrane or a slide glass.

**[0021]** In the first embodiment of the present invention, the cytotoxic lymphocyte is exemplified by a lymphokine-activated killer cell.

**[0022]** In the first embodiment of the present invention, the fibronectin fragment is exemplified by a polypeptide (m) comprising at least any one of the amino acid sequences shown in SEQ ID NOs: 1 to 8 of Sequence Listing, or a polypeptide (n) comprising at least one amino acid sequence having substitution, deletion, insertion or addition of one or the plural number of amino acids in any one of the above-mentioned amino acid sequences, wherein the polypeptide (n) has a function equivalent to that of the above-mentioned polypeptide (m). The fibronectin fragment is exemplified by those which have a cell adhesion activity and/or a heparin binding activity. The fibronectin fragment is also exemplified by at least one polypeptide selected from the group consisting of polypeptides having any one of the amino acid sequences shown in SEQ ID NOs: 9 to 20 and 25 of Sequence Listing.

**[0023]** In the first embodiment of the present invention, one embodiment of the preparation method which is carried out in a cell culture equipment is exemplified by a method which satisfies the conditions of:

(a) a ratio of the number of cells to a culture area in the cell culture equipment at initiation of culture being 1 cell/cm<sup>2</sup> to  $5 \times 10^5$  cells/cm<sup>2</sup>; and/or

(b) a concentration of cells in a medium at initiation of culture being 1 cell/mL to  $5 \times 10^5$  cells/mL.

**[0024]** In addition, such preparation method is exemplified by a method which does not require a step of diluting a cell culture solution.

**[0025]** In the first embodiment of the present invention, when at least any one of induction, maintenance and expansion of a cytotoxic lymphocyte is carried out in the presence of fibronectin, a fragment thereof or a mixture thereof in a cell culture equipment containing a medium, the method is exemplified by, for example, a method which comprises at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment, wherein the culture conditions immediately after at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment satisfy the conditions of:

(c) a concentration of cells in the cell culture solution being  $2 \times 10^5$  cells/mL to  $1 \times 10^8$  cells/mL; or

(d) a ratio of the number of cells in the cell culture solution to a culture area in the cell culture equipment being  $1 \times 10^5$  cells/cm<sup>2</sup> to  $1 \times 10^8$  cells/cm<sup>2</sup>.

**[0026]** In the preparation method of the first embodiment of the present invention, when at least any one of induction, maintenance and expansion of a cytotoxic lymphocyte is carried out in the presence of fibronectin, a fragment thereof or a mixture thereof in a cell culture equipment containing a medium, the method is exemplified by, but not limited to, a method comprising at least one step of diluting the cell culture solution, step of exchanging the medium or step of exchanging the cell culture equipment, wherein a total concentration of serum and plasma in the medium immediately after at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment is same as that at initiation of culture or lowered as compared to that at initiation of culture.

**[0027]** In the first embodiment of the present invention, a method further comprising a step of transducing a foreign gene into a cytotoxic lymphocyte is used as an example. Here, the transduction of the foreign gene is exemplified by a step comprising use of retrovirus, adenovirus, adeno-associated virus or simian virus.

**[0028]** A second embodiment of the present invention relates to a cytotoxic lymphocyte obtained by the method of the first embodiment of the present invention.

**[0029]** A third embodiment of the present invention relates to a medicament comprising as an effective ingredient the cytotoxic lymphocyte obtained by the method of the first embodiment of the present invention.

**[0030]** A fourth embodiment of the present invention relates to a medium for culturing a cytotoxic lymphocyte, char-

acterized in that the medium comprises as an effective ingredient fibronectin, a fragment thereof or a mixture thereof, and that a total concentration of serum and plasma in the medium is 0% by volume or more and less than 5% by volume.  
**[0031]** The present invention provides a method for preparing a cytotoxic lymphocyte, which is highly secure and of which burden on a patient is reduced.

## BRIEF DESCRIPTION OF THE DRAWINGS

### **[0032]**

Figure 1 is a schematic view showing a domain structure of fibronectin.

## BEST MODE FOR CARRYING OUT THE INVENTION

**[0033]** The present invention has been completed by the findings that, by preparing a cytotoxic lymphocyte in the presence of fibronectin and/or a fibronectin fragment in the method for induction, maintenance or expansion of a cytotoxic lymphocyte, a cytotoxic lymphocyte has a sufficient cytotoxic activity even at a high expansion fold, a high expression level of IL-2R, and a high ratio of the CD8-positive cell, even if the content of the serum or plasma in the medium is lowered or eliminated.

**[0034]** Incidentally, the preparation of a cytotoxic lymphocyte as used herein refers to a step encompassing each of the steps of induction (activation), maintenance and expansion of the cell, or the combined steps thereof. The preparation of a cytotoxic lymphocyte of the present invention is also referred to culture of a cytotoxic lymphocyte.

**[0035]** The present invention will be explained concretely hereinbelow.

### (1) Fibronectin and Fragment Thereof Used in the Present Invention

**[0036]** The fibronectin and a fragment thereof as mentioned herein may be those obtained from nature, or those which are artificially synthesized. The fibronectin and a fragment thereof can be prepared in a substantially pure form from a substance of natural origin, on the basis of the disclosure, for instance, of Ruoslahti E., et al. [*J. Biol. Chem.*, **256**(14), 7277-7281 (1981)]. The term "substantially pure fibronectin or fibronectin fragment" as referred to herein means that these fibronectin and fibronectin fragment do not substantially contain other proteins and the like existing together with fibronectin in nature. Each of the above-mentioned fibronectin and a fragment thereof can be used in the present invention alone or in admixture of plural kinds.

**[0037]** Here, it is known that there are a large number of splicing variants of fibronectin. As the fibronectin used in the present invention, any variant can be used so long as the desired effects of the present invention are exhibited. For example, in the case of fibronectin derived from plasma, it is known that a region referred to as ED-B present in upstream of a cell binding domain and a region referred to as ED-A present between the cell binding domain and the heparin binding domain are deleted. Such fibronectin derived from plasma can also be used in the present invention.

**[0038]** The useful information relating to the fibronectin fragments which can be used in the present invention and the preparation of the fragments can be obtained from Kimiduka F., et al. [*J. Biochem.*, **110**, 284-291 (1991)], Kornbriht A. R., et al. [*EMBO J.*, **4**(7), 1755-1759 (1985)], Sekiguchi K., et al. [*Biochemistry*, **25**(17), 4936-4941 (1986)], and the like. In addition, the amino acid sequence of fibronectin is disclosed in Genbank Accession No. NM\_002026 (NP\_002017).

**[0039]** In the present invention, the fibronectin fragment is exemplified by, for instance, a polypeptide (m) comprising at least one amino acid sequence comprising any of the regions of III-8 (amino acid sequence shown in

SEQ ID NO: 1 of Sequence Listing), III-9 (amino acid sequence shown in SEQ ID NO: 2 of Sequence Listing), III-10 (amino acid sequence shown in SEQ ID NO: 3 of Sequence Listing), III-11 (amino acid sequence shown in SEQ ID NO: 4 of Sequence Listing), III-12 (amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing), III-13 (amino acid sequence shown in SEQ ID NO: 6 of Sequence Listing), III-14 (amino acid sequence shown in SEQ ID NO: 7 of Sequence Listing), and CS-1 (amino acid sequence shown in SEQ ID NO: 8 of Sequence Listing) (see Figure 1), or a polypeptide (n) comprising at least one amino acid sequence having substitution, deletion, insertion or addition of one or the plural number of amino acids in any of the amino acid sequences described above, wherein the polypeptide (n) has a function equivalent to that of the above-mentioned polypeptide (m).

**[0040]** In addition, as the fragment, a fragment having a cell adhesion activity and/or a heparin binding activity can be preferably used. The cell adhesion activity can be evaluated by assaying binding of the fragment (its cell binding domain)

used in the present invention to a cell using a known method. For instance, the method as mentioned above includes a method of Williams D. A., et al. [*Nature*, **352**, 438-441 (1991)]. The method is a method of determining the binding of a cell to a fragment immobilized on a culture plate. In addition, the heparin binding activity can be evaluated by assaying binding of the fragment (its heparin binding domain) used in the present invention to heparin using a known method.

For instance, the binding of the fragment to heparin can be evaluated in the same manner by using heparin, for instance, a labeled heparin in place of the cell in the above-mentioned method of Williams D. A., et al.

**[0041]** Further, the fibronectin fragment is exemplified by a polypeptide selected from C-274 (amino acid sequence shown in SEQ ID NO: 9 of Sequence Listing), H-271 (amino acid sequence shown in SEQ ID NO: 10 of Sequence Listing), H-296 (amino acid sequence shown in SEQ ID NO: 11 of Sequence Listing), CH-271 (amino acid sequence shown in SEQ ID NO: 12 of Sequence Listing), CH-296 (amino acid sequence shown in SEQ ID NO: 13 of Sequence Listing), C-CS1 (amino acid sequence shown in SEQ ID NO: 14 of Sequence Listing), or CH-296Na (amino acid sequence shown in SEQ ID NO: 25 of Sequence Listing). Here, CH-296Na is a polypeptide prepared for the first time in the present application.

**[0042]** Each of the above-mentioned fragments CH-271, CH-296, CH-296Na, C-274 and C-CS1 is a polypeptide having a cell binding domain with a binding activity to VLA-5. Also, C-CS1, H-296, CH-296 and CH-296Na are polypeptides having CS-1 with a binding activity to VLA-4. Further, H-271, H-296, CH-271, CH-296 and CH-296Na are polypeptides having a heparin binding domain. Here, CH-296Na is a polypeptide comprising a region from the cell binding domain to CS-1 of fibronectin derived from plasma. Specifically, CH-296Na is a polypeptide wherein the region (ED-A) ranging from Asn at position 1631 to Thr at position 1720 is deleted from the polypeptide comprising the region from Pro at position 1270 to Thr at position 2016 of the amino acid sequence of the fibronectin disclosed in Genbank Accession No. NM\_002026 (NP\_002017).

**[0043]** In the present invention, a fragment in which each of the above domains is modified can also be used. The heparin binding domain of the fibronectin is constituted by three type III sequences (III-12, III-13 and III-14). A fragment containing a heparin binding domain having deletion of one or two of the above type III sequences can also be used in the present invention. For instance, the fragments may be exemplified by CHV-89 (amino acid sequence shown in SEQ ID NO: 15 of Sequence Listing), CHV-90 (amino acid sequence shown in SEQ ID NO: 16 of Sequence Listing) or CHV-92 (amino acid sequence shown in SEQ ID NO: 17 of Sequence Listing), which is a fragment in which a cell binding site of the fibronectin (VLA-5 binding domain: Pro1239 to Ser1515) and one of the III type sequences are bound, or CHV-179 (amino acid sequence shown in SEQ ID NO: 18 of Sequence Listing) or CHV-181 (amino acid sequence shown in SEQ ID NO: 19 of Sequence Listing), which is a fragment in which the cell binding site of the fibronectin and two of the type III sequences are bound. CHV-89, CHV-90 and CHV-92 contain III-13, III-14 and III-12, respectively, and CHV-179 contains III-13 and III-14, and CHV-181 contains III-12 and III-13, respectively.

**[0044]** In addition, a fragment having addition of an additional amino acid to each of the above-mentioned fragments can be used in the present invention. For instance, the fragment can be prepared by adding a desired amino acid to each of the above-mentioned fragment in accordance with the method for preparing H-275-Cys described in Preparation Examples set forth below. For instance, H-275-Cys (amino acid sequence shown in SEQ ID NO: 20 of Sequence Listing) is a fragment having a heparin binding domain of the fibronectin, and cysteine residue at a C-terminal.

**[0045]** The fragment used in the present invention may be those comprising a polypeptide comprising an amino acid sequence having substitution, deletion, insertion or addition of one or the plural number of amino acids in an amino acid sequence of a polypeptide constituting a fragment at least partially containing an amino acid sequence of naturally occurring fibronectin exemplified above, wherein the polypeptide has a function equivalent to that of the fragment, so long as the desired effects of the present invention are obtained.

**[0046]** It is preferable that the substitution or the like of the amino acids is carried out to an extent that it can change physicochemical characteristics and the like of an inherent polypeptide within the range that the function of the polypeptide can be maintained. For instance, it is preferable that the substitution or the like of amino acids is conservative, within the range that the characteristics inherently owned by the polypeptide (for instance, hydrophobicity, hydrophilicity, electric charge, pK and the like) are not substantially changed. For instance, it is preferable that the substitution of the amino acids is substitutions within each of the groups of: 1. glycine, alanine; 2. valine, isoleucine, leucine; 3. aspartic acid, glutamic acid, asparagine, glutamine; 4. serine, threonine; 5. lysine, arginine; 6. phenylalanine, tyrosine, and that deletion, addition or insertion of amino acids is deletion, addition or insertion in the amino acids having characteristics similar to the characteristics of the surroundings of the subject site in the polypeptide within the range that the characteristics of the surroundings of the subject site are not substantially changed.

**[0047]** The substitution or the like of the amino acids may be those naturally occurring being caused by difference between species or individuals, or may be artificially induced. Artificial induction may be carried out by a known method. The induction may be carried out by, for example, but not limited specifically to, preparing a given nucleic acid having substitution, deletion, addition or insertion of one or the plural number of nucleotides in the nucleic acid encoding the above-mentioned region or the given fragment derived from naturally occurring fibronectin, and using the nucleic acid to prepare a polypeptide comprising an amino acid sequence having substitution or the like in the amino acid sequence

of the polypeptide constituting the above-mentioned region or given fragment derived from naturally occurring fibronectin, having a function equivalent to that of the fragment or the like, using a known method.

**[0048]** In addition, the phrase "having a function equivalent" herein refers to that the polypeptide, which is a comparative control, has at least any of the functions of (i) a function of enhancing or maintaining a cytotoxic activity of a cytotoxic lymphocyte, (ii) a function of enhancing an expression level of IL-2R, (iii) a function of improving a ratio of CD8-positive cell, or (iv) a function of improving expansion fold of a cytotoxic lymphocyte, each of which is possessed by the naturally occurring fibronectin fragment. The above-mentioned functions can be appropriately confirmed in accordance with the method described in Examples set forth below. In addition, as the fragment comprising a polypeptide having substitution or the like of amino acids, the fragment having a cell adhesion activity and/or a heparin binding activity is preferred. The cell adhesion activity and the heparin binding activity can be evaluated in accordance with the above-mentioned methods for determining those activities.

**[0049]** As the fragment comprising a polypeptide having substitution or the like of amino acids, for instance, a fragment having one or more amino acids inserted as a linker between two different domains can also be used in the present invention.

**[0050]** Incidentally, as the fibronectin, similarly to the above-mentioned fragment, there can be used in the present invention a polypeptide having an amino acid sequence having substitution, deletion, insertion or addition of one or the plural number of amino acids in an amino acid sequence constituting the polypeptide of the fibronectin, wherein the polypeptide has at least any of the functions of the above-mentioned (i) to (iv).

**[0051]** The fibronectin fragment as referred to herein can also be prepared from a genetic recombinant on the basis of the description of, for instance, U.S. Patent No. 5,198,423. For instance, each of the fragments of H-271 (SEQ ID NO: 10), H-296 (SEQ ID NO: 11), CH-271 (SEQ ID NO: 12) and CH-296 (SEQ ID NO: 13) and a method of preparing these fragments are described in detail in the specification of this patent. In addition, CH-296Na (SEQ ID NO: 25) and the preparation method thereof are described in the section of (3) CH-296Na and Examples set forth below. In addition, the above-mentioned C-274 (SEQ ID NO: 9) fragment can be obtained in accordance with the method described in U.S. Patent No. 5,102,988. Further, a C-CS1 (SEQ ID NO: 14) fragment can be obtained in accordance with the method described in Japanese Patent Gazette No. 3104178. Each of the fragment of CHV-89 (SEQ ID NO: 15), CHV-90 (SEQ ID NO: 16) or CHV-179 (SEQ ID NO: 18) can be obtained in accordance with the method described in Japanese Patent Gazette No. 2729712. In addition, the CHV-181 (SEQ ID NO: 19) fragment can be obtained in accordance with the method described in WO 97/18318. The CHV-92 (SEQ ID NO: 17) fragment can be obtained by genetic engineering technique using a plasmid constructed in a usual manner on the basis of the plasmid described in the literatures by referring to Japanese Patent Gazette No. 2729712 and WO 97/18318.

**[0052]** These fragments or fragments which can be derived from these fragments in a usual manner can be prepared by using microorganisms deposited to the International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, Tsukuba Central 6,1-1, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan (Zip code 305-8566) under the following accession numbers, or by modifying a plasmid carried in each microorganism in accordance with a known method.

FERM BP-2264 (*Escherichia coli* carrying a plasmid encoding H-271, Date of Deposit: January 30, 1989);

FERM BP-2800 (*Escherichia coli* carrying a plasmid encoding CH-296, Date of Deposit: May 12, 1989);

FERM BP-2799 (*Escherichia coli* carrying a plasmid encoding CH-271, Date of Deposit: May 12, 1989);

FERM BP-7420 (*Escherichia coli* carrying a plasmid encoding H-296, Date of Deposit: May 12, 1989);

FERM BP-1915 (*Escherichia coli* carrying a plasmid encoding C-274, Date of Deposit: June 17, 1988);

FERM BP-5723 (*Escherichia coli* carrying a plasmid encoding C-CS1, Date of Deposit: March 5, 1990);

FERM BP-10073 (*Escherichia coli* carrying a plasmid encoding CH-296Na, Date of Deposit: July 23, 2004);

FERM P-12182 (*Escherichia coli* carrying a plasmid encoding CHV-89, Date of Deposit: April 8, 1991); and

FERM P-12183 (*Escherichia coli* carrying a plasmid encoding CHV-179, Date of Deposit: April 8, 1991).

**[0053]** Since the fibronectin is a gigantic glycoprotein, it is not necessarily easy to prepare and use a naturally occurring protein for the industrial purpose and for the purpose of the preparation of the medicament. In addition, since the fibronectin is a multifunctional protein, there may be considered some disadvantages caused by a region different from the region exhibiting the effect by the method of the present invention depending on the circumstances of its use. For these reasons, a fibronectin fragment can be preferably used in the present invention, more preferably a recombinant fibronectin fragment obtained as described above can be used from the viewpoints of availability, easy handling and safety. Further, there can be especially preferably used a fibronectin fragment which can exhibit an effect such as improvement in an expansion fold of a lymphocyte, increase in an expression level of IL-2R in an expanded lymphocyte, improvement in a ratio of CD8-positive cell in an expanded lymphocyte population, or increase in a cytotoxic activity as described below. In addition, the molecular weight of the fibronectin fragment used in the present invention is, but not particularly limited to, preferably from 1 to 200 kD, more preferably from 5 to 190 kD, even more preferably from 10 to 180 kD. The molecular weight can be determined, for example, by SDS-polyacrylamide gel electrophoresis.

**[0054]** Here, in the amino acid sequence of the polypeptide constituting the fibronectin fragment of the present invention,

the partial amino acid sequence other than the amino acid sequence of the polypeptide constituting a naturally occurring fibronectin fragment is arbitrary and not limited specifically, so long as the exhibition of the desired effects of the present invention is not inhibited.

## (2) Method for Preparing Cytotoxic Lymphocyte of the Present Invention

**[0055]** The method for preparing the cytotoxic lymphocyte of the present invention will be concretely explained below. The method of the present invention is a method for preparing a cytotoxic lymphocyte comprising the step of carrying out at least any one of induction, maintenance and expansion of a cytotoxic lymphocyte using a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 5%, in the presence of the above-mentioned fibronectin, a fragment thereof or a mixture thereof.

**[0056]** The "cytotoxic lymphocyte" as used herein means a group of cells containing a cytotoxic lymphocyte. In a narrow sense, the cytotoxic lymphocyte may refer only to a cytotoxic lymphocyte contained in the above-mentioned group of cells in some cases. In addition, the preparation of the cytotoxic lymphocyte in the present invention encompasses any of induction from a precursor cell which can be formed into the cytotoxic lymphocyte of the present invention to a lymphocyte having a cytotoxic activity, maintenance of the cytotoxic lymphocyte, and expansion of the cytotoxic lymphocyte using the cytotoxic lymphocyte and/or the precursor cell. In the method for preparing a cytotoxic lymphocyte of the present invention, the kind of a cell subjected to the method, conditions for culture and the like are appropriately adjusted, to carry out induction, maintenance or expansion of the cytotoxic lymphocyte.

**[0057]** The cytotoxic lymphocyte of the present invention includes, but not particularly limited to, for instance, lymphokine-activated killer cell (LAK cell), cytotoxic T cell (CTL), tumor-infiltrating lymphocyte (TIL), NK cell and the like, each having a cytotoxic activity.

**[0058]** In the present invention, the precursor cell which can be formed into a cytotoxic lymphocyte, i.e., the precursor cell which has an ability of differentiating into the lymphocyte, is exemplified by peripheral blood mononuclear cell (PBMC), NK cell, naive cell, memory cell, hemopoietic stem cell, umbilical cord blood mononuclear cell and the like. In addition, so long as a cell is a hemocyte, the cell can be used as a precursor cell in the present invention. Any of these cells which are collected from a living body can be used directly or those which are subjected to frozen storage can be used. Incidentally, in the method for preparing a cytotoxic lymphocyte of the present invention, a material containing the above-mentioned cells, for instance, a blood such as peripheral blood or umbilical cord blood; one obtained by removing components such as erythrocyte and plasma from the blood; a marrow fluid and the like can be used.

**[0059]** One of the major characteristics of the method for preparing a cytotoxic lymphocyte of the present invention resides in that the cytotoxic lymphocyte is prepared in the presence of an effective ingredient selected from fibronectin, a fragment thereof or a mixture thereof. Here, the method for preparing a cytotoxic lymphocyte of the present invention is carried out during the entire period of culture of the cytotoxic lymphocyte, or during any part of the period. In other words, the present invention encompasses those embodiments which comprise the above-mentioned step in a part of the steps of preparing a cytotoxic lymphocyte.

**[0060]** Furthermore, while a conventional method for expanding a cytotoxic lymphocyte required addition of serum and plasma at 5 to 20% by volume in a medium, the method for preparing a cytotoxic lymphocyte of the present invention is characterized in that the total concentration of serum and plasma in a medium is 0% by volume or more and less than 5% by volume. The total concentration of serum and plasma in a medium can be set to be preferably 0% by volume or more and 4% by volume or less, and especially preferably 0% by volume or more and 3% by volume or less. In an especially preferred embodiment of the present invention, preparation of sufficient amount of cytotoxic lymphocyte can be carried out without adding serum or plasma to a medium at all, and is a very useful method from the viewpoint of security or amelioration of burden on a patient. In addition, in the present invention, when the amount of serum and plasma used is desired to be further reduced, the amount of serum and plasma used can be gradually reduced in the middle of culture. In other words, the amount of serum and plasma used can be reduced more than usual by reducing the concentration of serum and plasma in a fresh medium used upon dilution of a cell culture solution, exchange of a medium or exchange of a cell culture equipment described below, for the concentration of serum and plasma at initiation of the culture, or by not adding serum or plasma in the fresh medium. Therefore, the present invention provides a method for preparing a cytotoxic lymphocyte, comprising at least one step of diluting the cell culture solution, step of exchanging the medium or step of exchanging the cell culture equipment, wherein the total concentration of serum and plasma in the medium immediately after at least one step of diluting the cell culture solution, step of exchanging the medium or step of exchanging the cell culture equipment is same as that at initiation of culture or lowered as compared to that at initiation of culture.

**[0061]** Here, origin of the serum or plasma may be any of autologous (meaning that the origin of the cytotoxic lymphocyte used is same as that of the precursor cell) serum or plasma or nonautologous (meaning that the origin of the cytotoxic lymphocyte used is different from that of the precursor cell) serum or plasma. Preferably, autologous serum or plasma can be used, from the viewpoint of security.



**[0062]** In the method of the present invention, the preparation of a cytotoxic lymphocyte, i.e., the induction, maintenance and/or expansion of the cytotoxic lymphocyte is usually performed in a medium containing given components in the presence of the above-mentioned effective ingredient of the present invention.

**[0063]** For instance, in the method of the present invention, when the induction or expansion of the cytotoxic lymphocyte is intended, the number of cells (cytotoxic lymphocytes and/or precursor cells) at the initiation of culture used in the present invention is not particularly limited. For instance, the number of cells is exemplified by from 1 cell/mL to  $1 \times 10^8$  cells/mL, preferably from 1 cell/mL to  $5 \times 10^7$  cells/mL, and more preferably from 1 cell/mL to  $2 \times 10^7$  cells/mL. In addition, the culture conditions are not particularly limited, and usual conditions for cell culture can be employed. For instance, cells can be cultured under the conditions of 37°C in the presence of 5% CO<sub>2</sub> and the like. In addition, the medium can be diluted by adding a fresh medium, the medium can be exchanged, or the cell culture equipment can be exchanged at appropriate intervals.

**[0064]** The medium used in the method for preparing a cytotoxic lymphocyte of the present invention is not particularly limited except for the total concentration of serum and plasma, and a known medium prepared by mixing components necessary for maintaining and growing a cytotoxic lymphocyte or its precursor cell can be used. For instance, a commercially available medium can be appropriately selected to be used. These media may contain appropriate proteins, cytokines and other components in addition to the inherent constituents. Preferably, a medium containing IL-2 is used in the present invention. The concentration of IL-2 in the medium is, but not particularly limited to, for instance, preferably from 0.01 to  $1 \times 10^5$  U/mL, more preferably from 0.1 to  $1 \times 10^4$  U/mL.

**[0065]** As the cell culture equipment used in the method for preparing a cytotoxic lymphocyte of the present invention, for example, without particular limitation, a petri dish, a flask, a bag, a large culture bath, a bioreactor and the like can be used. Here, as a bag, a CO<sub>2</sub> gas-permeable bag for cell culture can be used as described in Examples 34 to 38 and 45 to 52 described below. In addition, upon industrial preparation of a large amount of cytotoxic lymphocytes, a large culture bath can be used. Furthermore, any of those of open system and closed system can be used for the culture. Preferably, the culture is carried out in those of closed system, from the viewpoint of security of the resulting lymphocyte.

**[0066]** In addition, a precursor cell which can be formed into a cytotoxic lymphocyte can be co-cultured in a medium further containing an anti-CD3 antibody. The concentration of the anti-CD3 antibody in a medium is, but not particularly limited to, for instance, preferably from 0.001 to 100 µg/mL, especially preferably from 0.01 to 100 µg/mL. The anti-CD3 antibody can be added for the purpose of activating a receptor on a lymphocyte. Also, besides the above, a lymphocyte-stimulating factor such as lectin can be added. The concentration of the component in a medium is not particularly limited, so long as the desired effects can be obtained.

**[0067]** Besides the coexistence of these components including an effective ingredient of the present invention, by dissolving the components in a medium, there may be used by immobilization on an appropriate solid phase, for instance, a cell culture equipment (including any of those of open system and closed system), such as a petri dish, a flask or a bag, or to a cell culture carrier such as beads, a membrane or a slide glass. Here, immobilization on beads can be carried out in accordance with the description of Examples 61 and 62 described below, and the prepared beads can be used in accordance with the description of Examples 63 and 64 described below. The materials for those solid phases are not particularly limited so long as the materials can be used for cell culture. When the components are immobilized on, for instance, the above-mentioned equipment, it is preferable to immobilize a given amount of each component on the amount of the medium to be placed in the equipment so that the medium has a similar proportion to a desired concentration of the case where the components are used by dissolving the components in a medium upon placing the medium in the equipment. The amount of the components immobilized is not particularly limited, so long as the desired effects can be obtained. The above-mentioned carrier is used by immersing the carrier in a culture medium in the cell culture equipment during the cell culture. When the above-mentioned components are immobilized on the above-mentioned carrier, it is preferable to immobilize a given amount of each component on the amount of the medium to be placed in the equipment so that the medium has a similar proportion to a desired concentration of the case where the components are used by dissolving the components in a medium upon placing the carrier in the medium. The amount of the components immobilized is not particularly limited, so long as the desired effects can be obtained.

**[0068]** For instance, the immobilization of the fibronectin fragment can be carried out in accordance with the methods described in WO 97/18318 and WO 00/09168.

**[0069]** Once various components mentioned above or the effective ingredient of the present invention is immobilized on the solid phase, the cytotoxic lymphocyte can be easily separated from the effective ingredient or the like after the lymphocyte is obtained by the method of the present invention only by separating the lymphocyte from the solid phase, so that the contamination of the effective ingredient into the lymphocyte can be prevented.

**[0070]** Furthermore, there may be used together with the above-mentioned components a compound selected from the group consisting of acidic polysaccharides, acidic oligosaccharides, acidic monosaccharides and salts thereof which are effective for induction of a cytotoxic T cell having an antigen-specific cytotoxic activity, described in WO 02/14481, or a substance selected from the following (A) to (D):

- (A) a substance having a binding activity to CD44;
- (B) a substance capable of regulating a signal emitted by binding of a CD44 ligand to CD44;
- (C) a substance capable of inhibiting binding of a growth factor to a growth factor receptor; and
- (D) a substance capable of regulating a signal emitted by binding of a growth factor to a growth factor receptor.

**[0071]** The above-mentioned substance having a binding activity to CD44 is exemplified by, for instance, a CD44 ligand and/or an anti-CD44 antibody. The substance capable of regulating a signal emitted by binding of a CD44 ligand to CD44 includes, for instance, various inhibitors or activators for phosphoenzymes and dephosphorylases. The substance capable of inhibiting binding of a growth factor to a growth factor receptor includes, for instance, a substance having a binding activity to a growth factor and forming a complex with the growth factor, thereby inhibiting the binding of the growth factor to a growth factor receptor, or a substance having a binding activity to a growth factor receptor, thereby inhibiting the binding of the growth factor to a growth factor receptor. Furthermore, the substance capable of regulating a signal emitted by binding of a growth factor to a growth factor receptor includes, for instance, various inhibitors or activators for phosphoenzymes and dephosphorylases. The concentration of these components in the medium is not particularly limited, so long as the desired effects can be obtained. Also, these components may be used by immobilization on the appropriate solid phase as mentioned above in addition to the coexistence of these components in the medium by dissolving the components in the medium.

**[0072]** Here, each of various substances mentioned above can be used alone or in admixture of two or more kinds.

**[0073]** In the present invention, the phrase "in the presence of the above-mentioned effective ingredient" refers to the fact that the above-mentioned effective ingredient is present in a state that the effective ingredient can exhibit its function when the induction, maintenance or expansion of the cytotoxic lymphocyte is carried out, and the existing manner is not particularly limited. For instance, when the effective ingredient is dissolved in the medium to be used, the content of the effective ingredient of the present invention in the medium in which culture is carried out is not particularly limited, so long as the desired effects are obtained. The content of the effective ingredient is, for instance, preferably from 0.0001 to 10000  $\mu\text{g/mL}$ , more preferably from 0.001 to 10000  $\mu\text{g/mL}$ , even more preferably 0.005 to 5000  $\mu\text{g/mL}$ , especially preferably from 0.01 to 1000  $\mu\text{g/mL}$ .

**[0074]** When the expression level of IL-2R is determined for the cytotoxic lymphocyte obtained by the method of the present invention, a significant increase in expression level of IL-2R is recognized as compared to a cytotoxic lymphocyte obtained by carrying out at least any one of induction, maintenance and expansion in the absence of fibronectin, a fragment thereof or a mixture thereof. Here, the expression level of IL-2R can be determined by a known method, for instance, using an anti-IL-2R antibody.

**[0075]** As described above, the cytotoxic lymphocyte obtained by the method of the present invention has an increased expression level of IL-2R. IL-2R is an activation marker which is expressed on a surface of an activated T cell, and with the expression of this molecule, cytokine production, cytotoxic activity, proliferation activation or the like is activated. Therefore, the cytotoxic lymphocyte obtained by the method of the present invention is a group of cells having a high function.

**[0076]** In addition, since the cytotoxic lymphocyte obtained by the method of the present invention has an increased expression level of IL-2R, the cytotoxic lymphocyte has an increased sensitivity to a stimulation by IL-2 added to a medium, or IL-2 produced by a precursor cell of a cytotoxic lymphocyte, a lymphocyte itself or other coexisting cell. For this reason, the cytotoxic lymphocyte can be activated by itself even under the environment of a smaller amount of IL-2 (for instance, in a living body or the like).

**[0077]** Further, in the cytotoxic lymphocyte obtained by the method of the present invention, the existence ratio of (CD8-positive) cell having a CD8 marker is high as compared to that of the cytotoxic lymphocyte obtained by carrying out at least any one of induction, maintenance and expansion in the absence of fibronectin, a fragment thereof or a mixture thereof. This fact has some advantages, for instance, 1. that the CD8-positive cell produces a cytokine such as interferon- $\gamma$ , thereby causing immunological activation to change a helper T cell balance into the Th1 dominant system, 2. that the CD8-positive cell is a cellular immunocyte that can efficiently exclude a foreign substance such as a virus or a tumor cell, 3. that when the CD8-positive cell is obtained, the CD8-positive cell can be enriched with culturing the cell in accordance with the method of the present invention, while the CD8-positive cell has been conventionally purified with magnet beads or a flow cytometer, 4. that the cytotoxic lymphocyte is suitably used as a precursor cell during the induction of CTL, because the ratio of the CD8-positive cell is high, 5. that even a cell population having a lower ratio of the CD8-positive cell can be cultured with increasing the ratio of the CD8-positive cell and the like. Therefore, the method of the present invention is very useful in the preparation of a cytotoxic lymphocyte.

**[0078]** Here, the ratio of the CD8-positive cell in the cytotoxic lymphocyte obtained by the method of the present invention can be determined by, for instance, but not particularly limited to, using an anti-CD8 antibody.

**[0079]** In addition, the cytotoxic lymphocyte prepared according to the method of the present invention has an excellent characteristic that high cytotoxic activity as previously observed is maintained, even when a cell after the culture is maintained over a long period of time, or the cell is proliferated. In other words, the cytotoxic lymphocyte maintains a

high cytotoxic activity as compared to a cytotoxic lymphocyte obtained by carrying out at least any one of induction, maintenance and expansion in the absence of fibronectin, a fragment thereof or a mixture thereof. Therefore, there can be maintained as a lymphocyte having a stable cytotoxic activity by cloning the cultured cytotoxic lymphocyte. In addition, the induced cytotoxic lymphocyte can be proliferated and expanded by stimulating the cytotoxic lymphocyte with an antigen, various kinds of cytokines, or an anti-CD3 antibody. A known method can be used for the maintenance or expansion of the cytotoxic lymphocyte without being particularly limited.

**[0080]** The maintenance of the above-mentioned cytotoxic lymphocyte refers to the maintenance of the cytotoxic lymphocyte with keeping its cytotoxic activity. The culture conditions during the maintenance are not particularly limited, and the conditions used for ordinary cell culture can be used. For instance, the cells can be cultured under the conditions of 37°C in the presence of 5% CO<sub>2</sub>, and the like. In addition, the medium can be exchanged with a fresh one at appropriate time intervals. The medium to be used and other components simultaneously used therewith and the like are the same as those mentioned above.

**[0081]** One of the major characteristics of the maintenance and expansion of the cytotoxic lymphocyte in the method of the present invention resides in that the method comprises respectively continuously culturing and expanding the cytotoxic lymphocyte in a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 5% by volume, in the presence of the effective ingredient of the present invention, i.e. fibronectin, a fragment thereof or a mixture thereof. According to the expansion, the cell number of the cytotoxic lymphocyte can be increased in a state that the cytotoxic activity owned by the cytotoxic lymphocyte is maintained. In other words, as one embodiment of the method of the present invention, there is provided a method for expanding a cytotoxic lymphocyte.

**[0082]** The cytotoxic lymphocyte obtained by the method of the present invention has an ability to recognize a desired target cell, and for example, destroys the cell which is to be the target by its cytotoxic activity. The cytotoxic activity of the cytotoxic lymphocyte can be assessed by a known method. For example, the cytotoxic activity of the cytotoxic lymphocyte to a target cell labeled with a radioactive substance, a fluorescent substance or the like can be assessed by determining radioactivity or fluorescence intensity from the target cell destroyed by the cytotoxic lymphocyte. The cytotoxic activity can also be detected by determining the amount of cytokine such as GM-CSF or IFN-γ specifically released from a cytotoxic lymphocyte or the target cell. In addition, the cytotoxic activity can be directly confirmed by use of an antigenic peptide-MHC complex labeled with a fluorescent dye and the like. In this case, the cytotoxic activity of the cytotoxic lymphocyte can be assessed, for example, by contacting a cytotoxic lymphocyte with a first fluorescent marker coupled with a cytotoxic lymphocyte-specific antibody, followed by contacting with an antigenic peptide-MHC complex coupled with a second fluorescent marker, and carrying out FACS (fluorescence-activated cell sorting) analysis on the presence of double-labeled cell.

**[0083]** Further, the method for preparing a cytotoxic lymphocyte of the present invention has the feature that the culture can be initiated at a low number of cells. A large amount of lymphocytes is required in order to carry out adopted immunotherapy, but it is difficult to obtain a large amount of lymphocytes from a patient. In addition, in an ordinary expansion of the cytotoxic lymphocyte, there have been necessitated selection of a cell culture equipment having an appropriate culture area depending upon the number of cells to be used, and culture at an appropriate amount of the medium. In other words, usually, the culture is initiated under the high density conditions that the amount (number) of cells to a culturing area in a cell culture equipment [i.e. area (cm<sup>2</sup>) of a surface area of the equipment contacting with the medium] is  $1 \times 10^6$  cells/cm<sup>2</sup> or more, and the cell concentration is  $1 \times 10^6$  cells/mL or more. When the culture is carried out under the conditions below this cell level, an expansion fold [a ratio of the number of cells after the expansion to the number of cells before the expansion (the number of cells after expansion/the number of cells before expansion)] becomes very low, whereby requiring a long-term culture period before the cytotoxic lymphocytes are obtained in a large amount. Therefore, generally, a large number of lymphocytes are currently prepared by, for instance, initiating the culture using a small cell culture equipment, and thereafter using a stepwise, large-scaled cell culture equipment, or a method of increasing the number of cell culture equipments and repeating dilution procedures. As described above, a plurality of culture systems are required in the ordinary expansion of the cytotoxic lymphocyte.

**[0084]** According to the method of the present invention, even when initiated with a small amount of cells, the cell can be cultured with a high expansion fold regardless of the size of a cell culture equipment. Therefore, a complicated procedure which has been conventionally conducted, such as an exchange of the cell culture equipment or the cell culture solution and the dilution procedures of the cell culture solution, become unnecessary. In other words, according to the method of the present invention, the expansion of the cytotoxic lymphocyte can be satisfactorily carried out by culture procedures using one cell culture equipment, i.e., one culture system. Therefore, according to the method of the present invention, a method for preparing a cytotoxic lymphocyte which does not require the step of diluting the cell culture solution can be accomplished. Especially, when LAK cell is expanded according to the method of the present invention, LAK cell can be expanded by adding a precursor cell which can be formed into a LAK cell and a medium to a large-volume cell culture equipment, and adding only IL-2 thereto in subsequent steps. The present invention is very useful in the aspect that a large amount of LAK cell can be obtained by a simple procedure. Here, the fibronectin fragment can be preferably used as the effective ingredient of the present invention to be used from the viewpoint of obtaining a

higher expansion fold. As described above, according to the method of the present invention, a necessary amount of the cytotoxic lymphocyte can be obtained in a shorter time period.

**[0085]** For instance, when at least any one of induction, maintenance and expansion of a cytotoxic lymphocyte is initiated at a low number of cells in a cell culture equipment containing a medium in the presence of the effective ingredient of the present invention, the induction, maintenance or expansion can be carried out by using an amount of the cell satisfying the conditions selected from the followings (a) and (b) at a low concentration or low density at the initiation of culture:

(a) a ratio of the amount of cells to the culture area in the cell culture equipment to be used being preferably from 1 cell/cm<sup>2</sup> to  $5 \times 10^5$  cells/cm<sup>2</sup>, more preferably from 10 cells/cm<sup>2</sup> to  $1 \times 10^5$  cells/cm<sup>2</sup>, especially preferably from  $1 \times 10^2$  cells/cm<sup>2</sup> to  $5 \times 10^4$  cells/cm<sup>2</sup>; and

(b) a concentration of the cells in the medium being preferably from 1 cell/mL to  $5 \times 10^5$  cells/mL, more preferably from 10 cells/mL to  $1 \times 10^5$  cells/mL, and especially preferably from  $1 \times 10^2$  cells/mL to  $5 \times 10^4$  cells/mL.

**[0086]** The amount of cells as used herein refers to the number of cytotoxic lymphocytes and/or precursor cells.

**[0087]** In addition, in the method of the present invention, there can be exemplified a method comprising carrying out at least any one of induction, maintenance and expansion of a cytotoxic lymphocyte in one culturing system, which does not require the step of dilution procedure of the cell culture solution.

**[0088]** Furthermore, the method for preparing a cytotoxic lymphocyte of the present invention has the feature that the culture can also be carried out at a large number of cells. In other words, in the case where a method for preparing a cytotoxic lymphocyte in a cell culture equipment including a medium includes at least one step of diluting the cell culture solution with a fresh medium, step of exchanging the medium, or step of exchanging the cell culture equipment during the culture, even when the culture conditions immediately after these steps are set to be at a high concentration (for example, the concentration of the cells in the cell culture solution being from  $2 \times 10^5$  cells/mL to  $1 \times 10^8$  cells/mL, preferably from  $2 \times 10^5$  cells/mL to  $5 \times 10^7$  cells/mL, more preferably from  $2 \times 10^5$  cells/mL to  $2 \times 10^7$  cells/mL) or at a high density (for example, the ratio of the number of the cells in the cell culture solution to the culture area in the cell culture equipment being from  $1 \times 10^5$  cells/cm<sup>2</sup> to  $1 \times 10^8$  cells/cm<sup>2</sup>, preferably from  $1 \times 10^5$  cells/cm<sup>2</sup> to  $5 \times 10^7$  cells/cm<sup>2</sup>, more preferably from  $1 \times 10^5$  cells/cm<sup>2</sup> to  $2 \times 10^7$  cells/cm<sup>2</sup>), the method of the present invention can accomplish a good expansion fold as compared to that of the conventional method. In usual expansion of a cytotoxic lymphocyte, the number of the cells at the initiation of culture is often set to be at a comparably high concentration or high density, and the cell concentration in the cell culture solution or the cell density in the cell culture equipment is set to be low, in accordance with increase in proliferation ratio of the cells. The culture at a large number of cells of the present invention refers to preparation of a cytotoxic lymphocyte of which conditions are set to be at a high concentration or at a high density, wherein the concentration of cells in the cell culture solution is from  $2 \times 10^5$  cells/mL to  $1 \times 10^8$  cells/mL, or the ratio of the number of cells in the cell culture solution to the culture area in the cell culture equipment is from  $1 \times 10^5$  cells/cm<sup>2</sup> to  $1 \times 10^8$  cells/cm<sup>2</sup>, upon setting the cell concentration or cell density during the culture. Here, as used herein, the expression "immediately after the step of diluting the cell culture solution with a fresh medium, step of exchanging the medium, or step of exchanging the cell culture equipment" does not comprise the initiation of the culture.

**[0089]** Advantages of being able to carrying out the culture at a large number of cells as described above include reduction in the amount of the medium, the medium additives such as serum and plasma, the cell culture equipment which are used, labor, and space for the culture. Adoptive immunotherapy needs a large amount of lymphocytes, thereby needs a very large amount of medium or cell culture equipment to be used. Accordingly, it requires an extensive space for the culture and labor. The above is to be a great problem for spread of adoptive immunotherapy. Therefore, since the method of the present invention can solve the problem as described above, it is a very creative invention for institution or management of a facility.

**[0090]** As previously described, the method of the present invention can be applied to any of cell culture at a low concentration or low density, or cell culture at a high concentration or high density. Therefore, use of the method of the present invention enables preparation of a cytotoxic lymphocyte at various cell concentrations or cell densities, depending on culture conditions.

**[0091]** In addition, in the method of the present invention, the cell can be co-cultured with an appropriate feeder cell. When the cytotoxic lymphocyte is co-cultured with the feeder cell, it is desired that the medium is one that is suitable for maintenance and growth of both the cytotoxic lymphocyte and the feeder cell. As the medium, a commercially available medium can be used.

**[0092]** The feeder cell used for the method of the present invention is not particularly limited, so long as the feeder cell stimulates cytotoxic lymphocyte cooperatively with an anti-CD3 antibody to activate T cell receptor. In the present invention, for instance, PBMC or B cell transformed with Epstein-Barr virus (EBV-B cell) is used. Usually, a feeder cell is used after its proliferating ability is taken away by means of irradiation or the like. Incidentally, the content of the feeder cell in the medium may be determined according to the known method. For instance, the content is preferably from  $1 \times$

10<sup>5</sup> cells/mL to 1 × 10<sup>7</sup> cells/mL.

**[0093]** In a particularly preferred embodiment of the present invention, non-virus-infected cell, for instance, a cell other than EBV-B cell, is used as a feeder cell. By using the non-virus-infected cell, the possibility that EBV-B cell is admixed in an expanded cytotoxic lymphocyte can be eliminated, thereby making it possible to increase the safety in medical treatments utilizing cytotoxic lymphocyte, such as adoptive immunotherapy.

**[0094]** In addition, in the method of the present invention, the cell can also be co-cultured with an appropriate antigen-presenting cell. The antigen-presenting cell can be prepared by adding an antigenic peptide to a cell having an antigen-presenting ability, thereby allowing the cell to present the antigenic peptide on its surface [see, for instance, Bendnarek M. A., et al., *J. Immunol.*, **147**(12), 4047-4053 (1991)]. In addition, in the case where a cell having an antigen-presenting ability has an ability to process an antigen, an antigen is added to the cell, whereby the antigen is incorporated into the cell and processed therein, and fragmented antigenic peptides are presented on the cell surface. Incidentally, when an antigenic peptide is added to a cell having an antigen-presenting ability, an antigenic peptide matching the MHC restriction or an antigenic peptide which is not restricted by the MHC of the antigen-presenting cell used and the cytotoxic lymphocyte to be induced is used.

**[0095]** Incidentally, the antigen used in the present invention is not particularly limited, and includes, for instance, exogenous antigens such as bacteria and viruses, endogenous antigens such as tumor-associated antigens (cancer antigens), and the like.

**[0096]** In the present invention, it is preferable that the antigen-presenting cell is made non-proliferative. In order to make the cell non-proliferative, the cell may be, for instance, subjected to irradiation with X-ray or the like, or a treatment with an agent such as mitomycin.

**[0097]** When LAK cell is prepared by the preparation method of the present invention, the culture of LAK cell is carried out by incubating a precursor cell which can be formed into LAK cell together with IL-2 in the presence of the above-mentioned effective ingredient. The precursor cell which can be formed into LAK cell includes, but not particularly limited to, for instance, peripheral blood mononuclear cell (PBMC), NK cell, umbilical cord blood mononuclear cell, hemopoietic stem cell, blood components containing these cells, and the like.

**[0098]** In addition, the general conditions for culturing LAK cell may be set in accordance with the known conditions [for instance, see *Saibo Kogaku (Cell Technology)*, **14**(2), 223-227, (1995); *Saibo Baiyo (Cell Culture)* **17**(6), 192-195, (1991); *THE LANCET*, **356**, 802-807, (2000); *Current Protocols in Immunology*, **supplement 17**, UNIT 7.7], except that the above-mentioned medium is used. The culture conditions are not particularly limited, and the conditions which are used in ordinary cell culture can be employed. For instance, the culture can be carried out under the conditions of 37°C in the presence of 5 % CO<sub>2</sub> and the like. This co-culture is usually carried out for about 2 to about 15 days. In addition, the step of diluting the cell culture solution, the step of exchanging the medium, or the step of exchanging the cell culture equipment can be carried out at appropriate intervals.

**[0099]** In the same manner as those for the above-mentioned induction, maintenance or expansion of the LAK cell, as to CTL and TIL, a group of cells having a high cytotoxic activity can be prepared by culturing the cells in the presence of fibronectin, a fragment thereof or a mixture thereof. In the present invention, there is no particular limitation in the procedures of activating these cells so long as fibronectin, a fragment thereof or a mixture thereof is coexistent therewith and a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 5% by volume is used. The procedures can be carried out using a medium appropriate for culture or activation of the above-mentioned cells. As to the amount of fibronectin, a fragment thereof or a mixture thereof used, the method of adding the component and the like, appropriate ones may be selected in accordance with the above-mentioned method.

**[0100]** Here, the method for expanding a cytotoxic lymphocyte of the present invention is not limited particularly, so long as the above-mentioned effective ingredient is present in the culture system used in the method, and the total concentration of serum and plasma in the medium is 0% by volume or more and less than 5% by volume. The present invention encompasses those embodiments wherein the above-mentioned effective ingredient is present in the culture system, and wherein the total concentration of serum and plasma in the medium is 0% by volume or more and less than 5% by volume in the conventional method for expanding a cytotoxic lymphocyte other than those described above.

**[0101]** Diseases to which the cytotoxic lymphocyte prepared by the method of the present invention is administered are exemplified by, but not limited specifically to, for example, cancer, malignant tumor, hepatitis, or infectious diseases such as influenza, caused by a virus, a bacteria or a fungus. In addition, when a foreign gene is further introduced thereto as described below, the effects can be also expected for various genetic diseases. The cytotoxic lymphocyte prepared by the method of the present invention can also be utilized for donor lymphocyte infusion and the like for the purpose of prevention from an infectious disease after bone marrow transplantation or X-ray irradiation.

**[0102]** In another embodiment of the present invention, there is provided a medium for culturing a cytotoxic lymphocyte, comprising as an effective ingredient fibronectin, a fragment thereof or a mixture thereof, wherein the total concentration of serum and plasma in the medium is 0% by volume or more and less than 5% by volume. The medium further comprises other optional ingredient, for instance, a medium component, a protein, and a cytokine (preferably IL-2), which are used for known cell culture, and other desired components. Here, the medium can be prepared in accordance with a known

method, using the effective ingredient of the present invention, and autologous or nonautologous serum or plasma so as to have a total concentration of 0% by volume or more and less than 5% by volume in the medium. The content of the effective ingredient of the present invention and the like in the medium is not limited particularly, so long as the desired effects of the present invention can be obtained. The content can be appropriately determined as desired, for example, in accordance with the content of the effective ingredient and the like in the above-mentioned medium used in the method of the present invention. One embodiment of the medium of the present invention encompasses a medium containing a cell culture carrier to which fibronectin, a fragment thereof or a mixture thereof is immobilized and a medium provided being included in the cell culture equipment to which fibronectin, a fragment thereof or a mixture thereof is immobilized.

**[0103]** Usually, in the lymphocyte-containing culture obtained by using the method for preparing a cytotoxic lymphocyte as described above, cells other than cytotoxic lymphocyte such as helper T cell are admixed therein. However, since lymphocytes having a cytotoxic activity are contained in a large amount in the lymphocyte-containing culture obtained by the present invention, the cells in the culture can be harvested from the culture by centrifugation or the like, and directly used as a cytotoxic lymphocyte obtained by the method of the present invention. Moreover, if the above-mentioned effective ingredient or the like is immobilized on a cell culture equipment or the like, there is no risk of admixture of the component or the like in the resulting cytotoxic lymphocyte.

**[0104]** In addition, a cell population (or culture) rich in a cytotoxic lymphocyte can be further separated from the culture by a known method, and used as a cytotoxic lymphocyte obtained by the method of the present invention. In other words, the method for preparing a cytotoxic lymphocyte of the present invention can comprise the step of selecting a cell population rich in a cytotoxic lymphocyte from the culture obtained by the method.

**[0105]** The method of selecting a cell population rich in a cytotoxic lymphocyte is not particularly limited. The method is exemplified by, for instance, a method comprising selectively collecting only the desired cell from the culture using a cell culture equipment or carrier to which an antibody against a cell surface antigen expressed on the desired cell surface, for instance, an anti-CD8 antibody, is bound, or a method using a flow cytometer. The above-mentioned carrier is exemplified by magnetic beads or a column. In addition, the cell population rich in the desired cell can be obtained by removing by adsorbing out cells other than the desired cell from the culture. For instance, the helper T cell can be removed from the lymphocyte culture using an antibody against a cell surface antigen expressed on a surface of the helper T cell, for instance, an anti-CD4 antibody. In this step, a flow cytometer can be also used.

**[0106]** Further, the present invention provides a cytotoxic lymphocyte obtained by the method for preparing a cytotoxic lymphocyte of the present invention mentioned above. The lymphocyte has a high cytotoxic activity, which has a characteristic that there is little lowering of the cytotoxic activity, even when the lymphocyte is subjected to the continuous culture or expansion over a long period of time. In addition, the present invention provides a medicament (therapeutic agent) comprising the lymphocyte as an effective ingredient. Especially, the above-mentioned therapeutic agent comprising the lymphocyte is suitably used in adoptive immunotherapy. In the adoptive immunotherapy, the lymphocyte having a cytotoxic activity suitable for treating a patient is administered to the patient by, for instance, intravenous administration. The therapeutic agent is very useful for use in the above-mentioned diseases or donor lymphocyte infusion. The therapeutic agent can be prepared by, for instance, blending the lymphocyte prepared by the method of the present invention as an effective ingredient with, for instance, a known organic or inorganic carrier suitable for non-oral administration, an excipient, a stabilizing agent and the like, according to a method known in the pharmaceutical field. Incidentally, various conditions for the therapeutic agent, such as the content of lymphocyte of the present invention in the therapeutic agent and the dose of the therapeutic agent, can be appropriately determined according to the known adoptive immunotherapy.

**[0107]** The method for preparing a cytotoxic lymphocyte of the present invention can further comprise the step of transducing a foreign gene into the lymphocyte. In other words, one embodiment of the present invention provides a method for preparing a cytotoxic lymphocyte, further comprising the step of transducing a foreign gene into a cytotoxic lymphocyte. Here, the term "foreign" refers to those which are foreign to a lymphocyte into which a gene is to be transduced.

**[0108]** By carrying out the method for preparing a cytotoxic lymphocyte of the present invention, especially the method for expanding a cytotoxic lymphocyte, the ability for proliferation of the cultured lymphocyte is enhanced. Therefore, by combining the method for preparing a cytotoxic lymphocyte of the present invention with the step of transducing a gene, increase in the gene-transducing efficiency is expected.

**[0109]** Methods of transducing a foreign gene are not particularly limited, and an appropriate method can be selected from a known method for transducing a gene. The step of transducing a gene can be carried out at any given point during the preparation of a cytotoxic lymphocyte. For instance, it is preferable to carry out the step simultaneously with any step of the above-mentioned induction, maintenance and/or expansion of the lymphocyte or after the step, from the viewpoint of working efficiency.

**[0110]** As the above-mentioned method for transducing a gene, any of methods using a viral vector, and methods without using the vector can be employed in the present invention. The details of those methods have been already published in numerous literatures.

**[0111]** The above-mentioned viral vector is not particularly limited, and a known viral vector ordinarily used in the method for transducing a gene, for instance, retroviral vector, lentiviral vector, adenoviral vector, adeno-associated viral vector, simian viral vector, vaccinia viral vector, sendai viral vector, or the like is used. Especially preferably, as the viral vector, retrovirus, adenovirus, adeno-associated virus or simian virus is used. As the above-mentioned viral vector, those lacking replication ability so that the viral vector cannot self-replicate in an infected cell are preferable.

**[0112]** The retroviral vector is used for the purpose of gene therapy or the like because there can be stably incorporated a foreign gene inserted into the vector in chromosomal DNA in the cell into which the vector is to be transduced. Since the vector has a high infection efficiency to the cell during mitosis and proliferation, the gene transduction is preferably carried out in the step for preparing a cytotoxic lymphocyte, for instance, the step of expansion.

**[0113]** As the method for transducing a gene without using a viral vector, there can be employed, but not particularly limited to, for instance, a method using a carrier such as liposome or ligand-polylysine, calcium phosphate method, electroporation method, particle gun method or the like. In this case, there is transduced a foreign gene incorporated into plasmid DNA or linear DNA.

**[0114]** The foreign gene to be transduced into a cytotoxic lymphocyte in the present invention is not particularly limited, and an arbitrary gene which is desired to be transduced into the above-mentioned cell can be selected. As the gene as described above, besides a gene encoding a protein (for instance, an enzyme, a cytokine, a receptor or the like), for instance, a gene encoding an antisense nucleic acid, siRNA (small interfering RNA) or a ribozyme can be used. In addition, an appropriate marker gene which is capable of selecting a cell into which a gene is transduced may be transduced simultaneously.

**[0115]** The above-mentioned foreign gene can be, for instance, inserted into a vector, a plasmid or the like, so that the foreign gene is expressed under the control of an appropriate promoter, and used. In addition, in order to achieve an efficient transcription of a gene, there may exist in a vector other regulating element which cooperates with a promoter or a transcription initiation site, for instance, an enhancer sequence or a terminator sequence. In addition, for the purpose of inserting a foreign gene into a chromosome of a lymphocyte in which the gene is transduced by homologous recombination, for instance, a foreign gene may be arranged between flanking sequences comprising nucleotide sequences each having homology to nucleotide sequences located on both sides of the desired target insertion site of the gene in the chromosome. The foreign gene to be transduced may be one that is a naturally occurring or an artificially generated, or may be one in which DNA molecules having different origins from each other are bound by a known means such as ligation. Moreover, the foreign gene may be one having a sequence in which a mutation is introduced into a naturally occurring sequence depending upon its purpose.

**[0116]** According to the method of the present invention, for instance, a gene encoding an enzyme associated with the resistance to a drug used for the treatment of a patient with cancer or the like can be transduced into a cytotoxic lymphocyte, thereby giving the lymphocyte a drug resistance. If the cytotoxic lymphocyte as described above is used, adoptive immunotherapy and drug therapy can be combined, and, therefore, higher therapeutic effects can be obtained. The drug resistance gene is exemplified by, for instance, a multidrug resistance gene.

**[0117]** On the other hand, conversely to the above-mentioned embodiment, a gene so as to give a sensitivity against a particular drug can be transduced into a cytotoxic lymphocyte, thereby giving sensitivity against the drug. In this case, the lymphocyte after being transplanted to a living body can be removed by administering the drug. The gene for giving sensitivity against a drug is exemplified by, for instance, a thymidine kinase gene.

(3) CH-296Na

**[0118]** In the present invention, there are also provided a novel polypeptide having the amino acid sequence (x) shown in SEQ ID NO: 25 (CH-296Na) of Sequence Listing, or a polypeptide having an amino acids sequence (y) having deletion, insertion, addition or substitution of one or the plural number of amino acids in the amino acid sequence (x), wherein the polypeptide having the amino acid sequence (y) has a function equivalent to that of the polypeptide having the amino acid sequence (x), and a nucleic acid encoding the novel polypeptide. The nucleic acid is exemplified by a nucleic acid comprising (1) a DNA comprising the nucleotide sequence shown in SEQ ID NO: 26 (a nucleic acid encoding CH-296Na); (2) a DNA encoding a polypeptide comprising a nucleotide sequence having deletion, substitution, insertion or addition of one or the plural number of nucleotides in the nucleotide sequence shown in SEQ ID NO: 26, wherein the polypeptide has a function equivalent to that of the polypeptide encoded by the DNA (1); or (3) a DNA which hybridizes to a DNA comprising the nucleotide sequence shown in SEQ ID NO: 26 under stringent conditions, which encodes a polypeptide having a function equivalent to that of the polypeptide encoded by the DNA (1).

**[0119]** Here, in the present specification, the novel polypeptide is referred to as the polypeptide of the present invention, and the nucleic acid encoding the polypeptide is referred to as the nucleic acid of the present invention, in some cases.

**[0120]** Hereinafter, the polypeptide of the present invention, the nucleic acid encoding the polypeptide, and the method for preparing the polypeptide will be described.

**[0121]** The polypeptide of the present invention includes those having an amino acid sequence having one or more

of substitution, deletion, insertion or addition of one or the plural number of amino acids in the above-mentioned amino acid sequence, so long as the polypeptide has any of the desired functions [functions of the above-mentioned (i) to (iv)] in the preparation of a cytotoxic lymphocyte as mentioned above. The polypeptide of the present invention other than CH-296Na is exemplified by a polypeptide having one or more of any of substitution, deletion, insertion or addition of preferably 1 to 20 amino acids, more preferably 1 to 10 amino acids, and further preferably 1 to 5 amino acids in the amino acid sequence shown in SEQ ID NO: 25 of Sequence Listing. Here, substitution or the like of an amino acid can be carried out to an extent where it can change physicochemical characteristics and the like of an inherent polypeptide within the range where the function of the polypeptide can be maintained. The detail and the method for preparing the polypeptide is as described above.

**[0122]** The nucleic acid shown in SEQ ID NO: 26 of Sequence Listing encoding the polypeptide of the present invention can be obtained as a DNA fragment encoding CH-296Na by carrying out PCR using a cDNA encoding human fibronectin derived from plasma as a template. As a primer used in the PCR is not limited specifically. For example, Primer CH-296Na1 or Primer CH-296Na2 shown in SEQ ID NO: 27 or 28 of Sequence Listing can be used as the primer. In addition, the nucleic acid can be obtained by binding a plasmid of the above-mentioned FERM BP-2800 (*Escherichia coli* carrying a plasmid encoding CH-296) and a DNA fragment having a sequence which is present between a cell binding domain and heparin binding domain of a native fibronectin derived from plasma (11 of the type III repetitive sequence in Figure 1) using appropriate restriction site.

**[0123]** In addition, the nucleic acid of the present invention also includes a nucleic acid having one or more of any of substitution, deletion, insertion or addition of one or the plural number of nucleotide in the nucleotide sequence of the nucleic acid shown in SEQ ID NO: 26 of Sequence Listing. For example, the nucleic acid is exemplified by a nucleic acid having one or more of any of substitution, deletion, insertion or addition of 1 to 60 nucleotides, more preferably 1 to 30 nucleotides, further preferably 1 to 15 nucleotides in the nucleotide sequence shown in SEQ ID NO: 26 of Sequence Listing. Here, substitution or the like of a nucleotide can be carried out to an extent where it can change physicochemical characteristics of a polypeptide and the like encoded by the nucleic acid within the range where the function of the polypeptide can be maintained. The detail and the method for substitution or the like of a nucleotide are pursuant to the description for those of the above-mentioned substitution or the like of an amino acid.

**[0124]** Furthermore, the nucleic acid of the present invention includes a nucleic acid, which hybridizes to a nucleic acid comprising the nucleotide sequence shown in SEQ ID NO: 26 under stringent conditions, and which encodes a polypeptide having a function equivalent to that of the polypeptide of the present invention, i.e., at least any of the functions of the (i) to (iv) in the preparation of the cytotoxic lymphocyte mentioned above. The "stringent conditions" are not limited specifically, and can be set by appropriately determining temperature and salt concentration upon hybridization, preferably additionally upon washing, depending on the DNA which hybridizes to the DNA comprising the nucleotide sequence shown in SEQ ID NO: 26. The stringent conditions include, for example, the conditions described in a literature such as Sambrook et al., *Molecular cloning, A laboratory manual* 3<sup>rd</sup> edition, 2001, published by Cold Spring Harbor Laboratory Press.

**[0125]** Specifically, for example, the stringent conditions are exemplified by incubation at 50°C, preferably at 65°C in a solution containing  $6 \times \text{SSC}$  ( $1 \times \text{SSC}$  being 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0), 0.5% SDS,  $5 \times \text{Denhardt's}$  (0.1 % bovine serum albumin (BSA), 0.1 % polyvinyl pyrrolidone, 0.1 % Ficoll 400) and 100  $\mu\text{g/mL}$  salmon sperm DNA. When  $T_m$  value of the DNA used is known, the above-mentioned temperature may be lower than that value by 5 to 12°C. Furthermore, conditions, such as carrying out the step of removing the DNA hybridizing non-specifically by washing, wherein from the viewpoint of improving accuracy, washing is carried out under conditions of, for example,  $2 \times \text{SSC}$ , more stringently  $0.1 \times \text{SSC}$  and the like and/or conditions of higher temperature, such as 25°C or more, more stringently 37°C or more, further stringently 42°C or more, even more stringently 50°C or more, varying depending on the  $T_m$  value of the DNA used, may be added.

**[0126]** The present invention also encompasses a nucleic acid molecule which hybridizes to the polynucleotide of the present invention under lower stringent conditions. Variation of stringency of the hybridization and signal detection is carried out mainly by manipulation of formamide concentration (lower percentile of formamide causes lowered stringency), salt concentration or temperature. For example, lower stringent conditions include overnight incubation at 37°C in a solution containing  $6 \times \text{SSPE}$  ( $20 \times \text{SSPE} = 3 \text{ M NaCl}$ ; 0.2 M  $\text{NaH}_2\text{PO}_4$ ; 0.02 M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100  $\mu\text{g/mL}$  salmon sperm blocking DNA; followed by washing with  $1 \times \text{SSPE}$  and 0.1% SDS at 50°C. Furthermore, in order to accomplish lower stringency, the washing carried out after the stringent hybridization can be carried out at a higher salt concentration (for example,  $5 \times \text{SSC}$ ).

**[0127]** The above-mentioned conditions can be modified by adding and/or substituting an alternative blocking reagent used for suppressing background in a hybridization experiment. Typical blocking reagent includes Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA and commercially available product formulation. In addition, other elements other than the above-mentioned hybridization conditions are needed to be modified depending on such modification, in some cases.

**[0128]** On the other hand, a polypeptide having the amino acid sequence shown in SEQ ID NO: 25 of Sequence



Listing can be obtained by genetic engineering technique, using the nucleic acid this obtained. In other words, the polypeptide can be obtained by inserting the nucleic acid into an appropriate expression vector including, but not being limited specifically to, pET vector, pCold vector and the like, to express the polypeptide by a known method, for example, in *Escherichia coli* or the like.

## EXAMPLES

**[0129]** The present invention will be more concretely described by means of the examples, without intending to limit the scope of the present invention thereto in any way.

### Preparation Example 1 Preparation of Fibronectin Fragment

#### (1) Preparation of Fibronectin Fragment

**[0130]** H-271, a fragment derived from human fibronectin, was prepared from *Escherichia coli* HB101/pHD101 (FERM BP-2264) in accordance with the method described in U.S. Patent No. 5,198,423.

**[0131]** In addition, H-296, CH-271 and CH-296, fragments derived from human fibronectin, were each prepared from a culture obtained by culturing *Escherichia coli* HB101/pHD102 (FERM BP-7420), *Escherichia coli* HB101/pCH101 (FERM BP-2799) or *Escherichia coli* HB101/pCH102 (FERM BP-2800), in accordance with the method described in the above-mentioned gazette.

**[0132]** C-274, a fragment derived from human fibronectin, was prepared from a culture obtained by culturing *Escherichia coli* JM109/pTF7221 (FERM BP-1915) in accordance with the method described in U.S. Patent No. 5,102,988.

**[0133]** C-CS1, a fragment derived from human fibronectin, was prepared from a culture obtained by culturing *Escherichia coli* HB101/pCS25 (FERM BP-5723) in accordance with the method described in Japanese Patent Gazette No. 3104178.

**[0134]** CHV-89 and CHV-179, fragments derived from human fibronectin, were each prepared from a culture obtained by culturing *Escherichia coli* HB101/pCHV89 (FERM P-12182) or *Escherichia coli* HB101/pCHV179 (FERM P-12183), in accordance with the method described in Japanese Patent Gazette No. 2729712.

**[0135]** In addition, CHV-90, a fragment derived from human fibronectin, was prepared in accordance with the method described in Japanese Patent Gazette No. 2729712. Concretely, a plasmid pCHV90 was constructed in accordance with the procedures described in the gazette, and thereafter a transformant carrying the plasmid was cultured, and CHV-90 was prepared from the culture.

**[0136]** CHV-181, a fragment derived from human fibronectin, was prepared by constructing the plasmid (pCHV181) comprising a DNA encoding CHV-181 in accordance with the method described in WO 97/18318, thereafter culturing *Escherichia coli* HB101/pCHV181 into which the plasmid had been introduced, and preparing the fragment from the culture in the same manner as that for the above CHV-179.

#### (2) Preparation of CHV-92

**[0137]** As to pCHV181, a plasmid for expressing the above-mentioned polypeptide CHV-181, there was constructed a plasmid CHV92 having deletion of a region encoding a III-13 region in the region encoding CHV-181. The deletion procedures were performed in accordance with procedures for deleting a III-14 coding region from a plasmid pCHV179, which are described in Japanese Patent Gazette No. 2729712.

**[0138]** *Escherichia coli* HB101 transformed with the above-mentioned plasmid pCHV92 (*Escherichia coli* HB101/pCHV92) was cultured, and the purification procedures were carried out in accordance with the method of purifying the CHV-89 polypeptide described in Japanese Patent Gazette No. 2729712, to obtain a purified CHV-92 preparation from the resulting culture.

#### (3) Preparation of H-275-Cys

**[0139]** A plasmid for expressing a polypeptide H-275-Cys was constructed in accordance with the following procedures. Concretely, a plasmid pCH102 was prepared from *Escherichia coli* HB101/pCH102 (FERM BP-2800). PCR was carried out using a primer 12S having the nucleotide sequence shown in SEQ ID NO: 21 of Sequence Listing and a primer 14A having the nucleotide sequence shown in SEQ ID NO: 22 of Sequence Listing with the above plasmid as a template, to give a DNA fragment of about 0.8 kb, encoding a heparin binding domain of fibronectin. The resulting DNA fragment was digested with *Nco*I and *Bam*HI (both manufactured by TAKARA BIO INC.), and thereafter ligated with pTV118N (manufactured by TAKARA BIO INC.) which had been digested with *Nco*I and *Bam*HI, to construct a plasmid pRH1.

**[0140]** A plasmid vector pINIII-ompA<sub>1</sub> [Ghrayeb J., et al., *EMBO J.*, **3**(10), 2437-2442 (1984)] was digested with *Bam*HI

and *HincII* (manufactured by TAKARA BIO INC.) to collect a DNA fragment of about 0.9 kb, containing a lipoprotein terminator region. This fragment was mixed and ligated with the above-mentioned plasmid pRH1 which had been digested with *BamHI* and *HincII*, to give a plasmid pRH1-T containing a *lac* promoter, a DNA fragment encoding a heparin binding domain and a lipoprotein terminator in this order.

**[0141]** The reaction for PCR was carried out by using a primer Cys-A having the nucleotide sequence shown in SEQ ID NO: 23 of Sequence Listing and a primer Cys-S having the nucleotide sequence shown in SEQ ID NO: 24 of Sequence Listing with this plasmid pRH1-T as a template. Thereafter, the collected amplified DNA fragment was digested with *NotI* (manufactured by TAKARA BIO INC.), and the DNA fragment was further self-ligated. A cyclic DNA thus obtained was digested with *SpeI* and *Scal* (manufactured by TAKARA BIO INC.) to give a DNA fragment of 2.3 kb, and the resulting fragment was mixed and ligated with a DNA fragment of 2.5 kb, obtained by digesting the plasmid pRH1-T with *SpeI* and *Scal* (manufactured by TAKARA BIO INC.), to give a plasmid pRH-Cys. The plasmid encodes a polypeptide H-275-Cys in which four amino acids Met-Ala-Ala-Ser were added to an N-terminal side of the above-mentioned H-271, and further Cys was added to a C-terminal of the H-271.

**[0142]** The polypeptide H-275-Cys was prepared by the following method. *Escherichia coli* HB101 which had been transformed with the above-mentioned plasmid pRH-Cys (*Escherichia coli* HB101/pRH-Cys) was cultured overnight at 37°C in 120 mL of an LB medium. The bacterial cells collected from the culture medium were suspended in 40 mL of a buffer for disruption (50 mM Tris-HCl, 1 mM EDTA, 150 mM NaCl, 1 mM DTT, 1 mM PMSF, pH 7.5), and the suspension was subjected to ultrasonic treatment to disrupt the bacterial cells. The supernatant obtained by centrifugation was applied to Hi Trap-heparin column (manufactured by Pharmacia) which had been equilibrated with a purifying buffer (50 mM Tris-HCl, pH 7.5). The non-adsorbed fraction in the column was washed with the same buffer, and thereafter the elution was carried out with a purifying buffer having a 0 to 1 M NaCl concentration gradient. The eluate was analyzed by SDS-polyacrylamide gel electrophoresis, and fractions corresponding to a molecular weight of H-275-Cys were collected to give a purified H-275-Cys preparation.

#### Example 1 Determination of Expansion Fold in Culture System of LAK Cells (Lymphokine-Activated Killer Cells) Using Low-Serum Medium

##### (1) Isolation and Storage of PBMCs

**[0143]** Blood component was collected from a human normal individual donor, obtained with informed consent. The collected blood component was diluted 2-folds with PBS(-), overlaid on Ficoll-paque (manufactured by Pharmacia), and centrifuged at  $500 \times g$  for 20 minutes. The peripheral blood mononuclear cells (PBMCs) in the intermediate layer were collected with a pipette, and washed. The collected PBMCs were suspended in a storage solution of 90% FBS (manufactured by Bio Whittaker)/10% DMSO (manufactured by SIGMA), and stored in liquid nitrogen. During LAK induction, these stored PBMCs were rapidly melted in water bath at 37°C, and washed with RPMI 1640 medium (manufactured by Bio Whittaker) containing 10  $\mu\text{g/mL}$  DNase (manufactured by Calbiochem). Thereafter, the number of living cells was calculated by trypan blue staining method. The cells were subjected to each experiment.

##### (2) Immobilization of Anti-Human CD3 Antibody and FN fragment

**[0144]** An anti-human CD3 antibody and an FN fragment were immobilized to a culture equipment used in the following experiment. Concretely, 1 mL (in a case of a 24-well plate) or 2 mL (in a case of 12.5 cm<sup>2</sup> flask) each of PBS containing an anti-human CD3 antibody (manufactured by Janssen-Kyowa) (final concentration 5  $\mu\text{g/mL}$ ) was added to a 24-well cell culture plate or a 12.5 cm<sup>2</sup> cell culture flask (manufactured by Falcon). Upon the addition, each of the fibronectin fragments (FNfr) listed in Preparation Example 1 was added to a group with addition of an FN fragment so as to have a final concentration of 10  $\mu\text{g/mL}$  (in the case of the 24-well plate) or 25  $\mu\text{g/mL}$  (in the case of the 12.5 cm<sup>2</sup> flask). As a control, there was also set a group without addition of the FNfr.

**[0145]** After these culture equipments were incubated at room temperature for 5 hours, the culture equipments were stored at 4°C until use. Immediately before use, PBS containing the antibody and the FNfr was removed by aspiration from these culture equipments, and thereafter each well was washed twice with PBS, and then once with XVIVO20 medium (manufactured by Bio Whittaker), and the culture equipments were subjected to each experiment.

##### (3) Induction and Culture of LAK Cells

**[0146]** PBMCs which were prepared in item (1) of Example 1 were suspended in XVIVO20 containing 1% human AB serum (hereinafter simply referred to as 1% XVIVO20) so as to have a concentration of  $1 \times 10^6$  cells/mL, and thereafter the suspension was put on a plate immobilized with the anti-human CD3 antibody or a plate immobilized with the anti-human CD3 antibody and the FNfr, prepared in item (2) of Example 1, in a volume of 1 mL/well each, and IL-2 (manu-

factured by Shionogi & Co., Ltd.) was added thereto so as to have a final concentration of 1000 U/mL. These plates were subjected to culture at 37°C in 5% CO<sub>2</sub> (zeroth day of culture). On the second and third days from the initiation of culture, 1% XVIVO20 containing 1000 U/mL IL-2 was added thereto in a volume of 1 mL/well each. On the fourth day from the initiation of culture, a culture medium properly diluted with 1% XVIVO20 was transferred to a fresh flask to which nothing was immobilized, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. The culture was continued, the culture medium was properly diluted with 1% XVIVO20 every 2 or 3 days in the same manner as the fourth day from the initiation of culture, and IL-2 was added thereto so as to have a final concentration of 300 to 500 U/mL. On the eleventh or fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. The results are shown in Table 1.

Table 1

Serum Concentration (%)	Cultured Days	Fibronectin Fragment	Expansion Fold
1	11 Days	Control (Without Immobilization of FNfr)	× 252
1	11 Days	CH-296	× 670
1	11 Days	H-296	× 615.6
1	15 Days	Control (Without Immobilization of FNfr)	× 403.2
1	15 Days	CH-296	× 588
1	15 Days	H-296	× 708

**[0147]** As shown in Table 1, in the group using the culture equipment in which each of the fibronectin fragments was immobilized with at an early stage of the induction of the LAK cells using the medium containing a low-concentration serum, the expansion fold of the LAK cells was high as compared to that of the control group. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of the LAK cells using the medium containing a low-concentration serum.

#### Example 2 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (Expansion by Repetitive Stimulation)

##### (1) Induction and Culture of LAK Cells

**[0148]** PBMCs which were prepared in item (1) of Example 1 were suspended in 0.5% or 1% XVIVO20 so as to have a concentration of  $1 \times 10^6$  cells/mL, and thereafter the suspension was put on a plate immobilized with the anti-human CD3 antibody or a plate immobilized with the anti-human CD3 antibody and the FNfr, prepared in item (2) of Example 1, in a volume of 1 mL/well each, and IL-2 (manufactured by Shionogi & Co., Ltd.) was added thereto so as to have a final concentration of 1000 U/mL. These plates were subjected to culture at 37°C in 5% CO<sub>2</sub> (zeroth day of culture). On the second and third days from the initiation of culture, 0.5% or 1% XVIVO20 containing 1000 U/mL IL-2 was added thereto in a volume of 1 mL/well each. On the fourth day from the initiation of culture, a culture medium properly diluted with 0.5% or 1% XVIVO20 was transferred to a fresh flask to which nothing was immobilized, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the ninth day from the initiation of culture, a culture medium properly diluted with 0.5% or 1% XVIVO20 was transferred to a flask immobilized with the anti-human CD3 antibody or a flask immobilized with the anti-human CD3 antibody and the FNfr (provided that the concentration of the anti-human CD3 antibody used in the immobilization was 0.5 µg/mL), prepared in the same manner as in item (2) of Example 1, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the twelfth day from the initiation of culture, a culture medium properly diluted again with 0.5% or 1% XVIVO20 was transferred to a fresh flask to which nothing was immobilized, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. The results are shown in Table 2.

Table 2

Serum Concentration (%)	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Expansion Fold (folds)
0.5	Control (Without Immobilization of FNfr)	Anti-CD3	None	× 13
0.5	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	× 88
0.5	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	× 410
1	Control (Without Immobilization of FNfr)	Anti-CD3	None	× 403
1	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	× 1624
1	CH-296	Anti-CD3+CH-296	None	× 588
1	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	× 3560
1	H-296	Anti-CD3+H-296	None	× 708
1	H-296	Anti-CD3+H-296	Anti-CD3+H-296	× 3000

**[0149]** As shown in Table 2, in the group using repeatedly the culture equipment in which each of the fibronectin fragments and the anti-CD3 antibody was immobilized at an early stage and an intermediate stage of the induction of the LAK cells using the medium containing a low-concentration serum, an expansion fold of the LAK cells was high as compared to that of the control group. These expansion folds were far higher than the expansion fold in the group using repeatedly the culture equipment in which only the anti-CD3 antibody was immobilized at an early stage and an intermediate stage of the induction of the LAK cells. In other words, it was clarified that the LAK cells could be induced and cultured with a high expansion fold by stimulation using the fibronectin fragment and the anti-CD3 antibody at an early stage and an intermediate stage of induction of the LAK cells even when the medium containing a low-concentration serum was used.

#### Example 3 Induction of IL-2 Receptor (IL-2R) Expression in Culture System of LAK Cells Using, Low-Serum Medium

##### (1) Induction and Culture of LAK Cells

**[0150]** The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 2.

##### (2) Determination of Ratio of IL-2R Expression in LAK Cells

**[0151]** LAK cells which were prepared in item (1) of Example 3 in an amount of  $2 \times 10^5$  cells were fixed with PBS (manufactured by Nissui) containing 1% paraformaldehyde (manufactured by Nakalai Tesque, Inc.), and then washed with PBS. The fixed cells were suspended in 100  $\mu$ L of PBS containing 1% BSA (manufactured by SIGMA), FITC-labeled mouse IgG1 or FITC-labeled mouse anti-human IL-2R (CD25) antibody (both manufactured by DAKO) was added thereto, and thereafter the mixture was incubated on ice for 30 minutes. After the incubation, the cells were washed with PBS, and suspended again in PBS containing 1% paraformaldehyde. The cells were subjected to flow cytometry using FACS Vantage (manufactured by Becton Dickinson), and the content ratio of the IL-2R expression-positive cells was determined. The results are shown in Table 3. In the table, the content ratio of the IL-2R expression-positive cells (%) is shown as the ratio of IL-2R expression (%).

Table 3

Serum Concentration (%)	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Ratio of IL-2R Expression (%)
0.5	Control (Without Immobilization of FNfr)	Anti-CD3	None	3.48
0.5	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	43.22
0.5	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	81.11
0.5	H-296	Anti-CD3+H-296	Anti-CD3+H-296	71.49
1	Control (Without Immobilization of FNfr)	Anti-CD3	None	8.02
1	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	42.8
1	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	77.94
1	H-296	Anti-CD3+H-296	Anti-CD3+H-296	70.29

**[0152]** As shown in Table 3, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage and an intermediate stage of the induction of the LAK cells using the medium containing a low-concentration serum, the ratio of IL-2R expression on the surface of the LAK cells during the culture could be induced at a high level. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the ratio of IL-2R expression when the LAK cells were induced using the medium containing a low-concentration serum in the copresence of the fibronectin fragment.

#### Example 4 Content Ratio of CD8-Positive Cells in LAK Cell Population Using Low Serum Medium

##### (1) Induction and Culture of LAK Cells

**[0153]** The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 2.

##### (2) Determination of Content Ratio of CD8-Positive Cell Population in LAK Cells

**[0154]** LAK cells which were prepared in item (1) of Example 4 in an amount of  $2 \times 10^5$  cells were fixed with PBS containing 1% paraformaldehyde, and then washed with PBS. The fixed cells were suspended in 100  $\mu$ L of PBS containing 1% BSA, FITC-labeled mouse IgG1 or FITC-labeled mouse anti-human CD8 antibody (both manufactured by DAKO) was added thereto, and thereafter the mixture was incubated on ice for 30 minutes. After the incubation, the cells were washed with PBS, and suspended again in PBS containing 1% paraformaldehyde. The cells were subjected to flow cytometry using FACS Vantage, and the content ratio of the CD8-positive cells was determined. The results are shown in Table 4.

Table 4

Serum Concentration (%)	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Content Ratio of CD8-Positive Cells (%)
0.5	Control (Without Immobilization of FNfr)	Anti-CD3	Anti-CD3	26.95
0.5	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	44.67

Table continued

Serum Concentration (%)	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Content Ratio of CD8-Positive Cells (%)
1	Control (Without Immobilization of FNfr)	Anti-CD3	None	53.26
1	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	35.56
1	CH-296	Anti-CD3+CH-296	None	61.29
1	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	62.58

**[0155]** As shown in Table 4, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage or an early stage and an intermediate stage of the induction of the LAK cells using the medium containing a low-concentration serum, the content ratio of CD8-positive cells in the LAK cells during the culture could be induced at a high level. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the content ratio of the CD8-positive cells in the LAK cells when the LAK cells were induced using the medium containing a low-concentration serum in the copresence of the fibronectin fragment.

#### Example 5 Determination of Expansion Fold in Culture System of LAK Cells Using Serum-Free Medium

##### (1) Induction and Culture of LAK Cells

**[0156]** PBMCs which were prepared in item (1) of Example 1 were suspended in XVIVO20 without containing serum (hereinafter simply referred to as 0% XVIVO20) so as to have a concentration of  $1 \times 10^6$  cells/mL, and thereafter the suspension was put on a plate immobilized with the anti-human CD3 antibody or a plate immobilized with the anti-human CD3 antibody and the FNfr, prepared in item (2) of Example 1 in a volume of 1 mL/well each, and IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These plates were subjected to culture at 37°C in 5% CO<sub>2</sub> (zeroth day of culture). On the second and third days from the initiation of culture, 0% XVIVO20 containing 1000 U/mL IL-2 was added thereto in a volume of 1 mL/well each. On the fourth day from the initiation of culture, a culture medium properly diluted with 0% XVIVO20 was transferred to a fresh flask to which nothing was immobilized, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. The culture was continued, and the culture medium was properly diluted every 2 or 3 days with 0% XVIVO20 in the same manner as in the fourth day from the initiation of culture, and IL-2 was added thereto so as to have a final concentration of from 300 to 500 U/mL. On the eleventh day or the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. The results are shown in Table 5.

Table 5

Serum Concentration (%)	Cultured Days	Fibronectin Fragment	Expansion Fold (folds)
0	11 Days	Control (Without Immobilization of FNfr)	36
0	11 Days	CH-296	103.7
0	15 Days	Control (Without Immobilization of FNfr)	76.3
0	15 Days	CH-296	134.6
0	15 Days	Control (Without Immobilization of FNfr)	28.8
0	15 Days	H-296	46.8

**[0157]** As shown in Table 5, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells using the medium without containing serum, the expansion fold of the LAK cells was high as compared to that of the control group. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of the LAK cells using the medium without containing serum.

Example 6 Determination of Expansion Fold in Culture System of LAK Cells in Serum-Free Medium (Expansion by Repetitive Stimulation)

(1) Induction and Culture of LAK Cells

[0158] PBMCs which were prepared in item (1) of Example 1 were suspended in 0% XVIVO20 so as to have a concentration of  $1 \times 10^6$  cells/mL, and thereafter the suspension was put on a plate immobilized with the anti-human CD3 antibody or a plate immobilized with the anti-human CD3 antibody and the FNfr, prepared in item (2) of Example 1, in a volume of 1 mL/well each, and IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These plates were subjected to culture at 37°C in 5% CO<sub>2</sub> (zeroth day of culture). On the second and third days from the initiation of culture, 0% XVIVO20 containing 1000 U/mL IL-2 was added thereto in a volume of 1 mL/well each. On the fourth day from the initiation of culture, a culture medium properly diluted with 0% XVIVO20 was transferred to a fresh flask to which nothing was immobilized, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the ninth day from the initiation of culture, a culture medium properly diluted with 0% XVIVO20 was transferred to a flask immobilized with the anti-human CD3 antibody or a flask immobilized with the anti-human CD3 antibody and the FNfr (provided that the concentration of the anti-human CD3 antibody used in the immobilization was 0.5 µg/mL), prepared in the same manner as in item (2) of Example 1, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the twelfth day from the initiation of culture, a culture medium properly diluted again with 0% XVIVO20 was transferred to a fresh flask to which nothing was immobilized, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. The results are shown in Table 6.

Table 6

Serum Concentration (%)	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Expansion Fold (folds)
0	Control (Without Immobilization of FNfr)	Anti-CD3	None	× 29
0	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	× 36
0	CH-296	Anti-CD3+CH-296	None	× 56
0	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	× 199
0	H-296	Anti-CD3+H-296	None	× 47
0	H-296	Anti-CD3+H-296	Anti-CD3+H-296	× 209

[0159] As shown in Table 6, in the group using repeatedly the culture equipment in which each of the fibronectin fragments and the anti-CD3 antibody was immobilized at an early stage and an intermediate stage of the induction of the LAK cells using the medium without containing serum, an expansion fold of the LAK cells was high as compared to that of the control group. These expansion folds were far higher than the expansion fold in the group using repeatedly the culture equipment in which only the anti-CD3 antibody was immobilized at an early stage and an intermediate stage of the induction of the LAK cells. In other words, it was clarified that LAK cells could be induced and cultured with a high expansion fold by stimulation using the fibronectin fragment and the anti-CD3 antibody at an early stage and an intermediate stage of induction of the LAK cells even when the medium without containing serum was used.

Example 7 Induction of IL-2R Expression in Culture System of LAK Cells Using Serum-Free Medium

(1) Induction and Culture of LAK Cells

[0160] The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 6.

(2) Determination of Ratio of IL-2R Expression in LAK Cells

[0161] The content ratio of the IL-2R expression-positive cells was determined in the same manner as in item (2) of

# EP 1 666 589 A1

Example 3. The results are shown in Table 7. In the table, the content ratio of the IL-2R expression-positive cells (%) is shown as the ratio of IL-2R expression (%).

Table 7

Serum Concentration (%)	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Ratio of IL-2R Expression (%)
0	Control (Without Immobilization of FNfr)	Anti-CD3	None	1.7
0	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	50.5
0	CH-296	Anti-CD3+CH-296	None	3.0
0	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	82.2
0	H-296	Anti-CD3+H-296	None	3.2
0	H-296	Anti-CD+H-296	Anti-CD3+H-296	91.9

**[0162]** As shown in Table 7, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage and an intermediate stage of the induction of the LAK cells using the medium without containing serum, the ratio of IL-2R expression on the surface of the LAK cells during the culture could be induced at a high level. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the ratio of IL-2R expression when the LAK cells were induced using the medium without containing serum in the copresence of the fibronectin fragment.

## Example 8 Determination of Expansion Fold in Culture System of LAK Cells Using Serum-Free Medium (AIM V)

### (1) Induction and Culture of LAK Cells

**[0163]** The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 5, provided that a medium used during the induction and the culture was changed to AIM V medium without containing serum (manufactured by Invitrogen, hereinafter simply referred to as 0% AIM V). The results are shown in Table 8.

Table 8

Serum Concentration and Medium	Cultured Days	Fibronectin Fragment	Expansion Fold (folds)
0% AIM V	12 Days	Control (Without Immobilization of FNfr)	× 21
0% AIM V	12 Days	CH-296	× 110
0% AIM V	15 Days	Control (Without immobilization of FNfr)	× 44
0% AIM V	15 Days	CH-296	× 498
0% AIM V	12 Days	Control (Without Immobilization of FNfr)	Unproliferated, not detected
0% AIM V	12 Days	H-296	× 33
0% AIM V	15 Days	Control (Without Immobilization of FNfr)	Unproliferated, not detected
0% AIM V	15 Days	H-296	× 245

**[0164]** As shown in Table 8, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells using the medium without containing serum, the expansion fold of the LAK cells was high as compared to that of the control group. In addition, this effect was exhibited even when a basal medium for serum-free culture was changed. It was clarified from the above that each of the fibronectin fragments



was suitably used during the culture of the LAK cells using the medium without containing serum.

**Example 9 Determination of Expansion Fold in Culture System of LAK Cells in Serum-Free Medium (Induction and Culture of LAK Cells from Small Number of Cells / Culture Without Dilution Procedures)**

(1) Induction and Culture of LAK Cells

**[0165]** PBMCs which were prepared in item (1) of Example 1 were suspended in XVIVO20 (without containing serum) so as to have a concentration of  $1 \times 10^5$  cells/mL, and thereafter the suspension was put on a plate immobilized with the anti-human CD3 antibody or a 6-well plate immobilized with the anti-human CD3 antibody and the FNfr, prepared in the same manner as in item (2) of Example 1 in a volume of 1 mL/well each, 4 mL of XVIVO20 (without containing serum) was added thereto ( $1 \times 10^4$  cells/cm<sup>2</sup>), and IL-2 was further added thereto so as to have a final concentration of 500 U/mL. These plates were subjected to culture at 37°C in 5% CO<sub>2</sub> (zeroth day of culture). On the second, third and fourth days from the initiation of culture, IL-2 was added thereto so as to have a final concentration of 500 U/mL. The culture was continued, and IL-2 was added every 2 or 3 days on the seventh and subsequent days from the initiation of culture so as to have a final concentration of 500 U/mL. During the culture, dilution procedures of the culture medium were not carried out at all.

**[0166]** On the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. The results are shown in Table 9.

Table 9

Cultured Days	Fibronectin Fragment	Expansion Fold (folds)
15 Days	Control (Without Immobilization of FNfr)	Unproliferated, not detected
15 Days	CH-296	× 64.3

**[0167]** As shown in Table 9, in the group using the culture equipment in which each of the fibronectin fragments was immobilized during the induction of LAK cells from a small number of cells, a high expansion fold was obtained on the fifteenth day from the initiation of culture without necessitating the dilution procedures of the cells during the course of the induction. On the other hand, in the control group, the cells hardly proliferated even on the fifteenth day from the initiation of culture. In other words, it was clarified that the LAK cells could be induced and cultured in a high expansion fold when the LAK cells were induced from a small number of cells using the serum-free medium in the copresence of the fibronectin fragment without necessitating the dilution procedures.

**Example 10 Induction of IL-2R Expression in Culture System of LAK Cells Using Serum-Free Medium (Induction and Culture of LAK Cells from Small Number of Cells / Culture Without Dilution Procedures)**

(1) Induction and Culture of LAK Cells

**[0168]** The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 9.

(2) Determination of Ratio of IL-2R Expression in LAK Cells

**[0169]** The content ratio of the IL-2R expression-positive cells was determined in the same manner as in item (2) of Example 3. The results are shown in Table 10. In the table, the content ratio of the IL-2R expression-positive cells (%) is shown as the ratio of IL-2R expression (%).

Table 10

Cultured Days	Fibronectin Fragment	Ratio of IL-2R Expression (%)
15 Days	Control (Without Immobilization of FNfr)	Unproliferated, not detected
15 Days	CH-296	98.0

**[0170]** As shown in Table 10, in the group using the culture equipment in which each of the fibronectin fragments was immobilized during the induction of the LAK cells from a small number of cells, the ratio of IL-2R expression on the surface of the LAK cells during the culture could be induced at a high level without necessitating the dilution procedures

of the cells during the course of the induction. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the ratio of IL-2R expression when the LAK cells were induced from a small number of cells using the serum-free medium in the copresence of the fibronectin fragment without necessitating the dilution procedures.

#### Example 11 Content Ratio of CD8-Positive Cells in LAK Cell Population Cultured in Serum-Free Medium (AIM V)

##### (1) Induction and Culture of LAK Cells

**[0171]** The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 8.

##### (2) Determination of Content Ratio of CD8-Positive Cell Population in LAK Cells

**[0172]** The content ratio of the CD8-positive cells was determined in the same manner as in item (2) of Example 4. The results are shown in Table 11.

Table 11

Serum Concentration and Medium	Fibronectin Fragment	Content Ratio of CD8-Positive Cells (%)
0% AIM V	Control (Without Immobilization of FNfr)	24.7
0% AIM V	CH-296	45.8
0% AIM V	H-296	62.6

**[0173]** As shown in Table 11, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells using the medium without containing serum, the content ratio of the CD8-positive cells in the LAK cells during the culture could be induced at a high level. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the content ratio of the CD8-positive cells in the LAK cells when the LAK cells were induced using the medium without containing serum in the copresence of the fibronectin fragment.

#### Example 12 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (AIM V)

##### (1) Induction and Culture of LAK Cells

**[0174]** The induction and the culture of LAK cells were carried out in the same manner as in item (3) of Example 1, provided that a medium used during the induction and the culture was changed to AIM V medium containing 1% or 5% human AB serum (hereinafter simply referred to as 1% AIM V or 5% AIM V). The results are shown in Table 12.

Table 12

Serum Concentration and Medium	Cultured Days	Fibronectin Fragment	Expansion Fold (folds)
1% AIM V	11 Days	Control (Without Immobilization of FNfr)	× 7
1% AIM V	11 Days	CH-296	× 156
1 % AIM V	11 Days	H-296	× 39
1% AIM V	15 Days	Control (Without Immobilization of FNfr)	× 3
1% AIM V	15 Days	CH-296	× 651
1% AIM V	15 Days	H-296	× 305
5% AIM V	11 Days	Control (Without Immobilization of FNfr)	× 454
5% AIM V	11 Days	CH-296	× 1087
5% AIM V	11 Days	H-296	× 727

Table continued

Serum Concentration and Medium	Cultured Days	Fibronectin Fragment	Expansion Fold (folds)
5% AIM V	15. Days	Control (Without Immobilization of FNfr)	× 778
5% AIM V	15 Days	CH-296	× 1548
5% AIM V	15 Days	H-296	× 882

**[0175]** As shown in Table 12, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells using the medium (AIM V) containing a low-concentration serum, the expansion fold of the LAK cells was high as compared to that of the control group. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of the LAK cells using the AIM V medium containing a low-concentration serum.

#### Example 13 Effects on Expansion Fold in Culture System of LAK Cells Using Various Low-Serum Media

##### (1) Induction and Culture of LAK Cells

**[0176]** The induction and the culture of LAK cells were carried out in the same manner as in item (3) of Example 1, provided that a medium used during the induction and the culture was changed to XVIVO20 medium, XVIVO10 medium, or AIM V medium, each containing 1% human AB serum (hereinafter simply referred to as 1% XVIVO20, 1% XVIVO10 or 1% AIM V, respectively). The expansion fold in each medium was determined. The results are shown in Table 13.

Table 13

Serum Concentration and Medium	Cultured Days	Fibronectin Fragment	Expansion Fold (folds)
1% XVIVO20	11 Days	Control (Without Immobilization of FNfr)	× 49
1% XVIVO20	11 Days	CH-296	× 153
1% AIM V	11 Days	Control (Without Immobilization of FNfr)	× 79
1% AIM V	11 Days	CH-296	× 832
1% XVIVO20	15 Days	Control (Without Immobilization of FNfr)	× 272
1% XVIVO20	15 Days	CH-296	× 513
1% XVIVO10	15 Days	Control (Without Immobilization of FNfr)	× 113
1% XVIVO10	15 Days	CH-296	× 162
1% AIM V	15 Days	Control (Without Immobilization of FNfr)	× 744
1% AIM V	15 Days	CH-296	× 8928

**[0177]** As shown in Table 13, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells using the medium containing a low-concentration serum, the expansion fold of the LAK cells was high as compared to that of the control group. In addition, this effect was exhibited even when a basal medium was changed. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of the LAK cells using any medium containing a low-concentration serum.

#### Example 14 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium

##### (1) Induction and Culture of LAK Cells

**[0178]** The induction and the culture of LAK cells were carried out in the same manner as in item (3) of Example 1, provided that a medium used during the induction and the culture was changed to XVIVO20 medium containing 0.2%

# EP 1 666 589 A1

human AB serum. The results are shown in Table 14.

Table 14

Serum Concentration and Medium	Cultured Days	Fibronectin Fragment	Expansion Fold (folds)
0.2% XVIVO20	15 Days	Control (Without Immobilization of FNfr)	× 11
0.2% XVIVO20	15 Days	CH-296	× 67

**[0179]** As shown in Table 14, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells using the medium (XVIVO20) containing a low-concentration (0.2%) serum, the expansion fold of the LAK cells was high as compared to that of the control group. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of the LAK cells using the medium containing a low-concentration serum.

## Example 15 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (Expansion by Repetitive Stimulation)

### (1) Induction and Culture of LAK Cells

**[0180]** The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 2, provided that a medium used during the induction and the culture was changed to XVIVO20 medium containing 0.2% human AB serum or XVIVO10 medium containing 1% human AB serum. The results are shown in Table 15.

Table 15

Serum Concentration and Medium	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Expansion Fold (folds)
0.2% XVIVO20	Control (Without Immobilization of FNfr)	Anti-CD3	None	× 11
0.2% XVIVO20	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	× 9
0.2% XVIVO20	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	× 86
1% XVIVO10	Control (Without Immobilization of FNfr)	Anti-CD3	None	× 113
1% XVIVO10	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	× 281
1% XVIVO10	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	× 1282
1% XVIVO10	Control (Without Immobilization of FNfr)	Anti-CD3	None	× 24
1% XVIVO10	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	× 367
1% XVIVO10	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	× 1030
1% XVIVO10	H-296	Anti-CD3+H-296	Anti-CD3+H-296	× 1001

**[0181]** As shown in Table 15, in the group using repeatedly the culture equipment in which each of the fibronectin fragments and the anti-CD3 antibody was immobilized at an early stage and an intermediate stage of the induction of the LAK cells using the medium containing a low-concentration serum (0.2%), the expansion fold of the LAK cells was

high as compared to that of the control group. These expansion folds were far higher than the expansion fold in the group using repeatedly the culture equipment in which only the anti-CD3 antibody was immobilized at an early stage and an intermediate stage of the induction of the LAK cells. In addition, this effect was exhibited even when a basal medium was changed. In other words, it was clarified that the LAK cells could be induced and cultured with a high expansion fold by stimulation using the fibronectin fragment and the anti-CD3 antibody at an early stage and an intermediate stage of induction of the LAK cells even when the medium containing a low-concentration serum was used.

#### Example 16 Induction of IL-2 Receptor (IL-2R) Expression in Culture System of LAK Cells Using Low-Serum Medium

##### (1) Induction and Culture of LAK Cells

**[0182]** The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 2, provided that a medium used during the induction and the culture was changed to XVIVO20 medium containing 0.2% human AB serum or XVIVO10 medium containing 1% human AB serum.

##### (2) Determination of Ratio of IL-2R Expression in LAK Cells

**[0183]** The content ratio of the IL-2R expression-positive cells was determined in the same manner as in item (2) of Example 3. The results are shown in Table 16. In the table, the content ratio of the IL-2R expression-positive cells (%) is shown as the ratio of IL-2R expression (%).

Table 16

Serum Concentration and Medium	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Ratio of IL-2R Expression (%)
0.2% XVIVO20	Control (Without Immobilization of FNfr)	Anti-CD3	None	3.01
0.2% XVIVO20	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	59.08
0.2% XVIVO20	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	77.88
1% XVIVO10	Control (Without Immobilization of FNfr)	Anti-CD3	None	13.77
1% XVIVO10	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	58.28
1% XVIVO10	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	91.11

**[0184]** As shown in Table 16, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage and an intermediate stage of the induction of the LAK cells using the medium containing a low-concentration serum, the ratio of IL-2R expression on the surface of the LAK cells during the culture could be induced at a high level. In addition, this effect was exhibited even when a basal medium was changed. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the ratio of IL-2R expression when the LAK cells were induced using the medium containing a low-concentration serum in the copresence of the fibronectin fragment.

#### Example 17 Content Ratio of CD8-Positive Cells in LAK Cell Population Using Low Serum Medium

##### (1) Induction and Culture of LAK Cells

**[0185]** The induction and the culture of LAK cells were carried out in the same manner as in item (3) of Example 1, provided that a medium used during the induction and the culture was changed to XVIVO20 medium containing 0.2% or 1% human AB serum or XVIVO10 medium containing 1% human AB serum.

## EP 1 666 589 A1

### (2) Determination of Content Ratio of CD8-Positive Cell Population in LAK Cells

**[0186]** The content ratio of the CD8-positive cells was determined in the same manner as in item (2) of Example 4. The results are shown in Table 17.

Table 17

Serum Concentration and Medium	Fibronectin Fragment	Content Ratio of CD8-Positive Cells (%)
0.2% XVIVO20	Control (Without Immobilization of FNfr)	50.9
0.2% XVIVO20	CH-296	70.9
1% XVIVO20	Control (Without Immobilization of FNfr)	36.2
1% XVIVO20	CH-296	53.6
1% XVIVO20	H-296	50.6
1% XVIVO10	Control (Without Immobilization of FNfr)	19.9
1% XVIVO10	CH-296	45.5
1% XVIVO10	H-296	53.6

**[0187]** As shown in Table 17, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells using the medium containing a low-concentration serum, the content ratio of the CD8-positive cells in the LAK cells during the culture could be induced at a high level. In addition, this effect was exhibited even when a basal medium was changed. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the content ratio of the CD8-positive cells in the LAK cells when the LAK cells were induced using the medium containing a low-concentration serum in the copresence of the fibronectin fragment.

### Example 18 Content Ratio of CD8-Positive Cells in LAK Cell Population Using Low Serum Medium (Expansion by Repetitive Stimulation)

#### 1) Induction and Culture of LAK Cells

**[0188]** The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 2, provided that a medium used during the induction and the culture was changed to XVIVO20 medium containing 0.2% human AB serum or XVIVO10 medium containing 1% human AB serum.

### (2) Determination of Content Ratio of CD8-Positive Cell Population in LAK Cells

**[0189]** The content ratio of the CD8-positive cells was determined in the same manner as in item (2) of Example 4. The results are shown in Table 18.

Table 18

Serum Concentration and Medium	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Content Ratio of CD8-Positive Cells (%)
0.2% XVIVO20	Control (Without Immobilization of FNfr)	Anti-CD3	Anti-CD3	38.9
0.2% XVIVO20	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	44.5
1% XVIVO10	Control (Without Immobilization of FNfr)	Anti-CD3	Anti-CD3	25.6
1% XVIVO10	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	38.3

[0190] As shown in Table 18, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage or an intermediate stage of the induction of the LAK cells using the medium containing a low-concentration serum, the content ratio of the CD8-positive cells in the LAK cells during the culture could be induced at a high level. In addition, this effect was exhibited even when a basal medium was changed. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the content ratio of the CD8-positive cells in the LAK cells when the LAK cells were induced using the medium containing a low-concentration serum in the copresence of the fibronectin fragment.

#### Example 19 Determination of Expansion Fold in Culture System of LAK Cells Using Serum-Free Medium

##### (1) Induction and Culture of LAK Cells

[0191] The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 5, provided that a medium used during the induction and the culture was changed to XVIVO10 medium or AIM V medium without containing serum. The results are shown in Table 19.

Table 19

Serum Concentration and Medium	Cultured Days	Fibronectin Fragment	Expansion Fold (folds)
0% XVIVO10	11 Days	Control (Without Immobilization of FNfr)	× 32
0% XVIVO10	11 Days	CH-296	× 95
0% XVIVO10	15 Days	Control (Without Immobilization of FNfr)	× 205
0% XVIVO10	15 Days	CH-296	× 407
0% XVIVO10	11 Days	Control (Without Immobilization of FNfr)	× 29
0% XVIVO10	11 Days	H-296	× 78
0% XVIVO10	15 Days	Control (Without Immobilization of FNfr)	× 27
0% XVIVO10	15 Days	H-296	× 194
0% AIM V	11 Days	Control (Without Immobilization of FNfr)	× 25
0% AIM V	11 Days	CH-296	× 85
0% AIM V	11 Days	H-296	× 69
0% AIM V	15 Days	Control (Without Immobilization of FNfr)	× 61
0% AIM V	15 Days	CH-296	× 202
0% AIM V	15 Days	H-296	× 392

[0192] As shown in Table 19, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells using the medium without containing serum, the expansion fold of the LAK cells was high as compared to that of the control group. In addition, this effect was exhibited even when a basal medium was changed. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of the LAK cells using the medium without containing serum.

#### Example 20 Determination of Expansion Fold in Culture System of LAK Cells Using Serum-Free Medium (Expansion by Repetitive Stimulation)

##### (1) Induction and Culture of LAK Cells

[0193] The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 6, provided that a medium used during the induction and the culture was changed to XVIVO10 medium without containing serum. The results are shown in Table 20.

Table 20

Serum Concentration and Medium	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Expansion Fold (folds)
0% XVIVO10	Control (Without Immobilization of FNfr)	Anti-CD3	None	× 27
0% XVIVO10	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	× 288
0% XVIVO10	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	× 845
0% XVIVO10	H-296	Anti-CD3+H-296	Anti-CD3+H-296	× 893

**[0194]** As shown in Table 20, in the group using repeatedly the culture equipment in which each of the fibronectin fragments and the anti-CD3 antibody was immobilized at an early stage and an intermediate stage of the induction of the LAK cells using the medium without containing serum, the expansion fold of the LAK cells was high as compared to that of the control group. These expansion folds were far higher than the expansion fold in the group using repeatedly the culture equipment in which only the anti-CD3 antibody was immobilized at an early stage and an intermediate stage of the induction of the LAK cells. In addition, this effect was exhibited even when a basal medium was changed. In other words, it was clarified that the LAK cells could be induced and cultured with a high expansion fold by stimulation using the fibronectin fragment and the anti-CD3 antibody at an early stage and an intermediate stage of induction of the LAK cells even when the medium without containing serum was used.

#### Example 21 Induction of IL-2R Expression in Culture System of LAK Cells Using Serum-Free Medium

##### (1) Induction and Culture of LAK Cells

**[0195]** The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 6, provided that a medium used during the induction and the culture was changed to XVIVO10 medium without containing serum.

##### (2) Determination of Ratio of IL-2R Expression in LAK Cells

**[0196]** The content ratio of the IL-2R expression-positive cells was determined in the same manner as in item (2) of Example 3. The results are shown in Table 21. In the table, the content ratio of the IL-2R expression-positive cells (%) is shown as the ratio of IL-2R expression (%).

Table 21

Serum Concentration and Medium	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Ratio of IL-2R Expression (%)
0% XVIVO10	Control (Without Immobilization of FNfr)	Anti-CD3	None	24.99
0% XVIVO10	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	80.58
0% XVIVO10	CH-296	Anti-CD3+CH-296	None	40.17
0% XVIVO10	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	92.59
0% XVIVO10	H-296	Anti-CD3+H-296	None	30.09
0% XVIVO10	H-296	Anti-CD3+H-296	Anti-CD3+H-296	87.15

**[0197]** As shown in Table 21, in the group using the culture equipment in which each of the fibronectin fragments was



immobilized at an early stage and an intermediate stage of the induction of the LAK cells using the medium without containing serum, the ratio of IL-2R expression on the surface of the LAK cells during the culture could be induced at a high level. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the ratio of IL-2R expression when the LAK cells were induced using the medium without containing serum in the copresence of the fibronectin fragment.

#### Example 22 Content Ratio of CD8-Positive Cells in Cultured LAK Cell Population Using Serum-Free Medium

##### (1) Induction and Culture of LAK Cells

**[0198]** The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 5, provided that a medium used during the induction and the culture was changed to XVIVO20, XVIVO10 or AIM V medium, each without containing serum.

##### (2) Determination of Content Ratio of CD8-Positive Cell Population in LAK Cells

**[0199]** The content ratio of the CD8-positive cells was determined in the same manner as in item (2) of Example 4. The results are shown in Table 22.

Table 22

Serum Concentration and Medium	Fibronectin Fragment	Content Ratio of CD8-Positive Cells (%)
0% XVIVO20	Control (Without Immobilization of FNfr)	20.01
0% XVIVO20	CH-296	64.48
0% XVIVO10	Control (Without Immobilization of FNfr)	27.91
0% XVIVO10	CH-296	47.72
0% AIM V	Control (Without Immobilization of FNfr)	21.14
0% AIM V	CH-296	58.8
0% XVIVO10	Control (Without Immobilization of FNfr)	16.53
0% XVIVO10	CH-296	35.22
0% XVIVO10	H-296	27.29

**[0200]** As shown in Table 22, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells using the medium without containing serum, the content ratio of the CD8-positive cells in the LAK cells during the culture could be induced at a high level. In addition, this effect was exhibited even when a basal medium was changed. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the content ratio of the CD8-positive cells in the LAK cells when the LAK cells were induced using the medium without containing serum in the copresence of the fibronectin fragment.

#### Example 23 Content Ratio of CD8-Positive Cells in LAK Cell Population Using Serum-Free Medium (Expansion by Repetitive Stimulation)

##### (1) Induction and Culture of LAK Cells

**[0201]** The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 6, provided that a medium used during the induction and the culture was changed to XVIVO20 or XVIVO10 medium, without containing serum.

## (2) Determination of Content Ratio of CD8-Positive Cells in LAK Cells

**[0202]** The content ratio of the CD8-positive cells was determined in the same manner as in item (2) of Example 4. The results are shown in Table 23.

Table 23

Serum Concentration and Medium	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Content Ratio of CD8-Positive Cells (%)
0% XVIVO20	Control (Without Immobilization of FNfr)	Anti-CD3	None	20.01
0% XVIVO20	CH-296	Anti-CD3+CH-296	None	64.48
0% XVIVO20	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	35.21
0% XVIVO10	Control (Without Immobilization of FNfr)	Anti-CD3	None	27.91
0% XVIVO10	CH-296	Anti-CD3+CH-296	None	47.72
0% XVIVO10	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	37.97
0% XVIVO10	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	50.22
0% XVIVO10	Control (Without Immobilization of FNfr)	Anti-CD3	None	16.53
0% XVIVO10	CH-296	Anti-CD3+CH-296	None	35.22
0% XVIVO10	H-296	Anti-CD3+H-296	None	27.29
0% XVIVO10	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	75.33
0% XVIVO10	H-296	Anti-CD3+H-296	Anti-CD3+H-296	61.08

**[0203]** As shown in Table 23, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage or an early to intermediate stage of the induction of the LAK cells using the medium without containing serum, the content ratio of the CD8-positive cells in the LAK cells during the culture could be induced at a high level. In addition, this effect was exhibited even when a basal medium was changed. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the content ratio of CD8-positive cells in the LAK cells when the LAK cells were induced using the medium containing a low-concentration serum in the copresence of the fibronectin fragment.

Example 24 Induction of IL-2R Expression in Culture System of LAK Cells Using Low-Serum Medium (Induction and Culture of LAK Cells from Small Number of Cells / Culture Without Dilution Procedures)

## (1) Induction and Culture of LAK Cells

**[0204]** PBMCs which were prepared in item (1) of Example 1 were suspended in XVIVO20 containing 1% human AB serum (hereinafter simply referred to as 1% XVIVO20) so as to have a concentration of  $1 \times 10^5$  cells/mL or  $5 \times 10^4$  cells/mL, and thereafter the suspension was put on a plate immobilized with the anti-human CD3 antibody or a 6-well plate immobilized with the anti-human CD3 antibody and the FNfr, prepared in the same manner as in item (2) of Example 1 in a volume of 1 mL/well each, 4 mL of 1% XVIVO20 was added thereto ( $1 \times 10^4$  cells/cm<sup>2</sup> or  $5 \times 10^3$  cells/cm<sup>2</sup>), and IL-2 (manufactured by Shionogi & Co., Ltd.) was further added thereto so as to have a final concentration of 500 U/mL. These plates were subjected to culture at 37°C in 5% CO<sub>2</sub> (zeroth day of culture). On the second, third and fourth days from the initiation of culture, IL-2 was added thereto so as to have a final concentration of 500 U/mL. The culture was continued, and IL-2 was added every 2 or 3 days on the seventh and subsequent days from the initiation of culture so as to have a final concentration of 500 U/mL. During the culture, dilution procedures of the culture medium were not carried out at all. On the sixteenth day from the initiation of culture, the cells were collected.

## (2) Determination of Ratio of IL-2R Expression in LAK Cells

**[0205]** The content ratio of the IL-2R expression-positive cells was determined in the same manner as in item (2) of Example 3. In the table, the content ratio of the IL-2R expression-positive cells (%) is shown as the ratio of IL-2R expression (%). The results are shown in Table 24.

Table 24

Serum Concentration and Medium	Fibronectin Fragment	Ratio of IL-2R Expression (%)
1% XVIVO20	Control (Without Immobilization of FNfr)	12.15
	CH-296	97.47
	H-296	95.43

**[0206]** As shown in Table 24, in the group using the culture equipment in which each of the fibronectin fragments was immobilized during the induction of the LAK cells from a small number of cells, the ratio of IL-2R expression on the surface of the LAK cells during the culture could be induced at a high level without necessitating the dilution procedures of the cells during the course of the induction. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the ratio of IL-2R expression when the LAK cells were induced from a small number of cells using the low-serum medium in the copresence of the fibronectin fragment without necessitating the dilution procedures at all.

Example 25 Determination of Cytotoxic Activity in Culture System of LAK Cells Using Serum-Free or Low-Serum Medium

## (1) Induction and Culture of LAK Cells

**[0207]** The induction and the culture of LAK cells were carried out in the same manner as in item (3) of Example 1, provided that a medium used during the induction and the culture was changed to XVIVO20 medium containing from 0% to 5% human AB serum, or AIM V medium containing from 0% to 5% human AB serum, or XVIVO10 medium containing 5% human AB serum.

## (2) Determination of Cytotoxic Activity of Cultured LAK Cells

**[0208]** The cytotoxic activity of LAK prepared in item (1) of Example 25 on the fifteenth day after the culture was evaluated by a determination method for cytotoxic activity using Calcein-AM [Lichtenfels R., et al., *J. Immunol. Methods*, **172(2)**, 227-239 (1994)]. Cell line K562, Daudi was suspended in RPMI 1640 medium containing 5% FBS (manufactured by Bio Whittaker) so as to have a concentration of  $1 \times 10^6$  cells/mL. Thereafter, Calcein-AM (manufactured by Dotite) was added to the suspension so as to have a final concentration of 25  $\mu$ M, and the cells were cultured at 37°C for 1 hour. The cells were washed with a medium not containing Calcein-AM, to give Calcein-labeled target cells.

**[0209]** LAK cells prepared in item (1) of Example 25 were stepwise diluted with RPMI containing 5% human serum (hereinafter simply referred to as 5HRPMI) so as to have a concentration of from  $1 \times 10^6$  to  $3 \times 10^6$  cells/mL as effector cells. Thereafter, each of the dilutions was put in each well of 96-well cell culture plate in an amount of 100  $\mu$ L/well each. Thereto were added the Calcein-labeled target cells prepared to have a concentration of  $1 \times 10^5$  cells/mL in an amount of 100  $\mu$ L/well each. The plate containing the above-mentioned cell suspension was centrifuged at  $400 \times g$  for 1 minute, and thereafter incubated in a wet-type CO<sub>2</sub> incubator at 37°C for 4 hours. After 4 hours, 100  $\mu$ L of the culture supernatant was collected from each well, and the amount of calcein released (fluorescence intensity) into the culture supernatant was determined by using fluorescence plate reader (485 nm/538 nm). The cytotoxic activity of the LAK cells was calculated by the following formula 1:

Formula 1:

Cytotoxic Activity (%)

$$= \frac{[(\text{Found Value in Each Well} - \text{Minimum Released Amount}) / (\text{Maximum Released Amount} - \text{Minimum Released Amount})] \times 100}$$

**[0210]** In the above formula, the minimum released amount is the amount of calcein released in the well containing only the target cells, showing the amount of calcein naturally released from the target cells. In addition, the maximum released amount refers to the amount of calcein released when the cells are completely disrupted by adding a surfactant Triton X-100 (manufactured by Nakalai Tesque, Inc.) so as to have a final concentration of 0.05% to the target cells. The results are shown in Table 25. In the table, "E/T" shows a ratio on the basis of the number of the effector cells to the number of the target cells (effector cells/target cells).

Table 25

Serum Concentration and Medium	Fibronectin Fragment	E/T	Cytotoxic Activity (%) (Target Cells K562)	Cytotoxic Activity (%) (Target Cells Daudi)
0% XVIVO20	Control (Without Immobilization of FNfr)	20	28.7	13.3
0% XVIVO20	CH-296	20	46.7	23.8
0% XVIVO20	H-296	20	49.9	19.0
0.2% XVIVO20	Control (Without Immobilization of FNfr)	10	13.3	11.6
0.2% XVIVO20	CH-296	10	18.2	18.6
1% XVIVO20	Control (Without Immobilization of FNfr)	20	36.5	24.8
1% XVIVO20	H-296	20	62.8	39.0
5% XVIVO20	Control (Without Immobilization of FNfr)	30	57.0	56.6
5% XVIVO20	CH-296	30	78.1	59.1
0% AIM V	Control (Without Immobilization of FNfr)	30	25.2	23.4
0% AIM V	CH-296	30	36.8	28.1
5% AIM V	Control (Without Immobilization of FNfr)	30	55.3	49.8
5% AIM V	CH-296	30	77.2	53.6
5% AIM V	Control (Without Immobilization of FNfr)	10	35.1	50.5
5% AIM V	CH-296	10	71.6	51.8
5% AIM V	H-296	10	73.9	57.8
5% XVIVO10	Control (Without Immobilization of FNfr)	10	72.6	51.1
5%XVIVO10	CH-296	10	84.6	57.4
5%XVIVO10	H-296	10	89.3	69.5

**[0211]** As shown in Table 25, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells using the medium without containing serum or the medium containing a low-concentration serum, the cytotoxic activity of the LAK cells was high as compared to that of the control

group. In addition, this effect was exhibited even when a basal medium was changed. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of the LAK cells using the medium without containing serum or the medium containing a low-concentration serum.

**Example 26 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (AIM V) (Expansion by Repetitive Stimulation)-1**

(1) Induction and Culture of LAK Cells

**[0212]** The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 2, provided that a medium used during the induction and the culture was changed to AIM V medium containing 1% human AB serum. The results are shown in Table 26.

Table 26

Serum Concentration and Medium	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Expansion Fold (folds)
1% AIM V	Control (Without Immobilization of FNfr)	Anti-CD3	Anti-CD3	× 130
1% AIM V	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	× 2419

**[0213]** As shown in Table 26, in the group using repeatedly the culture equipment in which each of the fibronectin fragments and the anti-CD3 antibody was immobilized at an early stage and an intermediate stage of the induction of the LAK cells using AIM V medium containing a low-concentration serum (1%), the expansion fold of the LAK cells was high as compared to that of the control group. These expansion folds were far higher than the expansion fold in the group using repeatedly the culture equipment in which only the anti-CD3 antibody was immobilized at an early stage and an intermediate stage of the induction of the LAK cells. In other words, it was clarified that the LAK cells could be induced and cultured with a high expansion fold by stimulation using the fibronectin fragment and the anti-CD3 antibody at an early stage and an intermediate stage of induction of the LAK cells even when the medium containing a low-concentration serum was used.

**Example 27 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (AIM V) (Expansion by Repetitive Stimulation)-2**

(1) Immobilization of Anti-Human CD3 Antibody and FN Fragment

**[0214]** An anti-human CD3 antibody and an FN fragment were immobilized to a culture equipment (vessel) used in the following experiment. Concretely, 1.9 mL (in a case of a 12-well plate) or 2 mL (in a case of 12.5 cm<sup>2</sup> flask) each of PBS containing an anti-human CD3 antibody (final concentration 5 µg/mL) was added to a 12-well cell culture plate or a 12.5 cm<sup>2</sup> cell culture flask (manufactured by Falcon). Upon the addition, each of the fibronectin fragments (FNfr) listed in Preparation Example 1 was added to a group with addition of an FN fragment so as to have a final concentration of 10 µg/mL (in the case of the 12-well plate) or 25 µg/mL (in the case of the 12.5 cm<sup>2</sup> flask). As a control, there was also set a group without addition of the FNfr.

**[0215]** After these culture equipments were incubated at room temperature for 5 hours, the culture equipments were stored at 4°C until use. Immediately before use, PBS containing the antibody and the FNfr was removed by aspiration from these culture equipments, and thereafter each well was washed twice with PBS, and then once with AIM V medium, and the culture equipments were subjected to each experiment.

(2) Induction and Culture of LAK Cells

**[0216]** PBMCs which were prepared in item (1) of Example 1 were suspended in 1% AIM V so as to have a concentration of  $5 \times 10^5$  cells/mL, and thereafter the suspension was put on a plate immobilized with the anti-human CD3 antibody or a plate immobilized with the anti-human CD3 antibody and the FNfr, prepared in item (1) of Example 27 in a volume of 1 mL/well each, and IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These plates were subjected to culture at 37°C in 5% CO<sub>2</sub> (zeroth day of culture). On the second and third days from the initiation of culture,

1% AIM V containing 1000 U/mL IL-2 was added thereto in a volume of 1 mL/well each. On the fourth day from the initiation of culture, the culture medium was transferred to a 25 cm<sup>2</sup> cell culture flask (manufactured by Falcon) to which nothing was immobilized, 7 mL of 1% AIM V was further added thereto, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the seventh day from the initiation of culture, a part of a culture medium of which cell concentration was adjusted to  $2 \times 10^5$  cells/mL with 1% AIM V was transferred to a fresh flask to which nothing was immobilized, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the ninth day from the initiation of culture, a part of a culture medium of which cell concentration was adjusted to  $2 \times 10^5$  cells/mL with 1% AIM V was transferred to a flask immobilized with the anti-human CD3 antibody or a flask immobilized with the anti-human CD3 antibody and the FNfr (provided that the concentration of the anti-human CD3 antibody used in the immobilization was 0.5 µg/mL), prepared in the same manner as in item (1) of Example 27, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the twelfth day from the initiation of culture, a part of a culture medium of which cell concentration was properly adjusted to  $2 \times 10^5$  cells/mL with 1% AIM V was transferred again to a fresh flask to which nothing was immobilized, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. The expansion was carried out under the same conditions at  $n = 3$ , and each of the results of its mean  $\pm$  standard deviation is shown in Table 27.

Table 27

Serum Concentration and Medium	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Expansion Fold (folds)
1% AIM V	Control (Without Immobilization of FNfr)	Anti-CD3	None	$\times 3392 \pm 779$
1% AIM V	Without Immobilization of FNfr	Anti-CD3	Anti-CD3	$\times 4389 \pm 1234$
1% AIM V	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	$\times 8545 \pm 1328$
mean $\pm$ standard deviation				

**[0217]** As shown in Table 27, in the group using repeatedly the culture equipment in which each of the fibronectin fragments and the anti-CD3 antibody was immobilized at an early stage and an intermediate stage of the induction of the LAK cells using the medium containing a low-concentration serum (1%), the expansion fold of the LAK cells was high as compared to that of the control group. These expansion folds were far higher than the expansion fold in the group using repeatedly the culture equipment in which only the anti-CD3 antibody was immobilized at an early stage and an intermediate stage of the induction of the LAK cells. In other words, it was clarified that the LAK cells could be induced and cultured with a high expansion fold by stimulation using the fibronectin fragment and the anti-CD3 antibody at an early stage and an intermediate stage of induction of the LAK cells even when the medium containing a low-concentration serum was used.

#### Example 28 Content Ratio of CD8-Positive Cells in LAK Cell Population Using Serum-Free Medium (AIM V) (Expansion by Repetitive Stimulation)

##### (1) Induction and Culture of LAK Cells

**[0218]** The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 2, provided that a medium used during the induction and the culture was changed to AIM V medium without containing human AB serum.

##### (2) Determination of Content Ratio of CD8-Positive Cell Population in LAK Cells

**[0219]** The content ratio of the CD8-positive cells was determined in the same manner as in item (2) of Example 4. The results are shown in Table 28.

Table 28

Serum Concentration and Medium	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Content Ratio of CD8-Positive Cells (%)
0% AIM V	Control (Without Immobilization of FNfr)	Anti-CD3	None	43.8
0% AIM V	CH-296	Anti-CD3+CH-296	None	64.4
0% AIM V	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	76.6

[0220] As shown in Table 28, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage or an intermediate stage of the induction of the LAK cells using AIM V medium without containing serum, the content ratio of the CD8-positive cells in the cell population after the culture of the LAK cells during the culture could be induced at a high level. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the content ratio of the CD8-positive cells in the LAK cells when the LAK cells were induced using a medium containing a low-concentration serum in the copresence of the fibronectin fragment.

#### Example 29 Content Ratio of CD8-Positive Cells in LAK Cell Population Using Low-Serum Medium (AIM V) (Expansion by Repetitive Stimulation)

##### (1) Induction and Culture of LAK Cells

[0221] The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 2, provided that a medium used during the induction and the culture was changed to AIM V medium containing 1% human AB serum.

##### (2) Determination of Content Ratio of CD8-Positive Cell Population in LAK Cells

[0222] The content ratio of the CD8-positive cells was determined in the same manner as in item (2) of Example 4. The results are shown in Table 29.

Table 29

Serum Concentration and Medium	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Content Ratio of CD8-Positive Cells (%)
1% AIM V	Control (Without Immobilization of FNfr)	Anti-CD3	None	39.2
1% AIM V	Control (Without Immobilization of FNfr)	Anti-CD3	Anti-CD3	60.0
1% AIM V	CH-296	Anti-CD3+CH-296	None	49.2
1% AIM V	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	71.0

[0223] As shown in Table 29, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage or an early to intermediate stage of the induction of the LAK cells using AIM V medium containing a low-concentration serum, the content ratio of the CD8-positive cells in the LAK cell population after the culture could be induced at a high level. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the content ratio of the CD8-positive cells in the LAK cells when the LAK cells were induced using the medium containing a low-concentration serum in the copresence of the fibronectin fragment.

Example 30 Induction of IL-2 Receptor (IL-2R) Expression in Culture System of LAK Cells Using Serum-Free Medium (AIM V)

(1) Induction and Culture of LAK Cells

**[0224]** The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 2, provided that a medium used during the induction and the culture was changed to AIM V medium without containing human AB serum.

(2) Determination of Ratio of IL-2R Expression in LAK Cells

**[0225]** The content ratio of the IL-2R expression-positive cells was determined in the same manner as in item (2) of Example 3. The results are shown in Table 30. In the table, the content ratio of the IL-2R expression-positive cells (%) is shown as the ratio of IL-2R expression (%).

Table 30

Serum Concentration and Medium (%)	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Ratio of IL-2R Expression (%)
0% AIM V	Control (Without Immobilization of FNfr)	Anti-CD3	None	22.0
0% AIM V	Control (Without Immobilization of FNfr)	Anti-CD3	Anti-CD3	39.9
0% AIM V	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	51.9

**[0226]** As shown in Table 30, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage and an intermediate stage of the induction of the LAK cells using AIM V medium without containing serum, the ratio of IL-2R expression on the surface of the LAK cells after the culture could be induced at a high level. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the ratio of IL-2R expression when the LAK cells were induced using the medium without containing serum in the copresence of the fibronectin fragment.

Example 31 Induction of IL-2 Receptor (IL-2R) Expression in Culture System of LAK Cells Using Low-Serum Medium (AIM V) (Expansion by Repetitive Stimulation)

(1) Induction and Culture of LAK Cells

**[0227]** The induction and the culture of LAK cells were carried out in the same manner as in item (1) of Example 2, provided that a medium used during the induction and the culture was changed to AIM V medium containing 1% human AB serum.

(2) Determination of Ratio of IL-2R Expression in LAK Cells

**[0228]** The content ratio of the IL-2R expression-positive cells was determined in the same manner as in item (2) of Example 3. The results are shown in Table 31. In the table, the content ratio of the IL-2R expression-positive cells (%) is shown as the ratio of IL-2R expression (%).



Table 31

Serum Concentration and Medium (%)	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	Ratio of IL-2R Expression (%)
1% AIM V	Control (Without Immobilization of FNfr)	Anti-CD3	None	23.6
1% AIM V	CH-296	Anti-CD3+CH-296	None	27.2
1% AIM V	CH-296	Anti-CD3+CH-296	Anti-CD3+CH-296	69.1

**[0229]** As shown in Table 31, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage and an intermediate stage of the induction of the LAK cells using the medium containing a low-concentration serum, the ratio of IL-2R expression on the surface of the LAK cells during the culture could be induced at a high level. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the ratio of IL-2R expression when the LAK cells were induced using the medium containing a low-concentration serum in the copresence of the fibronectin fragment.

#### Example 32 Content Ratio of CD8-Positive Cells in LAK Cell Population Using Low-Serum Medium (AIM V)

##### (1) Induction and Culture of LAK Cells

**[0230]** The induction and the culture of LAK cells were carried out in the same manner as in item (3) of Example 1, provided that a medium used during the induction and the culture was changed to AIM V medium containing 1% human AB serum.

##### (2) Determination of Content Ratio of CD8-Positive Cell Population in LAK Cells

**[0231]** The content ratio of the CD8-positive cells was determined in the same manner as in item (2) of Example 4. The results are shown in Table 32.

Table 32

Serum Concentration and Medium	Fibronectin Fragment	Content Ratio of CD8-Positive Cells (%)
1% AIM V	Control (Without Immobilization of FNfr)	41.02
1% AIM V	CH-296	56.78

**[0232]** As shown in Table 32, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells using AIM V medium containing a low-concentration serum, the content ratio of the CD8-positive cells in the LAK cells during the culture could be induced at a high level. In other words, it was clarified that the LAK cells could be induced and cultured with increasing the content ratio of the CD8-positive cells in the LAK cells when the LAK cells were induced using the medium containing a low-concentration serum in the copresence of the fibronectin fragment.

#### Example 33 Determination of Cytotoxic Activity in Culture System of LAK Cells Using Serum-Free Medium or Low-Serum Medium

##### (1) Induction and Culture of LAK Cells

**[0233]** The induction and the culture of LAK cells were carried out in the same manner as in item (3) of Example 1 or in item (1) of Example 2, provided that a medium used during the induction and the culture was changed to XVIVO10, XVIVO20 or AIM V medium, containing 0% or 1% human AB serum.

## (2) Determination of Cytotoxic Activity of Cultured LAK Cells

**[0234]** The cytotoxic activity of LAK on the fifteenth day after the culture was determined in the same manner as in item (2) of Example 25. The results are shown in Table 33.

Table 33

Serum Concentration and Medium (%)	Fibronectin Fragment	Stimulation on 0th Day from Initiation of Culture	Stimulation on 9th Day from Initiation of Culture	E/T	Cytotoxic Activity (%) Target Cells K562	Cytotoxic Activity (%) Target Cells Daudi
0% XVIVO10	Control (Without Immobilization of FNfr)	Anti-CD3	None	10	11.88	10.84
0% XVIVO10	CH-296	Anti-CD3 + CH-296	None	10	19.55	26.23
1% AIM V Control	(Without Immobilization of FNfr)	Anti-CD3	None	10	16.82	33.02
1% AIM V	CH-296	Anti-CD3 + CH-296	None	10	46.54	42.3
0% XVIVO20	Control (Without Immobilization of FNfr)	Anti-CD3	Anti-CD3	10	24.5	13.3
0% XVIVO20	CH-296	Anti-CD3 + CH-296	Anti-CD3 + CH-296	10	30.8	23.3
1% XVIVO20	Control (Without Immobilization of FNfr)	Anti-CD3	Anti-CD3	10	18.5	13.9
1% XVIVO20	CH-296	Anti-CD3 + CH-296	Anti-CD3 + CH-296	10	30.8	28.5
1% XVIVO10	Control (Without Immobilization of FNfr)	Anti-CD3	Anti-CD3	10	13.8	8.4
1% XVIVO10	CH-296	Anti-CD3 + CH-296	Anti-CD3 + CH-296	10	33.0	31.8

**[0235]** As shown in Table 33, in the group using the culture equipment in which each of the fibronectin fragments was immobilized at an early stage or at an early stage and an intermediate stage of the induction of the LAK cells using the medium without containing serum or the medium containing a low-concentration serum, the cytotoxic activity of the LAK cells was high as compared to that of the control group. In addition, this effect was exhibited even when a basal medium was changed. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of the LAK cells using the medium without containing serum or the medium containing a low-concentration serum.

Example 34 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (XVIVO10) (Culture Using CO<sub>2</sub> Gas-Permeable Bag for Cell Culture)

(1) Immobilization of Anti-Human CD3 antibody and FN Fragment

**[0236]** An anti-human CD3 antibody and an FN fragment were immobilized to a culture equipment (CO<sub>2</sub> gas-permeable bag for cell culture) used in the following experiment. Concretely, 20 mL each of PBS containing an anti-human CD3

antibody (final concentration: 5 µg/mL) was added to a 85 cm<sup>2</sup> CO<sub>2</sub> gas-permeable bag for cell culture (manufactured by Baxter). Upon the addition, each of the fibronectin fragments (FNfr) described in Preparation Example 1 was added to a group with addition of an FN fragment so as to have a final concentration of 42.5 µg/mL. As a control, there was also set a group without addition of the FNfr.

[0237] After these culture equipments were incubated at room temperature for 5 hours, the culture equipments were stored at 4°C until use. Immediately before use, PBS containing the antibody and the FNfr was removed from these culture equipments, and thereafter each bag was washed twice with PBS, and once with a XVIVO10 medium containing 1% human AB serum (hereinafter simply referred to as 1% XVIVO10) to be subjected to each experiment.

## (2) Induction and Culture of LAK Cells

[0238] PBMCs which were prepared in item (1) of Example 1 were suspended in 1% XVIVO10 so as to have a concentration of  $1 \times 10^6$  cells/mL, and thereafter the cell suspension was placed in an amount of 10 mL/bag each into a CO<sub>2</sub> gas-permeable bag for cell culture, immobilized with the anti-human CD3 antibody or a CO<sub>2</sub> gas-permeable bag for cell culture, immobilized with the anti-human CD3 antibody and the FNfr, prepared in item (1) of Example 34, and IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These CO<sub>2</sub> gas-permeable bags for cell culture were incubated at 37°C in 5% CO<sub>2</sub> (zeroth day of culture). On the second day after the initiation of culture, 1% XVIVO10 containing 1000 U/mL IL-2 was added thereto in an amount of 20 mL/bag each. On the fourth day after the initiation of culture, IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the sixth day after the initiation of culture, 1% XVIVO10 was added thereto in an amount of 30 mL/bag each, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the eighth day after the initiation of culture, a part of a culture medium was properly diluted, and thereafter the dilution was transferred to a 85 cm<sup>2</sup> CO<sub>2</sub> gas-permeable bag for cell culture to which nothing was immobilized, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the eleventh and thirteenth days after the initiation of culture, IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the fifteenth day after the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. The results are shown in Table 34.

Table 34

Serum Concentration and Medium	Cultured Days	Fibronectin Fragment	Expansion Fold (folds)
1% XVIVO10	15 Days	Control (Without Immobilization of FNfr)	× 34
1% XVIVO10	15 Days	CH-296	× 101

[0239] As shown in Table 34, in the group using the CO<sub>2</sub> gas-permeable bag for cell culture in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells using the medium (XVIVO10) containing a low-concentration serum (1%) and the CO<sub>2</sub> gas-permeable bag for cell culture, the expansion fold of the LAK cells was high as compared to that of the control group. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of the LAK cells using the medium containing a low-concentration serum and the CO<sub>2</sub> gas-permeable bag for cell culture.

### Example 35 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (XVIVO10) (Culture in Combination of Flask for Cell Culture and CO<sub>2</sub> Gas-Permeable Bag for Cell Culture)

#### (1) Immobilization of Anti-Human CD3 Antibody and FN Fragment

[0240] An anti-human CD3 antibody and an FN fragment were immobilized to a culture equipment (25 cm<sup>2</sup> flask for cell culture) used in the following equipment. Concretely, 6 mL each of PBS containing an anti-human CD3 antibody (final concentration: 5 µg/mL) was added to a 25 cm<sup>2</sup> flask for cell culture (manufactured by Corning). Upon the addition, each of the fibronectin fragments (FNfr) described in Preparation Example 1 was added to a group with addition of an FN fragment so as to have a final concentration of 42.5 µg/mL. As a control, there was also set a group without addition of the FNfr.

[0241] After these culture equipments were incubated at room temperature for 5 hours, the culture equipments were stored at 4°C until use. Immediately before use, PBS containing the antibody and the FNfr was removed from these culture equipments, and each flask was washed twice with PBS, and once with XVIVO10 medium containing 1% human AB serum (hereinafter simply referred to as 1% XVIVO10) to be subjected to each experiment.

## (2) Induction and Culture of LAK Cells

**[0242]** PBMCs which were prepared in item (1) of Example 1 were suspended in 1% XVIVO10 so as to have a concentration of  $1 \times 10^6$  cells/mL, and thereafter the cell suspension was placed in an amount of 3 mL/flask each into the flask immobilized with the anti-human CD3 antibody or the flask immobilized with an anti-human CD3 antibody and the FNfr, prepared in item (1) of Example 35, and IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These flasks were incubated at 37°C in 5% CO<sub>2</sub> (zeroth day of culture). On the first day or the second day after the initiation of culture, 1% XVIVO10 containing 1000 U/mL IL-2 was added thereto in an amount of 7 mL/flask each. Hereinafter, the incubation was carried out depending upon the stimulation period with the anti-CD3 antibody  $\pm$  CH-296 by two methods. (i) On the fourth day after the initiation of culture, the culture medium was transferred to a 85 cm<sup>2</sup> CO<sub>2</sub> gas-permeable bag for cell culture to which nothing was immobilized. Thereafter, 1% XVIVO10 was added thereto in an amount of 20 mL/bag each, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. Further, on the sixth day after the initiation of culture, 1% XVIVO10 was added thereto in an amount of 30 mL/bag each, and IL-2 was added thereto so as to have a final concentration of 500 U/mL (stimulation period with anti-CD3 antibody  $\pm$  CH-296: 4 days). (ii) On the fourth day or the fifth day after the initiation of culture, IL-2 was added to the culture medium so as to have a final concentration of 500 U/mL. On the sixth day after the initiation of culture, the culture medium was transferred to a 85 cm<sup>2</sup> CO<sub>2</sub> gas-permeable bag for cell culture to which nothing was immobilized, 1% XVIVO10 was added thereto in an amount of 50 mL/bag each, and IL-2 was added thereto so as to have a final concentration of 500 U/mL (stimulation period with anti-CD3 antibody  $\pm$  CH-296: 6 days). In both of the conditions, on the eighth day after the initiation of culture, a part of the culture medium was properly diluted, and the dilution was transferred to a 85 cm<sup>2</sup> CO<sub>2</sub> gas-permeable bag for cell culture to which nothing was immobilized, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the eleventh and thirteenth days after the initiation of culture, IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the fifteenth day after the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. The results are shown in Table 35.

Table 35

Serum Concentration and Medium	Stimulation Period Anti-CD3 $\pm$ CH-296	Cultured Days	Fibronectin Fragment	Expansion Fold (folds)
1% XVIVO10	4 Days	15 Days	Control (Without Immobilization of FNfr)	$\times$ 235
1% XVIVO10	4 Days	15 Days	CH-296	$\times$ 498
-1% XVIVO10	6 Days	15 Days	Control (Without Immobilization of FNfr)	$\times$ 425
1% XVIVO10	6 Days	15 Days	CH-296	$\times$ 690

**[0243]** As shown in Table 35, in the group using the flask for cell culture in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium (XVIVO10) containing a low-concentration serum (1%), the expansion fold of the LAK cells was high as compared to that of the control group. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of the LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium containing a low-concentration serum.

**Example 36 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (AIM V) (Culture in Combination of Flask for Cell Culture and CO<sub>2</sub> Gas-Permeable Bag for Cell Culture)**

(1) Immobilization of Anti-Human CD3 Antibody and FN Fragment

**[0244]** An anti-human CD3 antibody and an FN fragment were immobilized to a culture equipment (25 cm<sup>2</sup> flask for cell culture) used in the following experiment in the same manner as in item (1) of Example 35. Immediately before use, PBS containing the antibody and the FNfr was removed from these culture equipments, and each flask was washed twice with PBS, and once with AIM V medium containing 1% human AB serum (hereinafter simply referred to as 1% AIM V) to be subjected to each experiment.

## (2) Induction and Culture of LAK Cells

[0245] PBMCs which were prepared in item (1) of Example 1 were suspended in 1% AIM V so as to have a concentration of  $1 \times 10^6$  cells/mL, and thereafter the cell suspension was placed in an amount of 3 mL/flask each into the flask immobilized with the anti-human CD3 antibody or the flask immobilized with the anti-human CD3 antibody and the FNfr, prepared in item (1) of Example 36, and IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These flasks were incubated in 5% CO<sub>2</sub> at 37°C (zeroth day of culture). On the first day after the initiation of culture, 1% AIM V containing 1000 U/mL IL-2 was added thereto in an amount of 7 mL/flask each. On the fourth day after the initiation of culture, the culture medium was transferred to a 85 cm<sup>2</sup> CO<sub>2</sub> gas-permeable bag for cell culture to which nothing was immobilized, 1% AIM V was added thereto in an amount of 20 mL/bag each, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the sixth day after the initiation of culture, 1% AIM V was added thereto in an amount of 30 mL/bag each, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the eighth day after the initiation of culture, a part of the culture medium was properly diluted, and thereafter transferred to a 85 cm<sup>2</sup> CO<sub>2</sub> gas-permeable bag for cell culture to which nothing was immobilized, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the eleventh and thirteenth days after the initiation of culture, IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the fifteenth day after the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. The results are shown in Table 36.

Table 36

Serum Concentration and Medium	Cultured Days	Fibronectin Fragment	Expansion Fold (folds)
1% AIM V	15 Days	Control (Without Immobilization of FNfr)	× 327
1% AIM V	15 Days	CH-296	× 566

[0246] As shown in Table 36, in the group using the flask for cell culture in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium (AIM V) containing a low-concentration serum (1%), the expansion fold of the LAK cells was high as compared to that of the control group. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of the LAK cells using the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium containing a low-concentration serum.

Example 37 Content Ratio of CD8-Positive Cells in LAK Cell Population Using Low-Serum Medium (XVIVO10) (Culture Using CO<sub>2</sub> Gas-Permeable Bag for Cell Culture)

## (1) Induction and Culture of LAK Cells

[0247] The induction and the culture of LAK cells were carried out in the same manner as in item (2) of Example 34.

## (2) Determination of Content Ratio of CD8-Positive Cell Population in LAK Cells

[0248] The content ratio of the CD8-positive cells was determined in the same manner as in item (2) of Example 4. The results are shown in Table 37.

Table 37

Serum Concentration and Medium	Cultured Days	Fibronectin Fragment	Content Ratio of CD8-Positive Cells (%)
1%XVIVO10	15 Days	Control (Without Immobilization of FNfr)	45.7
1% XVIVO10	15 Days	CH-296	61.6

[0249] As shown in Table 37, in the group using the CO<sub>2</sub> gas-permeable bag for cell culture in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells using the medium (XVIVO10) containing a low-concentration serum (1%) and the CO<sub>2</sub> gas-permeable bag for cell culture, the content ratio of the CD8-positive cells in the LAK cells after the culture could be induced at a high level. It was clarified from the above that each

of the fibronectin fragments was suitably used during the culture of the LAK cells using the medium containing a low-concentration serum and the CO<sub>2</sub> gas-permeable bag for cell culture.

**Example 38 Content Ratio of CD8-Positive Cells in LAK Cell Population Using Low-Serum Medium (XVIVO10) (Culture in Combination of Flask for Cell Culture and CO<sub>2</sub> Gas-Permeable Bag for Cell Culture)**

(1) Induction and Culture of LAK Cells

**[0250]** The induction and the culture of LAK cells were carried out in the same manner as in item (2) of Example 35.

(2) Determination of Content Ratio of CD8-Positive Cell Population in LAK Cells

**[0251]** The content ratio of the CD8-positive cells was determined in the same manner as in item (2) of Example 4. The results are shown in Table 38.

Table 38

Serum Concentration and Medium	Stimulation Period Anti-CD3±CH-296	Cultured Days	Fibronectin Fragment	Content Ratio of CD8-Positive Cells (%)
1% XVIVO10	4 Days	15 Days	Control (Without Immobilization of FNfr)	58.1
1% XVIVO10	4 Days	15 Days	CH-296	70.3
1% XVIVO10	6 Days	15 Days	Control (Without Immobilization of FNfr)	58.3
1% XVIVO10	6 Days	15 Days	CH-296	72.7

**[0252]** As shown in Table 38, in the group using the flask for cell culture in which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium (XVIVO10) containing a low-concentration serum (1%), the content ratio of the CD8-positive cells in LAK cells after the culture could be induced at a high level as compared to that of the control group. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of the LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium containing a low-concentration serum.

**Example 39 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (AIM V) (Concentrations at Initiation of culture and at Subculture)**

**[0253]** The influence on an expansion fold of the cell concentrations at the initiation of culture and during the subculture in the culture system of the LAK cells was confirmed.

**[0254]** The cell concentrations at the initiation of culture were set at

$0.5 \times 10^6$  cells/mL and  $1 \times 10^6$  cells/mL. The subculture cell concentrations on the fourth day of culture were set at  $0.025 \times 10^6$  cells/mL and  $0.05 \times 10^6$  cells/mL. The subculture cell concentrations on the seventh, ninth and eleventh days of the culture were set at  $0.2 \times 10^6$  cells/mL and  $0.5 \times 10^6$  cells/mL. The above patterns are shown in the following Table 39-1.

Table 39-1

	Concentration at Initiation of Culture	Concentration on Fourth Day from Initiation of Culture	Concentrations at Seventh, Ninth, and Eleventh Day from Initiation of Culture
Cell Concentration Pattern 1	0.500	0.025	0.2

Table continued

	Concentration at Initiation of Culture	Concentration on Fourth Day from Initiation of Culture	Concentrations at Seventh, Ninth, and Eleventh Day from Initiation of Culture
Cell Concentration Pattern 2	0.500	0.05	0.2
Cell Concentration Pattern 3	0.500	0.05	0.5
Cell Concentration Pattern 4	1.000	0.025	0.2
Cell Concentration Pattern 5	1.000	0.05	0.2
Cell Concentration Pattern 6	1.000	0.05	0.5
*Cell Concentration ( × 10 <sup>6</sup> cells/mL)			

## (1) Immobilization of Anti-Human CD3 Antibody and FN Fragment

**[0255]** An anti-human CD3 antibody and an FN fragment were immobilized to a culture equipment used in the following experiment. Concretely, 1 mL each of PBS containing the anti-human CD3 antibody (final concentration: 5  $\mu$ g/mL) was added to a 24-well cell culture plate. Upon the addition, the fibronectin fragment (CH-296) described in Preparation Example 1 was added to a group with addition of an FN fragment so as to have a final concentration of 25  $\mu$ g/mL. As a control, there was also set a group without addition of CH-296.

**[0256]** After these culture equipments were incubated at room temperature for 5 hours, and the culture equipments were stored at 4°C until use. Immediately before use, PBS containing the anti-human CD3 antibody and CH-296 was removed by aspiration from these culture equipments, and each well was washed twice with PBS, and once with an RPMI medium to be subjected to each experiment.

## (2) Induction and Culture of LAK Cells

**[0257]** PBMCs which were prepared in item (1) of Example 1 were suspended in AIM V containing 1% human AB serum so that groups in which the cells were cultured in cell concentration patterns 1, 2 and 3 have a concentration of  $0.5 \times 10^6$  cells/mL, and that groups in which the cells were cultured in cell concentration patterns 4, 5 and 6 have a concentration of  $1 \times 10^6$  cells/mL. Thereafter, the cell suspension was put in an amount of 1 mL/well each on a plate immobilized with the anti-human CD3 antibody or a plate immobilized with the anti-human CD3 antibody and CH-296, prepared in item (1), and IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These plates were incubated at 37°C in 5% CO<sub>2</sub> (zeroth day of culture). On the second and third days after the initiation of culture, 1% AIM V containing 1000 U/mL IL-2 was added thereto in an amount of 1 mL/well each.

**[0258]** On the fourth day after the initiation of culture, the groups in which the cells were cultured in cell concentration patterns 1 and 4 were diluted with AIM V containing 1% human AB serum (maximum amount of liquid: 6 mL) so as to have a concentration of  $0.025 \times 10^6$  cells/mL, and the groups in which the cells were cultured in cell concentration patterns 2, 3, 5 and 6 were diluted with AIM V containing 1% human AB serum (maximum amount of liquid: 6 mL) so as to have a concentration of  $0.05 \times 10^6$  cells/mL, and the dilutions were transferred to a 12.5 cm<sup>2</sup> cell culture flask to which nothing was immobilized, respectively. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0259]** On the seventh, ninth and eleventh days after the initiation of culture, the groups in which the cells were cultured in cell concentration patterns 1, 2, 4 and 5 were each diluted with AIM V containing 1% human AB serum (maximum amount of liquid: 6 mL) so as to have a concentration of  $0.2 \times 10^6$  cells/mL, and the groups in which the cells were cultured in cell concentration patterns 3 and 6 were each diluted with AIM V containing 1% human AB serum (maximum amount of liquid: 6 mL) so as to have a concentration of  $0.5 \times 10^6$  cells/mL, and the dilutions were transferred to a 12.5 cm<sup>2</sup> cell culture flask to which nothing was immobilized, respectively. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0260]** On the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. Each experiment was carried out three times. Each of the average results is shown in Table 39-2.

Table 39-2

	Stimulation on Zeroth Day from Initiation of Culture	Expansion Fold (folds)
5	Cell Concentration Pattern 1	Anti-CD3
		Anti-CD3+ CH-296
	Cell Concentration Pattern 2	Anti-CD3
		Anti-CD3+ CH-296
10	Cell Concentration Pattern 3	Anti-CD3
		Anti-CD3+ CH-296
	Cell Concentration Pattern 4	Anti-CD3
		Anti-CD3+ CH-296
15	Cell Concentration Pattern 5	Anti-CD3
		Anti-CD3+ CH-296
	Cell Concentration Pattern 6	Anti-CD3+ CH-296

**[0261]** As shown in Table 39-2, in the culture of the LAK cells at various cell concentrations at the initiation of culture and the subculture, in any cell concentration groups, a high expansion fold was obtained in the group stimulated with CH-296 and the anti-CD3 antibody, as compared to that of the control group (stimulation only with the anti-CD3 antibody). In other words, it was shown that the LAK cells could be clearly induced and cultured at a high expansion fold by stimulation with CH-296 for cell concentrations at the initiation of culture and during the subculture, which were variable under various circumstances.

Example 40 Content Ratio of CD8-Positive Cells in LAK Cell Population Cultured Using Low-Serum Medium (AIM V) (Concentrations at Initiation of Culture and at Subculture)

(1) Induction and Culture of LAK Cells

**[0262]** The induction and the culture of LAK cells were carried out in the same manner as in Example 39.

(2) Determination of Content Ratio of CD8-Positive Cell Population in LAK Cells

**[0263]** The content ratio of the CD8-positive cells was determined in the same manner as in item (2) of Example 4. The results are shown in Table 40.

Table 40

	Stimulation on Zeroth Day from Initiation of Culture	Content Ratio of CD8-Positive Cells (%)
40	Cell Concentration Pattern 1	Anti-CD3
		Anti-CD3+ CH-296
45	Cell Concentration Pattern 2	Anti-CD3
		Anti-CD3+ CH-296
	Cell Concentration Pattern 3	Anti-CD3
		Anti-CD3+ CH-296
50	Cell Concentration Pattern 4	Anti-CD3
		Anti-CD3+ CH-296
	Cell Concentration Pattern 5	Anti-CD3
		Anti-CD3+ CH-296
55	Cell Concentration Pattern 6	Anti-CD3+ CH-296



**[0264]** As shown in Table 40, in the culture of the LAK cells at various cell concentrations at the initiation of culture and at the subculture, in any cell concentration groups, the content ratio of the CD8-positive cells in the LAK cells during culture could be induced at a high level in the group stimulated with CH-296 and the anti-CD3 antibody, as compared to that of the control group (stimulation with only anti-CD3 antibody). In other words, it was clarified that the LAK cells could be induced and cultured with clearly increasing the content ratio of the CD8-positive cells in the LAK cells by stimulation with CH-296 for cell concentrations at the initiation of culture and at the subculture, which were variable under various circumstances.

**Example 41 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (AIM V) (High-Concentration, High-Density Culture)**

**[0265]** In the culture system of LAK cells, if the final amount of culture medium and the final culture area can be controlled as much as possible, the medium, the material and labor can be reduced. The influence on the expansion fold was confirmed when the cells were cultured in a high concentration at a high density.

**[0266]** There were set a group without controlling cell concentration and cell density upon the subculture (normal culture group); a group in which cell concentrations upon the subculture on the seventh and tenth days of culture were respectively 1.8 times and about 6 times that of the normal culture group (high-concentration culture group, provided that the cell density is similarly 1.8 times and about 6 times, proportional to the concentration); a group in which cell concentrations upon the subculture on the seventh and tenth days of culture were respectively 1.3 times and about 2.5 times that of the normal culture group and cell densities were respectively about 3.9 times and 7.5 times (high-concentration, high-density culture group). The cell concentration and the cell density upon subculture in each of the above groups are shown in the following Table 41-1.

Table 41-1

		Zeroth Day of Culture	Fourth Day of Culture	Seventh Day of Culture	Tenth Day of Culture
Normal Culture Group	Cell Concentration ( $\times 10^6$ cells/mL)	0.333	0.050	0.100	0.15
	Cell Density ( $\times 10^6$ cells/cm <sup>2</sup> )	0.263	0.024	0.048	0.072
High-Concentration Culture Group	Cell Concentration ( $\times 10^6$ cells/mL)	0.333	0.050	0.180	0.893
	Cell Density ( $\times 10^6$ cells/cm <sup>2</sup> )	0.263	0.024	0.086	0.429
High-Concentration, High-Density Culture Group	Cell Concentration ( $\times 10^6$ cells/mL)	0.333	0.050	0.13	0.38
	Cell Density ( $\times 10^6$ cells/cm <sup>2</sup> )	0.263	0.024	0.186	0.543

(1) Immobilization of Anti-Human CD3 Antibody and FN Fragment

**[0267]** An anti-human CD3 antibody and an FN fragment were immobilized to culture equipments used in the following experiment. Concretely, 1.9 mL each of PBS containing the anti-human CD3 antibody (final concentration: 5  $\mu$ g/mL) was added to a 12-well cell culture plate. Upon the addition, a fibronectin fragment (CH-296) described in Preparation Example 1 was added to a group with addition of an FN fragment so as to have a final concentration of 25  $\mu$ g/mL. As a control, there was also set a group without addition of CH-296.

**[0268]** After these culture equipments were incubated at room temperature for 5 hours, the culture equipments were stored at 4°C until use. Immediately before use, PBS containing the anti-human CD3 antibody and CH-296 was removed by aspiration from these culture equipments, and thereafter each well was washed twice with PBS, and once with RPMI medium. Each experiment was carried out using the culture equipment.

## (2) Induction and Culture of LAK Cells

**[0269]** In each culture group, PBMCs which were prepared in item (1) of Example 1 were suspended in AIM V containing 1% human AB serum so as to have a concentration of  $0.33 \times 10^6$  cells/mL, and thereafter the cell suspension was put on a plate immobilized with the anti-human CD3 antibody or a plate immobilized with the anti-human CD3 antibody and CH-296, prepared in item (1) of Example 41, in a volume of 3 mL/well each, and IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These plates were incubated at 37°C in 5% CO<sub>2</sub> (zeroth day of culture).

**[0270]** On the fourth day from the initiation of culture, each culture group was diluted with AIM V containing 1% human AB serum (maximum amount of liquid: 6 mL) so as to have a concentration of  $0.05 \times 10^6$  cells/mL, and the dilution was transferred to a 12.5 cm<sup>2</sup> cell culture flask to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0271]** On the seventh day from the initiation of culture, the normal culture group and the high-concentration culture group were diluted with AIM V containing 1% human AB serum (maximum amount of liquid: 6 mL), so as to have a concentration of the normal culture group of  $0.1 \times 10^6$  cells/mL, and a concentration of the high-concentration culture group of  $0.18 \times 10^6$  cells/mL. The dilution was transferred to a 12.5 cm<sup>2</sup> cell culture flask to which nothing was immobilized. In addition, the high-concentration, high-density culture group was diluted with AIM V containing 1% human AB serum (maximum amount of liquid: 9 mL), so as to have a concentration of  $0.13 \times 10^6$  cells/mL, and the dilution was transferred to a 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0272]** On the tenth day from the initiation of culture, the normal culture group and the high-concentration culture group were diluted with AIM V containing 1% human AB serum (maximum amount of liquid: 6 mL), so as to have a concentration of the normal culture group of  $0.15 \times 10^6$  cells/mL, and a concentration of and the high-concentration culture group of  $0.893 \times 10^6$  cells/mL. The dilution was transferred to a 12.5 cm<sup>2</sup> cell culture flask to which nothing was immobilized. In addition, the high-concentration, high-density culture group was diluted with AIM V containing 1% human AB serum (maximum amount of liquid: 9 mL), so as to have a concentration of  $0.38 \times 10^6$  cells/mL, and the dilution was transferred to a 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0273]** On the eleventh day from the initiation of culture, in each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0274]** On the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. Each experiment was carried out twice. Each of the average results is shown in 41-2.

Table 41-2

	Stimulation on Zeroth Day from Initiation of Culture	Expansion Fold (fold)
Normal Culture Group	Anti-CD3	601
	Anti-CD3 + CH-296	2325
High-Concentration Culture Group	Anti-CD3	112
	Anti-CD3 + CH-296	1131
High-Concentration, High-Density Culture Group	Anti-CD3	215
	Anti-CD3 + CH-296	1307

**[0275]** As shown in Table 41-2, in the normal culture group, the high-concentration culture group or the high-concentration, high-density culture group, a high expansion fold was obtained in the group stimulated with CH-296 and the anti-CD3 antibody in any one of the groups, as compared to that of the control group (stimulation only with anti-CD3 antibody). In other words, an effect on expansion was clearly found by stimulation with CH-296 in the high-concentration, high-density culture which could reduce the medium, the material and labor.

Example 42 Content Ratio of CD8-Positive Cells in LAK Cell Population Cultured Using Low-Serum Medium (AIM V) (High-Concentration, High-Density Culture)

(1) Induction and Culture of LAK Cells

**[0276]** The induction and the culture of LAK cells were carried out in the same manner as in Example 41.

(2) Determination of Content Ratio of CDS-Positive Cell Population in LAK Cells

**[0277]** The content ratio of the CD8-positive cells was determined in the same manner as in item (2) of Example 4. The results are shown in Table 42.

Table 42

	Stimulation on Zeroth Day from Initiation of Culture	Content Ratio of CD8-Positive Cells (%)
Normal Culture Group	Anti-CD3	53
	Anti-CD3 + CH-296	63
High-Concentration Culture Group	Anti-CD3	55
	Anti-CD3 + CH-296	72
High-Concentration, High-Density Culture Group	Anti-CD3	63
	Anti-CD3 + CH-296	65

**[0278]** As shown in Table 42, in the normal culture group, the high-concentration culture group or the high-concentration, high-density culture group, the content ratio of the CD8-positive cells in LAK cells in all the groups during culture could be induced at a high level in the group stimulated with CH-296 and the anti-CD3 antibody in any one of the groups, as compared to that of the control group (stimulation only with anti-CD3 antibody). In other words, it was clarified that LAK cells could be clearly induced and cultured while increasing the content ratio of the CD8-positive cells in LAK cells by stimulation with CH-296 in the high-concentration, high-density culture which could reduce the medium, the material and labor.

Example 43 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (AIM V) (Serum Concentrations 0%, 0.15%, 5% → 0.1%)

**[0279]** When blood is taken in a volume of 30 mL at one time in the culture of LAK cells, approximately 15 mL of plasma is obtained. When culture in a medium containing this plasma in a final volume of up to 10 L is taken into consideration, a plasma concentration would be 0.15%. In addition, when the culture is initiated from a plasma concentration of 5%, on the fourth or subsequent days, a plasma concentration in a medium during the subculture and the dilution of the cells would be about 0.1%. In view of the above, the influence of the serum concentration on the culture system of LAK cells was confirmed.

**[0280]** At the initiation of culture, there was set a group containing 0%, 0.15% or 5% human AB serum, respectively. PBMCs which were prepared in item (1) of Example 1 were suspended in AIM V containing human AB serum at each concentration, so as to have a concentration of  $0.33 \times 10^6$  cells/mL, and thereafter the suspension was put on a plate immobilized with the anti-human CD3 antibody or a plate immobilized with the anti-human CD3 antibody and CH-296, prepared in item (1) of Example 41, in a volume of 3 mL/well each, and IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These plates were incubated at 37°C in 5% CO<sub>2</sub> (zeroth day of culture).

**[0281]** On the fourth day from the initiation of culture, a group subjected to culture with AIM V containing 0% or 0.15% human AB serum was each diluted with AIM V containing 0% or 0.15% human AB serum, so as to have a maximum concentration of  $0.05 \times 10^6$  cells/mL, and the dilution was transferred to a 12.5 cm<sup>2</sup> cell culture flask to which nothing was immobilized (amount of liquid: 2.5 mL). A group subjected to culture with AIM V containing 5% human AB serum was diluted with AIM V containing 0.1% human AB serum (amount of liquid: 6 mL) so as to have a concentration of  $0.05 \times 10^6$  cells/mL, and the dilution was transferred to a 12.5 cm<sup>2</sup> cell culture flask to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0282]** On the seventh day from the initiation of culture, a group subjected to culture with AIM V containing 0% or 0.15% human AB serum was each diluted with AIM V containing the same serum concentration, so as to have a

concentration of  $0.11 \times 10^6$  cells/mL, and the dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized (maximum amount of liquid: 12.6 mL). A group subjected to culture with AIM V containing 5% human AB serum was diluted with AIM V containing 0.1% human AB serum so as to have a concentration of  $0.11 \times 10^6$  cells/mL, and the dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized (maximum amount of liquid: 12.6 mL). In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0283]** On the tenth day from the initiation of culture, a group subjected to culture with AIM V containing 0% or 0.15% human AB serum was each diluted with AIM V containing the same serum concentration, so as to have a concentration of  $0.22 \times 10^6$  cells/mL, and the dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized (maximum amount of liquid: 12.6 mL). A group subjected to culture with AIM V containing 5% human AB serum was diluted with AIM V containing 0.1% human AB serum so as to have a concentration of  $0.6 \times 10^6$  cells/mL, and the dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized (maximum amount of liquid: 12.6 mL). In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0284]** On the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. Each experiment was carried out twice. Each of the average results is shown in Table 43.

Table 43

Serum Concentration and Medium	Stimulation on Zeroth Day from Initiation of Culture	Expansion Fold (fold)
0% AIM V	Anti-CD3	25
	Anti-CD3 + CH-296	322
0.15% AIM V	Anti-CD3	42
	Anti-CD3 + CH-296	197
5% → 0.1% AIM V	Anti-CD3	175
	Anti-CD3 + CH-296	353

**[0285]** As shown in Table 43, in the culture of LAK cells using AIM V medium containing each serum concentration, a high expansion fold was obtained in the group stimulated with CH-296 and the anti-CD3 antibody in any one of serum concentration groups, as compared to that of the control group (stimulation only with anti-CD3 antibody). In other words, in the culture of LAK cells at a serum concentration assuming that 30 mL of blood was collected, the LAK cells could be clearly induced and cultured at a high expansion fold by stimulation with CH-296 and the anti-CD3 antibody. In addition, the cells during the culture at this time were in a high concentration and at a high density. The expansion fold was clearly high even under the conditions as described above by stimulation with CH-296, so that the effectiveness of CH-296 was found.

**Example 44 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (AIM V)**  
 (Serum Concentrations 3% → 1% → 0% → 0%, 3% → 1% → 0.1% → 0%, 3% → 0.5% → 0.2% → 0.2% (About One-Half Amount of Final Culture Medium), 3% → 0.5% → 0.2% → 0.05%)

**[0286]** From the same viewpoint as that of Example 43, the influence of serum concentrations on the culture system of LAK cells was confirmed taking plasma concentrations obtained by collection of 30 mL blood into consideration.

**[0287]** The human AB serum concentration was 3% at the initiation of culture. There were respectively set a group in which the cells were diluted with AIM V medium containing 1% or 0.5% human AB serum on the fourth day of culture; a group in which the cells were diluted with AIM V medium containing 0%, 0.1 % or 0.2% human AB serum on the seventh day of culture; and a group in which the cells were diluted with AIM V medium containing 0%, 0.05% or 0.2% human AB serum on the tenth day of culture. The above patterns are shown in the following Table 44-1.

Table 44-1

	Fourth Day from Initiation of Culture	Seventh Day from Initiation of Culture	Tenth Day from Initiation of Culture
Serum Concentration Pattern 1	1%	0%	0%

Table continued

	Fourth Day from Initiation of Culture	Seventh Day from Initiation of Culture	Tenth Day from Initiation of Culture
5	Serum Concentration Pattern 2	1%	0.1%
	Serum Concentration Pattern 3	0.5%	0.2%
10	Serum Concentration Pattern 4	0.5%	0.2%
			0.05%
*showing human AB serum concentration contained in the medium for diluting the cell culture medium			

[0288] PBMCs which were prepared in item (1) of Example 1 were suspended in AIM V containing 3% human AB serum so as to have a concentration of  $0.33 \times 10^6$  cells/mL, and thereafter the suspension was put on a plate immobilized with the anti-human CD3 antibody or a plate immobilized with the anti-human CD3 antibody and CH-296, prepared in item (1) of Example 41, in a volume of 3 mL/well each, and IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These plates were incubated at 37°C in 5% CO<sub>2</sub> (zeroth day of culture).

[0289] On the fourth day from the initiation of culture, groups subjected to culture under the serum concentration patterns 1 and 2 were diluted with AIM V containing 1% human AB serum (amount of liquid: 6 mL) so as to have a concentration of  $0.05 \times 10^6$  cells/mL, and the dilution was transferred to a 12.5 cm<sup>2</sup> cell culture flask to which nothing was immobilized. Groups subjected to culture under the serum concentration patterns 3 and 4 were diluted with AIM V containing 0.5% human AB serum (amount of liquid: 6 mL) so as to have a concentration of  $0.058 \times 10^6$  cells/mL, and the dilution was transferred to a 12.5 cm<sup>2</sup> cell culture flask to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

[0290] On the seventh day from the initiation of culture, the group subjected to culture under the serum concentration pattern 1 was diluted with AIM V without containing human AB serum (amount of liquid: 12.6 mL) so as to have a concentration of  $0.28 \times 10^6$  cells/mL, and the group subjected to culture under the serum concentration pattern 2 was diluted with AIM V containing 0.1% human AB serum (amount of liquid: 12.6 mL) so as to have a concentration of  $0.28 \times 10^6$  cells/mL, and the dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized, respectively. Groups subjected to culture under the serum concentration patterns 3 and 4 were diluted with AIM V containing 0.2% human AB serum (amount of liquid: 12.6 mL) so as to have a concentration of  $0.48 \times 10^6$  cells/mL, and the dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

[0291] On the tenth day from the initiation of culture, groups subjected to culture under the serum concentration patterns 1 and 2 were diluted with AIM V without containing human AB serum (amount of liquid: 12.6 mL) so as to have a concentration of  $0.51 \times 10^6$  cells/mL, and the dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. The group subjected to culture under the serum concentration pattern 3 was diluted with AIM V containing 0.2% human AB serum (amount of liquid: 12.6 mL) so as to have a concentration of  $0.839 \times 10^6$  cells/mL, and the group subjected to culture under the serum concentration pattern 4 was diluted with AIM V containing 0.05% human AB serum (amount of liquid: 12.6 mL) so as to have a concentration of  $0.43 \times 10^6$  cells/mL, and the dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized, respectively. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

[0292] On the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. Each experiment was carried out twice. Each of the average results is shown in Table 44-2.

Table 44-2

	Stimulation on Zeroth Day from Initiation of Culture	Expansion Fold (fold)
50	Serum Concentration Pattern 1	Anti-CD3
		Anti-CD3 + CH-296
55	Serum Concentration Pattern 2	Anti-CD3
		Anti-CD3 + CH-296
	Serum Concentration Pattern 3 (About One- Half Amount of Final Culture Medium)	Anti-CD3
		Anti-CD3 + CH-296

Table continued

	Stimulation on Zeroth Day from Initiation of Culture	Expansion Fold (fold)
5	Serum Concentration Pattern 4	
	Anti-CD3	190
	Anti-CD3 + CH-296	416

[0293] As shown in Table 44-2, in the culture of LAK cells using AIM V medium containing each serum concentration, a high expansion fold was obtained in the group stimulated with CH-296 and the anti-CD3 antibody, in any one of serum concentration groups, as compared to that of the control group (stimulation only with anti-CD3 antibody). In other words, in the culture of LAK cells at a serum concentration assuming that 30 mL blood was collected, the LAK cells could be clearly induced and cultured at a high expansion fold by stimulation with CH-296 and the anti-CD3 antibody than the stimulation with the anti-CD3 antibody alone. In addition, the cells during the culture at this time were in a high concentration and at a high density and. The expansion fold was clearly high by stimulation with CH-296 even under the conditions as described above, so that the effectiveness of CH-296 was found.

Example 45 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (AIM V) (Culture in Combination of Flask for Cell Culture and CO<sub>2</sub> Gas-Permeable Bag for Cell Culture)

(1) Induction and Culture of LAK Cells

[0294] The induction and the culture of LAK cells were carried out in the same manner as in item (2) of Example 36. The results are shown in Table 45.

Table 45

Serum Concentration and Medium	Stimulation Period Anti-CD3±CH-296	Cultured Days	Fibronectin Fragment	Expansion Fold (folds)
1% AIM V	4 Days	15 Days	Control (Without Immobilization of FNfr)	× 327
1% AIM V	4 Days	15 Days	CH-296	× 566
1% AIM V	6 Days	15 Days	Control (Without Immobilization of FNfr)	× 371
1% AIM V	6 Days	15 Days	CH-296	× 425

[0295] As shown in Table 45, in the group using the flask for cell culture to which each of the fibronectin fragments was immobilized at an early stage of the induction of LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium (AIM V) containing a low-concentration serum (1%), the expansion fold of LAK cells was high as compared to that of the control group. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium containing a low-concentration serum.

Example 46 Determination of Expansion Fold in Culture System of LAK Cells Using Freshly Isolated PBMCs and Autologous Plasma-Containing Medium (with AIM V Medium Containing 0.5% Autologous Plasma, Culture in Combination of Flask for Cell Culture and CO<sub>2</sub> Gas-Permeable Bag for Cell Culture)

(1) Isolation and Storage of PBMCs

[0296] Thirty milliliters of blood was collected with a blood collecting injection syringe from a human normal individual donor, obtained with informed consent, and thereafter the collected blood was centrifuged at 500 × g for 20 minutes to collect autologous plasma and a buffy coat layer. The collected buffy coated layer was diluted with PBS, overlaid on Ficoll-paque (manufactured by Pharmacia), and centrifuged at 500 × g for 20 minutes. Peripheral blood mononuclear cells (PBMCs) in an intermediate layer was collected with a pipette, and washed. Regarding the collected freshly isolated PBMCs, the number of living cells was calculated by trypan blue staining method. Each experiment was carried out using the culture equipment.

[0297] The collected autologous plasma was inactivated at 56°C for 30 minutes, and thereafter centrifuged at 800 ×

g for 30 minutes, and the supernatant was used as an inactivated autologous plasma (hereinafter simply referred to as autologous plasma).

## (2) Immobilization of Anti-Human CD3 Antibody and FN Fragment

**[0298]** An anti-human CD3 antibody and an FN fragment were immobilized to a culture equipment (25 cm<sup>2</sup> flask for cell culture) used in the following experiment, in the same manner as in item (1) of Example 35. Immediately before use, PBS containing the antibody and the FNfr was removed from the culture equipment, and each flask was washed twice with PBS, and once with AIM V medium. Each experiment was carried out using the culture equipment.

## (3) Induction and Culture of LAK Cells

**[0299]** Freshly isolated PBMCs which were prepared in item (1) of Example 46 were suspended in AIM V containing 0.5% autologous plasma (hereinafter simply referred to as 0.5% autologous plasma AIM V) so as to have a concentration of  $1 \times 10^6$  cells/mL, and thereafter the cell suspension was placed in a flask immobilized with the anti-human CD3 antibody or a flask immobilized with the anti-human CD3 antibody and the FNfr, prepared in item (2) of Example 46, in a volume of 3 mL/flask each, and IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These flasks were incubated at 37°C in 5% CO<sub>2</sub> (zeroth day of culture). On the first day from the initiation of culture, 0.5% autologous plasma AIM V containing 1000 U/mL IL-2 was added thereto in an amount of 7 mL/flask. On the fourth day from the initiation of culture, a culture medium was transferred to a 85 cm<sup>2</sup> CO<sub>2</sub> gas-permeable bag for cell culture (Optisite bag or X-Fold bag manufactured by Baxter) to which nothing was immobilized. Thereafter, 0.5% autologous plasma AIM V was then added thereto in an amount of 20 mL/bag each, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the sixth day from the initiation of culture, 0.5% autologous plasma/AIM V was added thereto in an amount of 30 mL/bag each, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the eighth day from the initiation of culture, a part of the culture medium was appropriately diluted, the dilution was then transferred to a 85 cm<sup>2</sup> CO<sub>2</sub> gas-permeable bag for cell culture (Optisite bag or X-Fold bag) to which nothing was immobilized, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the eleventh and thirteenth days from the initiation of culture, IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. The results are shown in Table 46.

Table 46

Plasma Concentration, Medium and CO <sub>2</sub> Gas-Permeable Bag for Cell Culture	PBMCs Donor	Cultured Days	Fibronectin Fragment	Expansion Fold (fold)
0.5% Autologous Plasma AIM V and Optisite Bag	A	15 Days	Control (Without Immobilization of FNfr)	× 22
0.5% Autologous Plasma AIM V and Optisite Bag	A	15 Days	CH-296	× 259
0.5% Autologous Plasma AIM V and X-Fold Bag	A	15 Days	CH-296	× 360
0.5% Autologous Plasma AIM V and Optisite Bag	B	15 Days	Control (Without Immobilization of FNfr)	× 34
0.5% Autologous Plasma AIM V and Optisite Bag	B	15 Days	CH-296	× 432
0.5% Autologous Plasma AIM V and X-Fold Bag	B	15 Days	CH-296	× 360

**[0300]** As shown in Table 46, in the group using the flask for cell culture to which each of the fibronectin fragments was immobilized at an early stage of the induction of the LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium (AIM V) containing low-concentration autologous plasma (0.5%), the expansion fold of LAK cells was high regardless of the kinds of the CO<sub>2</sub> gas-permeable bags for cell culture. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of LAK cells

in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium containing a low-concentration plasma.

Example 47 Determination of Ratio of CD8-Positive Cells in LAK Cell Population Using Freshly Isolated PBMCs and Autologous Plasma-Containing Medium (with AIM V Medium Containing 0.5% Autologous Plasma, Culture in Combination of Flask for Cell Culture and CO<sub>2</sub> Gas-Permeable Bag for Cell Culture)

(1) Induction and Culture of LAK Cells

**[0301]** The induction and the culture of LAK cells were carried out in the same manner as in item (3) of Example 46. On the fifteenth day from the initiation of culture, in the same manner as in item (2) of Example 4, the content ratio of CD8-positive cells was determined. The results are shown in Table 47.

Table 47

Plasma Concentration, Medium and CO <sub>2</sub> Gas- Permeable Bag for Cell Culture	PBMCs Donor	Cultured Days	Fibronectin Fragment	Ratio of CD8-Positive Cells (%)
0.5% Autologous Plasma AIM V and Optisite Bag	B	15 Days	Control (Without Immobilization of FNfr)	45.0
0.5% Autologous Plasma AIM V and Optisite Bag	B	15 Days	CH-296	89.8
0.5% Autologous Plasma AIM V and X- Fold Bag	B	15 Days	CH-296	90.0

**[0302]** As shown in Table 47, in the group using the flask for cell culture to which each of the fibronectin fragments was immobilized at an early stage of the induction of LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium (AIM V) containing the low-concentration autologous plasma (0.5%), the CD8 cell-positive ratio in LAK cells population was high regardless of the kinds of the CO<sub>2</sub> gas-permeable bags for cell culture. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium containing a low-concentration plasma.

Example 48 Determination of Expansion Fold in Culture System of LAK Cells Using Freshly Isolated PBMCs and Autologous Plasma-Containing Medium (with AIM V Medium Containing 0.5% Autologous Plasma, Culture in Combination of Flask for Cell Culture and CO<sub>2</sub> Gas-Permeable Bag for Cell Culture)

(1) Immobilization of Anti-Human CD3 Antibody and FN Fragment

**[0303]** An anti-human CD3 antibody and an FN fragment were immobilized to a culture equipment (25 cm<sup>2</sup> flask for cell culture) used in the following experiment, in the same manner as in item (1) of Example 35. Immediately before use, PBS containing the antibody and the FNfr was removed from the culture equipment, and each flask was washed twice with PBS and once with AIM V medium. Each experiment was carried out using the culture equipment.

(2) Induction and Culture of LAK Cells

**[0304]** Freshly isolated PBMCs which were prepared in the same manner as in item (1) of Example 46 were suspended in AIM V containing 0.5% autologous plasma (hereinafter simply referred to as 0.5% autologous plasma AIM V) so as to have a concentration of  $1 \times 10^6$  cells/mL, and thereafter the cell suspension was placed in a flask immobilized with the anti-human CD3 antibody or a flask immobilized with the anti-human CD3 antibody and the FNfr, prepared in item (1) of Example 48, in an amount of 3 mL/flask each, and IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These flasks were incubated at 37°C in 5% CO<sub>2</sub> (zeroth day of culture). On the first day from the initiation of culture, 0.5% autologous plasma AIM V containing 1000 U/mL IL-2 was added thereto in an amount of 7 mL/flask



each. On the fourth day from the initiation of culture, a culture medium was transferred to a 85 cm<sup>2</sup> CO<sub>2</sub> gas-permeable bag for cell culture (Optisite bag) to which nothing was immobilized, 0.5% autologous plasma AIM V was then added thereto in an amount of 20 mL/bag each, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the sixth day from the initiation of culture, 0.5% autologous plasma/AIM V was added thereto in an amount of 30 mL/bag each, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the eighth day from the initiation of culture, a part of the culture medium was appropriately diluted, the dilution was then transferred to a 85 cm<sup>2</sup> CO<sub>2</sub> gas-permeable bag (Optisite bag) for cell culture to which nothing was immobilized, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the eleventh and thirteenth days from the initiation of culture, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0305]** In addition, similarly, a part (7 mL out of 10 mL) of a culture medium which was cultured until the fourth day was transferred to a 180 cm<sup>2</sup> CO<sub>2</sub> gas-permeable bag for cell culture to which nothing was immobilized, 0.5% autologous plasma AIM V was then added thereto in an amount of 58 mL/bag each, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the sixth day from the initiation of culture, 0.5% autologous plasma/AIM V was added thereto in an amount of 65 mL/bag each, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the eighth day from the initiation of culture, a part of the culture medium was appropriately diluted, the dilution was then transferred to a 180 cm<sup>2</sup> CO<sub>2</sub> gas-permeable bag for cell culture (Optisite bag) to which nothing was immobilized, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the eleventh and thirteenth days from the initiation of culture, IL-2 was added thereto so as to have a final concentration of 500 U/mL. Upon the addition, there was also set a system in which 130 mL of 0.5% autologous plasma/AIM V was added on the eleventh day from the initiation of culture. On the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. The results are shown in Table 48.

Table 48

Plasma Concentration, Medium and CO <sub>2</sub> Gas-Permeable Bag for Cell Culture	Culture Area of Bag	Addition of Medium on Eleventh Day	Cultured Days	Fibronectin Fragment	Expansion Fold (fold)
0.5% Autologous Plasma AIM V and Optisite Bag	85 cm <sup>2</sup>	No	15 Days	Control (Without Immobilization of FNfr)	× 22
0.5% Autologous Plasma AIM V and Optisite Bag	85 cm <sup>2</sup>	No	15 Days	CH-296	× 259
0.5% Autologous Plasma AIM V and Optisite Bag	180 cm <sup>2</sup>	No	15 Days	CH-296	× 473
0.5% Autologous Plasma AIM V and Optisite Bag	180 cm <sup>2</sup>	Yes	15 Days	CH-296	× 911

**[0306]** As shown in Table 48, in the group using the flask for cell culture to which each of the fibronectin fragments was immobilized at an early stage of the induction of LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium (AIM V) containing the low-concentration autologous plasma (0.5%), the expansion fold of LAK cells was high regardless of culture area, culture method, final amount of medium for the CO<sub>2</sub> gas-permeable bag for cell culture. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium containing a low-concentration plasma.

Example 49 Determination of Ratio of CD8-Positive Cells in LAK Cell Population Using Freshly Isolated PBMCs and Autologous Plasma-Containing Medium (with AIM V Medium Containing 0.5% Autologous Plasma, Culture in Combination of Flask for Cell Culture and CO<sub>2</sub> Gas-Permeable Bag for Cell Culture)

(1) Induction and Culture of LAK Cells

**[0307]** The induction and the culture of LAK cells were carried out in the same manner as in item (2) of Example 48. On the fifteenth day from the initiation of culture, the content ratio of CD8-positive cells was determined in the same manner as in item (2) of Example 4. The results are shown in Table 49.

Table 49

Plasma Concentration, Medium and CO <sub>2</sub> Gas-Permeable Bag for Cell Culture	Culture Area of Bag	Addition of Medium on Eleventh Day	Cultured Days	Fibronectin Fragment	Content Ratio of CD8-Positive Cells (%)
0.5% Autologous Plasma AIM V and Optisite Bag	85 cm <sup>2</sup>	No	15 Days	Control (Without Immobilization of FNfr)	37.4
0.5% Autologous Plasma AIM V and Optisite Bag	85 cm <sup>2</sup>	No	15 Days	CH-296	70.0
0.5% Autologous Plasma AIM V and Optisite Bag	180 cm <sup>2</sup>	No	15 Days	CH-296	56.2
0.5% Autologous Plasma AIM V and Optisite Bag	180 cm <sup>2</sup>	Yes	15 Days	CH-296	58.4

**[0308]** As shown in Table 49, in the group using the flask for cell culture to which each of the fibronectin fragments was immobilized at an early stage of the induction of LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium (AIM V) containing the low-concentration autologous plasma (0.5%), the CD8 cell-positive ratio in the LAK cell population was high regardless of culture area, culture method, final amount of medium for the CO<sub>2</sub> gas-permeable bag for cell culture. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium containing a low-concentration plasma.

Example 50 Determination of Cytotoxic Activity in Culture System of LAK Cells Using Freshly Isolated PBMCs and Autologous Plasma-Containing Medium (with AIM V Medium Containing 0.5% Autologous Plasma and Culture in Combination of Flask for Cell Culture and CO<sub>2</sub> Gas-Permeable Bag for Cell Culture)

(1) Induction and Culture of LAK Cells

**[0309]** The induction and the culture of LAK cells were carried out in the same manner as in item (3) of Example 46.

(2) Determination of Cytotoxic Activity of Cultured LAK Cells

**[0310]** The cytotoxic activity of LAK on the fifteenth day after the culture was determined in the same manner as in item (2) of Example 25,. The results are shown in Table 50.

Table 50

Plasma Concentration, Medium and CO <sub>2</sub> Gas-Permeable Bag for Cell Culture	Cultured Days	Fibronectin Fragment	E/T	Cytotoxic Activity (%) (Target Cells K562)	Cytotoxic Activity (%) (Target Cells Daudi)
0.5% Autologous Plasma AIM V and Optisite Bag	15 Days	Control (Without Immobilization of FNfr)	90	50.9	56.2
			30	32.9	49.6
			10	16.9	35.7
0.5% Autologous Plasma AIM V and Optisite Bag	15 Days	CH-296	90	75.9	62.3
			30	48.3	53.7
			10	19.6	40.2

**[0311]** As shown in Table 50, in the group using a flask for cell culture to which each of the fibronectin fragments was immobilized at an early stage of the induction of LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium (AIM V) containing the low-concentration autologous plasma (0.5%), the cytotoxic activity of LAK cells was high as compared to that of the control group. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium containing a low-concentration plasma.

Example 51 Determination of Expansion Fold in Culture System of LAK Cells Using Freshly Isolated PBMCs and Autologous Plasma-Containing Medium (with AIM V Medium Containing 0.5% Autologous Plasma and Culture in Combination of Flask for Cell Culture and CO<sub>2</sub> Gas-Permeable Bag for Cell Culture)

(1) Immobilization of Anti-Human CD3 Antibody and FN Fragment

**[0312]** An anti-human CD3 antibody and an FN fragment were immobilized to a culture equipment (25 cm<sup>2</sup> flask for cell culture) used in the following experiment, in the same manner as in item (1) of Example 35. Immediately before use, PBS containing the antibody and the FNfr was removed from the culture equipment, and each flask was twice washed with PBS, and once with AIM V medium. Each experiment was carried out using the culture equipment.

(2) Induction and Culture of LAK Cells

**[0313]** Freshly isolated PBMCs which were prepared in the same manner as in item (1) of Example 46 were suspended in AIM V containing 0.5% autologous plasma (hereinafter simply referred to as 0.5% autologous plasma AIM V), so as to have a concentration of  $5 \times 10^5$  cells/mL (provided that the number of living cells was counted using Tulk solution (manufactured by Kanto Kagaku)), the cell suspension was then placed in a flask immobilized with the anti-human CD3 antibody or a flask immobilized with the anti-human CD3 antibody and the FNfr, prepared in item (1) of Example 51, in an amount of 3 mL/flask each, and IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These flasks were incubated at 37°C in 5% CO<sub>2</sub> (zeroth day of culture). On the first day from the initiation of culture, 0.5% autologous plasma AIM V containing 1000 U/mL IL-2 was added thereto in an amount of 7 mL/flask each. On the fourth day from the initiation of culture, a part (7 mL out of 10 mL) of the culture medium was transferred to a 180 cm<sup>2</sup> CO<sub>2</sub> gas-permeable bag for cell culture to which nothing was immobilized, 0.5% autologous plasma AIM V was then added thereto in an amount of 58 mL/bag each, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the sixth day from the initiation of culture, 0.5% autologous plasma/AIM V was added thereto in an amount of 65 mL/bag each, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the eighth day from the initiation of culture, a part of the culture medium was appropriately diluted, the dilution was transferred to a 180 cm<sup>2</sup> CO<sub>2</sub> gas-permeable bag for cell culture (Optisite bag) to which nothing was immobilized, and IL-2 was added thereto so as to have a final concentration of 500 U/mL. On the eleventh and thirteenth days from the initiation of culture, IL-2 was added thereto so as to have a final concentration of 500 U/mL. Upon the addition, there was also set a system in which 130 mL of AIM V without containing autologous plasma or with 0.5% autologous plasma/AIM V was added on the eleventh day from the initiation of culture. On the fifteenth day from the initiation of culture, the number of living cells

# EP 1 666 589 A1

was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. The results are shown in Table 51.

Table 51

Plasma Concentration, Medium and CO <sub>2</sub> Gas-Permeable Bag for Cell Culture	PBMCs Donor	Addition of Medium on Eleventh Day	Medium Added on Eleventh Day	Fibronectin Fragment	Expansion Fold (fold)
0.5% Autologous Plasma AIM V and Optisite Bag	C	No	No	Control (Without Immobilization of FNfr)	× 570
		No	No	CH-296	× 1034
		Yes	0.5% Autologous Plasma AIM V	CH-296	× 1857
		Yes	0% Autologous Plasma AIM V	CH-296	× 1882
		No	No	CH-296	× 1213
		Yes	0.5% Autologous Plasma AIM V	CH-296	× 1647
0.5% Autologous Plasma AIM V and Optisite Bag	D	No	No	Control (Without Immobilization of FNfr)	× 947
		No	No	CH-296	× 1213
		Yes	0.5% Autologous Plasma AIM V	CH-296	× 1647
		Yes	0% Autologous Plasma AIM V	CH-296	× 1832
		No	No	CH-296	× 931
		Yes	0.5% Autologous Plasma AIM V	CH-296	× 1960
0.5% Autologous Plasma AIM V and Optisite Bag	E	No	No	Control (Without Immobilization of FNfr)	× 743
		No	No	CH-296	× 931
		Yes	0.5% Autologous Plasma AIM V	CH-296	× 1960
		Yes	0% Autologous Plasma AIM V	CH-296	× 1747
		No	No	CH-296	× 931
		Yes	0.5% Autologous Plasma AIM V	CH-296	× 1960

**[0314]** As shown in Table 51, in the group using the flask for cell culture to which each of the fibronectin fragments was immobilized at an early stage of the induction of LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium (AIM V) containing the low-concentration autologous plasma (0.5%), the expansion fold of LAK cells was high regardless of culture area, culture method, final amount of medium for the CO<sub>2</sub> gas-permeable bag for cell culture. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium containing a low-concentration plasma.

**Example 52 Determination of Ratio of CD8-Positive Cells in LAK Cell Population Using Freshly Isolated PBMCs and Autologous Plasma-Containing Medium (with AIM V Medium Containing 0.5% Autologous Plasma Culture in Combination of Flask for Cell Culture and CO<sub>2</sub> Gas-Permeable Bag for Cell Cultured**

(1) Induction and Culture of LAK Cells

**[0315]** The induction and the culture of LAK cells were carried out in the same manner as in item (2) of Example 51. On the fifteenth day from the initiation of culture, the content ratio of CD8-positive cells was determined in the same

manner as in item (2) of Example 4. The results are shown in Table 52.

Table 52

Plasma Concentration, Medium and CO <sub>2</sub> Gas-Permeable Bag for Cell Culture	PBMCs Donor	Addition of Medium on Eleventh Day	Medium Added on Eleventh Day	Fibronectin Fragment	Ratio of CD8-Positive Cells (%)
0.5% Autologous Plasma AIM V and Optisite Bag	C	No	No	Control (Without Immobilization of FNfr)	59.1
		No	No	CH-296	80.8
		Yes	0.5% Autologous Plasma AIM V	CH-296	83.3
		Yes	0% Autologous Plasma AIM V	CH-296	83.6
0.5% Autologous Plasma AIM V and Optisite Bag	D	No	No	Control (Without Immobilization of FNfr)	77.2
		No	No	CH-296	83.4
		Yes	0.5% Autologous Plasma AIM V	CH-296	84.0
		Yes	0% Autologous Plasma AIM V	CH-296	85.9
0.5% Autologous Plasma AIM V and Optisite Bag	E	No	No	Control (Without Immobilization of FNfr)	72.6
		No	No	CH-296	84.6
		Yes	0.5% Autologous Plasma AIM V	CH-296	86.8
		Yes	0% Autologous Plasma AIM V	CH-296	89.4

**[0316]** As shown in Table 52, in the group using the flask for cell culture to which each of the fibronectin fragments was immobilized at an early stage of the induction of LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium (AIM V) containing a low-concentration autologous plasma (0.5%), the ratio of CD8-positive cells in the LAK cell population was high regardless of culture area, culture method, final amount of medium for the CO<sub>2</sub> gas-permeable bag for cell culture. It was clarified from the above that each of the fibronectin fragments was suitably used during the culture of LAK cells in the combination of the flask for cell culture and the CO<sub>2</sub> gas-permeable bag for cell culture using the medium containing a low-concentration plasma.

#### Example 53 Induction of IL-2 Receptor (IL-2 R) Expression in Culture System of LAK Cells Using Low-Serum Medium (AIM V)

##### (1) Induction and Culture of LAK Cells

**[0317]** The induction and the culture of LAK cells were carried out in the same manner as in item (3) of Example 1. Upon the induction and the culture, a medium to be used was changed to AIM V medium containing 1% human AB serum.

## (2) Determination of Ratio of IL-2R Expression in LAK Cells

**[0318]** The content ratio of the IL-2R expression-positive cells was determined in the same manner as in item (2) of Example 3. The results are shown in Table 53. In the table, the content ratio of IL-2R expression-positive cells (%) is shown as the ratio of IL-2R expression (%).

Table 53

Serum Concentration and Medium	Fibronectin Fragment	Ratio of IL-2R Expression (%)
1% AIM V	Control (Without Immobilization of FNfr)	23.5
1% AIM V	CH-296	27.2

**[0319]** As shown in Table 53, in the group using the culture equipment to which each of the fibronectin fragments was immobilized at an early stage of the induction of LAK cells using AIM V medium containing a low-concentration serum, the ratio of IL-2R expression on the surface of LAK cells during culture could be induced at a high level. In other words, it was clarified that, the LAK cells could be induced and cultured with increasing the ratio of IL-2R expression using the medium containing a low-concentration serum, in the copresence of the fibronectin fragment during the induction of LAK cells.

Example 54 Expression of Retronectin Mutant Protein (CH-296Na)

## (1) Construction of CH-296Na Expression Vector

**[0320]** PCR was carried out using synthetic DNA primers of SEQ ID NOs: 27 and 28 (Primer CH-296Na1 and Primer CH-296Na2, respectively), with pCH102, a CH-296 expression vector, as a template. The resulting DNA fragment was treated with restriction enzymes *Nde*I and *Hind*III. On the other hand, a pCold14ND2 vector was prepared, having an *Nde*I site at a translation initiation codon prepared from pCold04 described in Example 5 of WO 99/27117 Pamphlet in accordance with the method of Example 4 of the same pamphlet. The above-mentioned DNA fragment was inserted into an *Nde*I-*Hind*III restriction enzyme site of the pCold14ND2 vector to give a vector pCold14ND2-CH296. Next, PCR was carried out with a pLF2435 vector having a cDNA encoding from a part to a C-terminal of a cell binding domain of fibronectin as a template, using synthetic DNA primers of SEQ ID NOs: 28 and 29 (Primer CH-296Na2 and Primer CH-296Na3, respectively). The resulting DNA fragment was treated with restriction enzymes *Bam*HI and *Hind*III. The DNA fragment thus obtained was ligated with a product obtained by treating pCold14ND2-CH296 with restriction enzymes *Bam*HI and *Hind*III, to prepare a vector for expressing CH-296Na.

## (2) Expression and Purification of CH-296Na

**[0321]** *Escherichia coli* BL21 was transformed using pCold14-CH296Na prepared in the above-mentioned item (1) of Example 54, and the resulting transformant was grown on LB medium (containing 50  $\mu$ g/mL ampicillin) containing agar having a 1.5% (w/v) concentration. The grown colony was inoculated on 30 mL LB liquid medium (containing 50  $\mu$ g/mL ampicillin), and the colony was cultured overnight at 37°C. A whole amount of cultured cells was inoculated on 3 L of the same LB medium, and the cells were cultured at 37°C up to a logarithmic growth phase. Upon this culture, a 5 L minijar fermenter (manufactured by Biot) was used, and the culture was carried out under the conditions of 150 rpm and Air = 1.0 L/min. After the above-mentioned culture, the culture medium was cooled to 15°C, IPTG was then added thereto so as to have a final concentration of 1.0 mM, and the culture was carried out in this state at 15°C for 24 hours to induce expression. Thereafter, bacterial cells were harvested by centrifugation, and resuspended in a cell disruption solution [50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 50 mM NaCl] in an amount of 4 times the volume of the bacterial cells. The bacterial cells were disrupted by ultrasonic disruption, and the disruption was centrifuged (11,000 rpm, 20 minutes) to separate the disruption into an extract of supernatant and precipitates. The supernatant was dialyzed against 2 L of a buffer A [50 mM Tris-HCl (pH 7.5), 50 mM NaCl], and about 40 mL of the resulting solution was used for further purification by ion-exchange chromatography as follows.

**[0322]** Concretely, a column ( $\phi$ 4 cm, 20 cm) of SP-Sepharose (manufactured by Amersham Pharmacia) having a resin volume corresponding to 100 mL, saturated with the buffer A was furnished, and the dialyzed sample was applied to the column. The column was washed with 300 mL of the buffer A, and thereafter the elution from the column was carried out using, in order, 200 mL each of a buffer B [50 mM Tris-HCl (pH 7.5), 200 mM NaCl], a buffer C [50 mM Tris-HCl (pH 7.5), 300 mM NaCl], and a buffer D [50 mM, Tris-HCl (pH 7.5), 500 mM NaCl], and an about 100 mL portion each was collected, to give fractions 1 to 6. The collected fractions were subjected to 10% SDS-PAGE, and consequently,

fractions 2 and 3 (about 200 mL) which were found to contain the desired protein having a molecular weight of about 71 kDa in a large amount were collected, and dialyzed against 2 L of the buffer A.

**[0323]** Next, a column ( $\phi$ 3 cm, 16 cm) of Q-Sepharose (manufactured by Amersham Pharmacia) having a resin volume corresponding to 50 mL, saturated with the buffer A was furnished, and the dialyzed sample was applied to the column. The column was washed with 200 mL of the buffer A, and thereafter the elution from the column was carried out using, in order, 150 mL each of a buffer E [50 mM Tris-HCl (pH 7.5), 140 mM NaCl], the buffer B, and the buffer C, and an about 100 mL portion each was collected, to give fractions 1 to 5. Those fractions were subjected to 10% SDS-PAGE, and consequently a fraction 1 which was found to contain only the desired protein in a large amount, was collected in an amount of about 100 mL, and dialyzed against 2 L of a buffer F [50 mM sodium carbonate buffer, pH 9.5].

**[0324]** Subsequently, the dialyzed fraction was concentrated about 4 times to a volume of 25 mL, with Centricon-10 (manufactured by Millipore Corporation), and the concentrate was confirmed by 10% SDS-PAGE. Consequently, the desired protein having a molecular weight of about 71 kDa was detected as an approximately single band, which was named as CH-296Na. Thereafter, a protein concentration was determined using a MicroBCA kit (manufactured by Pierce). As a result, the protein concentration was found to be 3.8 mg/mL.

**Example 55 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (AIM V)**  
(Serum Concentrations 5% → 1% → 0% → 0%, 5% → 1% → 0.05% → 0.05%, 3% → 1% → 0.05% → 0.05%, 3% → 1% → 0.1% → 0.05%, 1% → 1% → 0.1% → 0.05%)

**[0325]** From the same viewpoint as that of Example 43, and the influence of the serum concentration on the culture system of LAK cells was confirmed, taking a plasma concentration obtained by collecting 30 mL blood into consideration.

**[0326]** There were respectively set a group containing a human AB serum concentration of 5%, 3% or 1% at the initiation of culture, and a group subsequently diluted with AIM V medium containing a human AB serum concentration as shown in the following Table 54. Here, groups in which the subculture concentrations were changed on each subculture day as shown in the following Table 54 were set, respectively.

Table 54 Serum Concentration Patterns

			on Zeroth Day from Initiation of Culture	on Fourth Day from Initiation of Culture	on Seventh Day from Initiation of Culture	on Tenth Day from Initiation of Culture
	Serum Concentration	Serum Concentration	5%	1%	0%	0%
	Pattern 1-1	Subculture Concentration	-	0.1	0.321	0.873
	Serum Concentration	Serum Concentration	5%	1%	0.05%	0.05%
	Pattern 1-2	Subculture Concentration	-	0.2	0.321	0.841
	Serum Concentration	Serum Concentration	3%	1%	0.05%	0.05%
	Pattern 2-1	Subculture Concentration	-	0.1	0.321	0.746
	Serum Concentration	Serum Concentration	3%	1%	0.1%	0.05%
	Pattern 2-2	Subculture Concentration	-	0.2	0.321	0.643
	Serum Concentration	Serum Concentration	1%	1%	0.1%	0.05%
	Pattern 3-1	Subculture Concentration	-	0.1	0.321	0.643
	Serum Concentration	Serum Concentration	1%	1%	0.1%	0.05%
	Pattern 3-2	Subculture Concentration	-	0.05	0.417	1.214

Table continued

Serum Concentration	Serum Concentration	1%	1%	0.1%	No Subculture, No Addition of Medium
Pattern 3-3	Subculture Concentration	-	0.05	0.23	

\*Cell Subculture Concentration: ( $\times 10^6$  cells/mL)

\*Serum concentrations in the table are the concentrations at the initiation for the zeroth day from the initiation of culture, and serum concentrations contained in the medium used for dilution for the subsequent days.

**[0327]** PBMCs which were prepared in item (1) of Example 1 were suspended in AIM V containing 5%, 3% or 1% human AB serum so as to have a concentration of  $0.33 \times 10^6$  cells/mL, and thereafter the suspension was put on a plate immobilized with the anti-human CD3 antibody or a plate immobilized with the anti-human CD3 antibody and CH-296, prepared in item (1) of Example 41, in a volume of 3 mL/well each, and IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These plates were incubated at 37°C in 5% CO<sub>2</sub> (zeroth day of culture).

**[0328]** On the fourth day from the initiation of culture, each of the groups was diluted with AIM V containing 1% human AB serum (amount of liquid: 6 mL) so as to have a concentration of  $0.1 \times 10^6$  cells/mL for groups in which the culture was carried out under the serum concentration patterns 1-1, 2-1 and 3-1, or so as to have a concentration of  $0.2 \times 10^6$  cells/mL for groups in which the culture was carried out under the serum concentration patterns 1-2 and 2-2, or so as to have a concentration of  $0.05 \times 10^6$  cells/mL for groups in which the culture was carried out under the serum concentration patterns 3-2 and 3-3. The dilution was transferred to a 12.5 cm<sup>2</sup> cell culture flask to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0329]** On the seventh day from the initiation of culture, the group in which the culture was carried out under the serum concentration pattern 1-1 was diluted with AIM V without containing human AB serum (amount of liquid: 12.6 mL) so as to have a concentration of  $0.321 \times 10^6$  cells/mL, groups in which the culture was carried out in the serum concentration patterns 1-2 and 2-1 were diluted with AIM V containing 0.05% human AB serum (amount of liquid: 12.6 mL) so as to have a concentration of  $0.321 \times 10^6$  cells/mL, and each of the groups was diluted with AIM V containing 0.1% human AB serum (amount of liquid: 12.6 mL), so as to have a concentration of  $0.321 \times 10^6$  cells/mL for groups in which the culture was carried out under the serum concentration patterns 2-2 and 3-1, or so as to have a concentration of  $0.417 \times 10^6$  cells/mL for the group in which the culture was carried out under the serum concentration pattern 3-2, or so as to have a concentration of  $0.23 \times 10^6$  cells/mL for the group in which the culture was carried out under the serum concentration pattern 3-3, respectively. Each group was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0330]** On the tenth day from the initiation of culture, the group in which the culture was carried out under the serum concentration pattern 1-1 was diluted with AIM V without containing human AB serum (amount of liquid: 12.6 mL) so as to have a concentration of  $0.873 \times 10^6$  cells/mL, and each of the groups was diluted with AIM V containing 0.05% human AB serum (amount of liquid: 12.6 mL), so as to have a concentration of  $0.841 \times 10^6$  cells/mL for the group in which the culture was carried out under the serum concentration pattern 1-2, or so as to have a concentration of  $0.746 \times 10^6$  cells/mL for the group in which the culture was carried out under the serum concentration pattern 2-1, or so as to have a concentration of  $0.643 \times 10^6$  cells/mL for the groups in which the culture was carried out under the serum concentration patterns 2-2 and 3-1, or so as to have a concentration of  $1.214 \times 10^6$  cells/mL for the group in which the culture was carried out under the serum concentration pattern 3-2, respectively. The dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0331]** On the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. Each experiment was carried out twice. Each of the average results is shown in Table 55.

Table 55

	Stimulation on Zeroth Day from Initiation of Culture	Expansion Fold (fold)
Serum Concentration Pattern 1-1	Anti-CD3	460
	Anti-CD3 + CH-296	708
Serum Concentration Pattern 1-2	Anti-CD3	354
	Anti-CD3 + CH-296	616



# EP 1 666 589 A1

Table continued

	Stimulation on Zeroth Day from Initiation of Culture	Expansion Fold (fold)
5	Serum Concentration Pattern 2-1	Anti-CD3
	Anti-CD3 + CH-296	338
	Serum Concentration Pattern 2-2	Anti-CD3
	Anti-CD3 + CH-296	630
10	Serum Concentration Pattern 3-1	Anti-CD3
	Anti-CD3 + CH-296	289
	Serum Concentration Pattern 3-2	Anti-CD3
	Anti-CD3 + CH-296	514
15	Serum Concentration Pattern 3-3	Anti-CD3
	Anti-CD3 + CH-296	317
	Serum Concentration Pattern 3-3	Anti-CD3
	Anti-CD3 + CH-296	551
	Serum Concentration Pattern 3-3	Anti-CD3
	Anti-CD3 + CH-296	243
	Serum Concentration Pattern 3-3	Anti-CD3
	Anti-CD3 + CH-296	587
	Serum Concentration Pattern 3-3	Anti-CD3
	Anti-CD3 + CH-296	257
	Serum Concentration Pattern 3-3	Anti-CD3
	Anti-CD3 + CH-296	564

[0332] As shown in Table 55, during the culture of LAK cells using AIM V medium containing each serum concentration, in any of serum concentration groups and in any of subculture concentration group, a high expansion fold was obtained in the group stimulated with CH-296 and the anti-CD3 antibody as compared to that of the control group (stimulation only with anti-CD3 antibody). In other words, in the culture of LAK cells at a serum concentration on the assumption of 30 mL blood collection, the LAK cells could be clearly induced and cultured at a high expansion fold by stimulation with CH-296 and the anti-CD3 antibody than the stimulation with only the anti-CD3 antibody. In addition, the cells during this culture were in a high concentration and at a high density, and the expansion fold was clearly high by stimulation with CH-296 even under the conditions mentioned above, so that the effectiveness of CH-296 was found.

Example 56 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (AIM V) (IL-2 concentrations 100 U/mL - 150 U/mL → 150 U/mL → 300 U/mL, 200 U/mL → 300 U/mL → 300 U/mL → 400 U/mL, 1000 U/mL → 500 U/mL → 500 U/mL → 500 U/mL)

[0333] The influence of IL-2 concentration on the culture system of LAK cells was confirmed.

[0334] IL-2 concentrations to be added at the initiation of culture and during the subculture were set as shown in the following Table 56-1.

Table 56-1

	on Zeroth Day from Initiation of Culture	on Fourth Day from Initiation of Culture	on Seventh Day from Initiation of Culture	on Tenth Day from Initiation of Culture
IL-2 Concentration Pattern 1	100	150	150	300
IL-2 Concentration Pattern 2	200	300	300	400
IL-2 Concentration Pattern 3	1000	500	500	500
*IL-2 concentration (U/mL)				

[0335] PBMCs which were prepared in item (1) of Example 1 were suspended in AIM V containing 3% human AB serum so as to have a concentration of  $0.33 \times 10^6$  cells/mL, and thereafter the suspension was put on a plate immobilized with the anti-human CD3 antibody or a plate immobilized with the anti-human CD3 antibody and CH-296, prepared in item (1) of Example 41, in a volume of 3 mL/well each, and IL-2 was added thereto so as to have a final concentration of 100 U/mL, 200 U/mL or 1000 U/mL. These plates were incubated at 37°C in 5% CO<sub>2</sub> (zeroth day of culture).

[0336] On the fourth day from the initiation of culture, each group was diluted with AIM V containing 1% human AB serum (amount of liquid: 6 mL) so as to have a concentration of  $0.1 \times 10^6$  cells/mL, and the dilution was transferred to a 12.5 cm<sup>2</sup> cell culture flask to which nothing was immobilized. IL-2 was added thereto so as to have a final concentration of 150 U/mL in the IL-2 concentration pattern 1, or so as to have a final concentration of 300 U/mL in the IL-2 concentration pattern 2, or so as to have a final concentration of 500 U/mL in the IL-2 concentration pattern 3, respectively.

**[0337]** On the seventh day from the initiation of culture, each group was diluted with AIM V containing 0.05% human AB serum (amount of liquid: 12.6 mL) so as to have a concentration of  $0.262 \times 10^6$  cells/mL, and the dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. IL-2 was added thereto so as to have a final concentration of 150 U/mL in the IL-2 concentration pattern 1, or so as to have a final concentration of 300 U/mL in the IL-2 concentration pattern 2, or so as to have a final concentration of 500 U/mL in the IL-2 concentration pattern 3, respectively.

**[0338]** On the tenth day from the initiation of culture, each group was diluted with AIM V containing 0.05% human AB serum (amount of liquid: 12.6 mL) so as to have a concentration of  $0.585 \times 10^6$  cells/mL, and the dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. IL-2 was added thereto so as to have a final concentration of 300 U/mL in the IL-2 concentration pattern 1, or so as to have a final concentration of 400 U/mL in the IL-2 concentration pattern 2, or so as to have a final concentration of 500 U/mL in the IL-2 concentration pattern 3.

**[0339]** On the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. Each experiment was carried out twice. Each of the average results is shown in Table 56-2.

Table 56-2

Stimulation on Zeroth Day from Initiation of Culture		Expansion Fold (fold)
IL-2 Concentration Pattern 1	Anti-CD3	312
	Anti-CD3 + CH-296	522
IL-2 Concentration Pattern 2	Anti-CD3	331
	Anti-CD3 + CH-296	730
IL-2 Concentration Pattern 3	Anti-CD3	146
	Anti-CD3 + CH-296	571

**[0340]** As shown in Table 56-2, during the culture of LAK cells in which the culture was carried out in various IL-2 concentrations during the subculture, in any of the IL-2 concentration groups, a high expansion fold was obtained in the group stimulated with CH-296 and the anti-CD3 antibody as compared to that of the control group (stimulation only with anti-CD3 antibody). In other words, even when the IL-2 concentrations were changed, the LAK cells could be induced and cultured clearly at a high expansion fold by stimulation with CH-296 and the anti-CD3 antibody, than that of stimulation only with the anti-CD3 antibody. In addition, the cells during this culture were in a high concentration and at a high density. Also, the serum concentration was set assuming that blood is collected in a volume of 30 mL, and a total amount of the culture medium is 10 L, and the expansion fold was clearly high even under the conditions mentioned above by stimulation with CH-296, so that the effectiveness of CH-296 was found.

#### Example 57 Content Ratio of CD8-Positive Cells in LAK Cell Population Cultured Using Low-Serum Medium (AIM V) (Studies on IL-2 Concentration)

##### (1) Induction and Culture of LAK Cells

**[0341]** The induction and the culture of LAK cells were carried out in the same manner as in Example 56.

##### (2) Determination of Content Ratio of CD8-Positive Cell Population in LAK Cells

**[0342]** The content ratio of the CD8-positive cells was determined in the same manner as in item (2) of Example 4. The results are shown in Table 57.

Table 57

Stimulation on Zeroth Day from Initiation of Culture		Content Ratio of CD8-Positive Cells (%)
IL-2 Concentration Pattern 1	Anti-CD3	60
	Anti-CD3 + CH-296	65
IL-2 Concentration Pattern 2	Anti-CD3	60
	Anti-CD3 + CH-296	62

Table continued

	Stimulation on Zeroth Day from Initiation of Culture	Content Ratio of CD8-Positive Cells (%)
5	IL-2 Concentration Pattern 3	
	Anti-CD3	59
	Anti-CD3 + CH-296	67

**[0343]** As shown in Table 57, in any of the groups in which the IL-2 concentrations were changed at the initiation of culture or during the subculture, the content ratio of the CD8-positive cells in LAK cells during the culture could be induced at a high level in the group stimulated with CH-296 and the anti-CD3 antibody as compared to that of the control group (stimulated only with anti-CD3 antibody). In other words, it was clarified that the LAK cells could be clearly induced and cultured while increasing the content ratio of the CD8-positive cells in the LAK cells by stimulation with CH-296, even when the IL-2 concentrations were changed.

**Example 58 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (AIM V)**  
(Studies on Initial Concentration at Initiation of Culture)

**[0344]** The influence of the initial cell concentration at the initiation of culture on the expansion fold in the culture system of LAK Cells on the assumptions of 30 mL blood collection, and about 10 L of a final culture medium amount was confirmed.

**[0345]** Each group having an initial cell concentration at the initiation of culture of  $0.083 \times 10^6$  cells/mL,  $0.167 \times 10^6$  cells/mL or  $0.33 \times 10^6$  cells/mL was set.

(1) Immobilization of Anti-Human CD3 Antibody and FN Fragment

**[0346]** An anti-human CD3 antibody and an FN fragment were immobilized to a culture equipment used in the following experiment. Concretely, 1.9 mL each or 4.8 mL each of PBS containing the anti-human CD3 antibody (final concentration: 5  $\mu$ g/mL) was added to a 12-well cell culture plate or a 6-well cell culture plate (manufactured by Falcon). Upon the addition, a fibronectin fragment (CH-296) described in Preparation Example 1 was added to a group with addition of an FN fragment so as to have a final concentration of 25  $\mu$ g/mL. As a control, there was also set a group without addition of CH-296.

**[0347]** These culture equipments were incubated at room temperature for 5 hours, and stored at 4°C until use. Immediately before use, PBS containing the anti-human CD3 antibody and CH-296 was removed by aspiration from these culture equipments, and each well was washed twice with PBS, and once with RPMI medium. Each experiment was carried out using the culture equipment.

(2) Induction and Culture of LAK Cells

**[0348]** PBMCs which were prepared in item (1) of Example 1 were suspended in AIM V containing 3% human AB serum so as to have a concentration of  $0.083 \times 10^6$  cells/mL,  $0.167 \times 10^6$  cells/mL or  $0.33 \times 10^6$  cells/mL. Thereafter, the suspension was put on a 6-well cell culture plate immobilized with the anti-human CD3 antibody or a 6-well cell culture plate immobilized with the anti-human CD3 antibody and CH-296, prepared in item (1) of Example 58, in a volume of 7.5 mL/well each, in a group in which the culture was initiated at a concentration of  $0.083 \times 10^6$  cells/mL or  $0.167 \times 10^6$  cells/mL; or the suspension was put on a 12-well cell culture plate immobilized with the anti-human CD3 antibody or a 12-well cell culture plate immobilized with the anti-human CD3 antibody and CH-296, prepared in item (1) of Example 58, in a volume of 3 mL/well each, in a group in which the culture was initiated at  $0.33 \times 10^6$  cells/mL. IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These plates were incubated at 37°C in 5% CO<sub>2</sub> (zeroth day of culture).

**[0349]** On the fourth day from the initiation of culture, each group was diluted with AIM V containing 1% human AB serum (amount of liquid: 6 mL) so as to have a maximum concentration of  $0.1 \times 10^6$  cells/mL, and the dilution was transferred to a 12.5 cm<sup>2</sup> cell culture flask to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0350]** On the seventh day from the initiation of culture, each group was diluted with AIM V containing 0.05% human AB serum (maximum amount of liquid: 12.6 mL), so as to have a concentration of  $0.227 \times 10^6$  cells/mL for the group in which culture was initiated at a concentration of  $0.083 \times 10^6$  cells/mL, or so as to have a concentration of  $0.276 \times 10^6$  cells/mL for the group in which culture was initiated at a concentration of  $0.167 \times 10^6$  cells/mL, or so as to have a concentration of  $0.465 \times 10^6$  cells/mL for the group in which culture was initiated at a concentration of  $0.33 \times 10^6$

cells/mL, respectively. The dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0351]** On the tenth day from the initiation of culture, each group was diluted with AIM V containing 0.05% human AB serum (amount of liquid: 12.6 mL), so as to have a concentration of  $0.58 \times 10^6$  cells/mL for the group in which culture was initiated at a concentration of  $0.083 \times 10^6$  cells/mL, so as to have a concentration of  $0.75 \times 10^6$  cells/mL for the group in which culture was initiated at a concentration of  $0.167 \times 10^6$  cells/mL, or so as to have a concentration of  $0.79 \times 10^6$  cells/mL for the group in which culture was initiated at a concentration of  $0.33 \times 10^6$  cells/mL, respectively. The dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0352]** On the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. Each experiment was carried out twice. Each of the average results is shown in Table 58.

Table 58

Initial Cell Concentration at Initiation of Culture ( $\times 10^6$ cells/mL)	Stimulation on Zeroth Day from Initiation of Culture	Expansion Fold (fold)
0.083	Anti-CD3	70
	Anti-CD3 + CH-296	593
0.167	Anti-CD3	104
	Anti-CD3 + CH-296	525
0.33	Anti-CD3	272
	Anti-CD3 + CH-296	565

**[0353]** As shown in Table 58, even in the group in which the culture was initiated at any of cell concentrations, a high expansion fold was obtained in the group stimulated with CH-296 and the anti-CD3 antibody as compared to that of the control group (stimulation only with anti-CD3 antibody). In other words, even when the culture was initiated at various cell concentrations, the LAK cells could be clearly induced and cultured at a high expansion fold by stimulation with CH-296 and the anti-CD3 antibody as compared to that of stimulation only with the anti-CD3 antibody. In addition, the culture was carried out on the assumption of 30 mL blood collection, and 10 L of a final culture medium amount, and the expansion fold was clearly high by stimulation with CH-296 even under the conditions mentioned above, so that the effectiveness of CH-296 was found. Further, in the control group, although a case where the expansion fold was greatly fluctuated depending on the initial cell concentration at the initiation of culture was confirmed, stable expansion folds were obtained in the groups stimulated with CH-296, regardless of the initial cell concentration at the initiation of culture.

#### Example 59 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (AIM V) (Stimulation Period)

**[0354]** The influence of the day numbers of stimulation at the initiation of culture only with the anti-CD3 antibody or with the anti-CD3 antibody and CH-296 in the culture system of LAK cells on the expansion fold was confirmed.

**[0355]** Each group in which the day number of stimulation was 2 days, 3 days or 4 days was set.

**[0356]** PBMCs which were prepared in item (1) of Example 1 were suspended in AIM V containing 3% human AB serum so as to have a concentration of  $0.33 \times 10^6$  cells/mL in each group, the suspension was then put on a plate immobilized with the anti-human CD3 antibody or a plate immobilized with the anti-human CD3 antibody and CH-296, prepared in item (1) of Example 41, in a volume of 3 mL/well each, and IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These plates were incubated at 37°C in 5% CO<sub>2</sub> (zeroth day of culture).

**[0357]** On the second day or the third day from the initiation of culture, the group with 2-day stimulation or the group with 3-day stimulation was transferred as it was to a fresh 12-well culture plate to which nothing was immobilized.

**[0358]** On the fourth day from the initiation of culture, each group was diluted with AIM V containing 1% human AB serum (amount of liquid: 6 mL) so as to have a concentration of  $0.1 \times 10^6$  cells/mL, and each dilution was transferred to a 12.5 cm<sup>2</sup> cell culture flask to which nothing was immobilized. In each group, IL-2 was respectively added thereto so as to have a final concentration of 500 U/mL.

**[0359]** On the seventh day from the initiation of culture, each group was diluted with AIM V containing 0.05% human AB serum (amount of liquid: 12.6 mL) so as to have a concentration of  $0.45 \times 10^6$  cells/mL, and each dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. In each group, IL-2 was respectively added thereto so as to have a final concentration of 500 U/mL.

**[0360]** On the tenth day from the initiation of culture, each group was diluted with AIM V containing 0.05% human AB serum (amount of liquid: 12.6 mL) so as to have a concentration of  $0.6 \times 10^6$  cells/mL, and each dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. In each group, IL-2 was respectively added thereto so as to have a final concentration of 500 U/mL.

**[0361]** On the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number with of the cells the number at the initiation of culture. Each experiment was carried out twice. Each of the average results is shown in Table 59.

Table 59

	Stimulation on Zeroth Day from Initiation of Culture	Expansion Fold (fold)
Stimulation Period: 2 days	Anti-CD3	266
	Anti-CD3 + CH-296	438
Stimulation Period: 3 days	Anti-CD3	424
	Anti-CD3 + CH-296	562
Stimulation Period: 4 days	Anti-CD3	257
	Anti-CD3 + CH-296	568

**[0362]** As shown in Table 59, during the culture of LAK cells cultured for the various stimulation periods from the initiation of culture, in any groups with any stimulation period, the high expansion folds were obtained in the groups stimulated with CH-296 and the anti-CD3 antibody as compared to those of the control group (stimulation only with anti-CD3 antibody). In other words, even when the stimulation period was changed, the LAK cells could be clearly induced and cultured at a high expansion fold by stimulation with CH-296 and the anti-CD3 antibody, than that of stimulation only with the anti-CD3 antibody. In addition, the cells during this culture were in a high concentration and at a high density, and the serum concentration was on assumption of 30 mL blood collection and a total culture medium amount of 10 L and, the expansion fold was clearly high by stimulation with CH-296 even under the conditions described above, so that the effectiveness of CH-296 was found.

#### Example 60 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (AIM V) (CH-296Na)

**[0363]** An expansion fold in the culture system of LAK cells using CH-296Na as an FN fragment was determined.

**[0364]** A group in which CH-296Na was immobilized to a cell culture plate, and a group in which CH-296Na was added as it was to a cell culture medium were set.

#### (1) Immobilization of Anti-Human CD3 Antibody and FN Fragment

**[0365]** An anti-human CD3 antibody and an FN fragment were immobilized to a culture equipment used in the following experiment. Concretely, 1.9 mL each of PBS containing the anti-human CD3 antibody (final concentration: 5 µg/mL) was added to a 12-well cell culture plate. Upon the addition, a fibronectin fragment (CH-296Na) described in Example 54 was added to a group with addition of an FN fragment so as to have a final concentration of 28.6 µg/mL. As a control, there was also set a group without addition of CH-296Na.

**[0366]** These culture equipments were incubated at room temperature for 5 hours, and stored at 4°C until use. Immediately before use, PBS containing the anti-human CD3 antibody and CH-296Na was removed by aspiration from these culture equipments, and each well was washed twice with PBS, and once with RPMI medium. Each experiment was carried out using the culture equipment.

#### (2) Induction and Culture of LAK Cells

**[0367]** PBMCs which were prepared in item (1) of Example 1 were respectively suspended in AIM V containing 3% human AB serum so as to have a concentration of  $0.33 \times 10^6$  cells/mL, and thereafter the suspension was put on a cell culture plate immobilized with the anti-human CD3 antibody or a cell culture plate immobilized with the anti-human CD3 antibody and CH-296Na, prepared in item (1) of Example 60, in a volume of 3 mL/well each. In addition, in the group in which CH-296Na was added as it was to a cell culture medium, CH-296Na was added to the cells which were put on the cell culture plate immobilized with the anti-human CD3 antibody, so as to have a final concentration of 1 µg/mL. In each group, IL-2 was added thereto so as to have a final concentration of 1000 U/mL. These plates were incubated at

37°C in 5% CO<sub>2</sub> (zeroth day of culture).

**[0368]** On the fourth day from the initiation of culture, each group was diluted with AIM V containing 1% human AB serum (amount of liquid: 6 mL) so as to have a concentration of  $0.1 \times 10^6$  cells/mL, and the dilution was transferred to a 12.5 cm<sup>2</sup> cell culture flask to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0369]** On the seventh day from the initiation of culture, each group was diluted with AIM V containing 0.05% human AB serum (amount of liquid: 12.6 mL), respectively, so as to have a concentration of  $0.5 \times 10^6$  cells/mL, and each dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0370]** On the tenth day from the initiation of culture, each group was diluted with AIM V containing 0.05% human AB serum (amount of liquid: 12.6 mL), respectively, so as to have a concentration of  $0.94 \times 10^6$  cells/mL, and each dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0371]** On the fifteenth day at the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. Each experiment was carried out twice. Each of the average results is shown in Table 60.

Table 60

Stimulation on Zeroth Day from Initiation of Culture	Expansion Fold (fold)
Anti-CD3	222
Immobilized with Anti-CD3 + CH-296Na	922
Addition of Anti-CD3 + CH-296Na Solution	651

**[0372]** As shown in Table 60, a high expansion fold was obtained in any group in which CH-296Na was immobilized or added as a solution, as compared to that of the control group (stimulation only with anti-CD3 antibody). In other words, the LAK cells could be clearly induced and cultured in a high expansion fold by stimulation with CH-296Na and the anti-CD3 antibody, as compared to that of stimulation only with the anti-CD3 antibody. Here, the culture was on the assumptions of 30 mL blood collection, and a final culture medium amount of 10 L, and the expansion fold was clearly high by stimulation with CH-296Na under the conditions as described above, so that the effectiveness of CH-296Na was found.

#### Example 61 Preparation of CH-296 Beads

**[0373]** As beads for immobilizing CH-296, Dynabeads M-450 Epoxy (manufactured by Dynal) were used.  $2.8 \times 10^8$  Dynabeads M-450 Epoxy were washed three times with a 0.1 M phosphate buffer (pH 7.0). The washed  $2.8 \times 10^8$  Dynabeads M-450 Epoxy were suspended in 0.7 mL of PBS containing 140 µg of CH-296, and an immobilization reaction was carried out overnight at 4°C while gently mixing. The reaction solution was removed, and replaced three times with 0.7 mL of PBS containing 0.1% human serum albumin (HSA), and then stored at 4°C, to give CH-296 beads.

**[0374]** In addition, beads without containing CH-296 were treated in the same manner, to give control beads.

#### Example 62 Preparation of CD3/CH-296 Beads

**[0375]** As beads for immobilizing CH-296 and the anti-human CD3 antibody, Dynabeads M-450 Epoxy were used.  $4 \times 10^8$  Dynabeads M-450 Epoxy were washed three times with a 0.1 M phosphate buffer (pH 7.0). The washed  $4 \times 10^8$  Dynabeads M-450 Epoxy were suspended in 1 mL of PBS containing 160 µg of CH-296 and 32 µg of the anti-human CD3 antibody, and an immobilization reaction was carried out overnight at 4°C while gently mixing. The reaction solution was removed, and replaced three times with 1 mL of PBS containing 0.1% human serum albumin (HSA), and then stored at 4°C, to give CD3/CH-296 beads.

#### Example 63 Determination of Expansion Fold in Culture System of LAK Cells Using Low-Serum Medium (AIM V) (Stimulation with Beads Immobilized with FNfr)

**[0376]** The effects on an LAK cell culture using a fibronectin fragment (CH-296) immobilized to a cell culture carrier (beads) was confirmed.

**[0377]** A group stimulated with the CD3 beads in which the anti-CD3 antibody was immobilized to the beads and the control beads to which nothing was immobilized (CD3 beads group), a group stimulated with the CD3 beads and the CH-296 beads in which the CH-296 was immobilized to the beads (CD3 beads + CH-296 beads group), and a group

stimulated with CD3 /CH-296 beads in which the anti-CD3 antibody and CH-296 were immobilized to beads (CD3 / CH-296 beads group) were set.

**[0378]** PBMCs which were prepared in item (1) of Example 1 were suspended in AIM V containing 1% human AB serum so as to have a concentration of  $0.33 \times 10^6$  cells/mL. Thereafter, the suspension was put on a 12-well culture plate to which nothing was immobilized in a volume of 3 mL/well each, so that CD3 beads (Dynabeads M-450 CD3 (panT), Bellitus, DB11113) were added thereto in an amount of  $1 \times 10^6$  beads/well and control beads which were prepared in Example 61 were added thereto in an amount of  $3.8 \times 10^6$  beads/well in the CD3 beads group, or that the CD3 beads were added thereto in an amount of  $1 \times 10^6$  beads/well, and CH-296 beads which were prepared in Example 61 were added thereto in an amount of  $0.76 \times 10^6$  beads/well in the CD3 beads + CH-296 beads group, or that CD3/CH-296 beads which were prepared in Example 62 were added thereto in an amount of  $2.3 \times 10^6$  beads/well in the CD3 / CH-296 beads group. IL-2 was added to each well so as to have a final concentration of 1000 U/mL. These plates were incubated at 37°C in 5% CO<sub>2</sub> (zeroth day of culture).

**[0379]** On the fourth day from the initiation of culture, in each group, each of the beads contained in the culture medium was removed with a magnetic stand, and thereafter the culture medium was diluted with AIM V containing 1% human AB serum (amount of liquid: 6 mL) so as to have a concentration of  $0.07 \times 10^6$  cells/mL, and the dilution was transferred to a 12.5 cm<sup>2</sup> cell culture flask to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0380]** On the seventh day from the initiation of culture, each group was diluted with AIM V containing 1% human AB serum (amount of liquid: 12.6 mL) so as to have a concentration of  $0.25 \times 10^6$  cells/mL, and each dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0381]** On the tenth day from the initiation of culture, each group was diluted with AIM V containing 1% human AB serum (amount of liquid: 12.6 mL) so as to have a concentration of  $0.685 \times 10^6$  cells/mL, and the dilution was transferred to a fresh 25 cm<sup>2</sup> cell culture flask kept upright to which nothing was immobilized. In each group, IL-2 was added thereto so as to have a final concentration of 500 U/mL.

**[0382]** On the fifteenth day from the initiation of culture, the number of living cells was counted by trypan blue staining method, and calculated as an expansion fold by comparing the number of the cells with the number at the initiation of culture. Each experiment was carried out twice. Each of the average results is shown in Table 61.

Table 61

	Stimulation on Zeroth Day from Initiation of Culture	Expansion Fold (fold)
CD3 Beads	Anti-CD3	420
CD3 Beads + CH-296 Beads	Anti-CD3 + CH-296	830
CD3 / CH-296 Beads	Anti-CD3 + CH-296	748

**[0383]** As shown in Table 61, in the LAK cell culture stimulated with each of the beads, a high expansion fold was obtained in the group stimulated in the CD3 beads + CH-296 beads group and the CD3 / CH-296 beads group, as compared to that of the CD3 beads. In other words, in the culture of LAK cells using beads as a cell culture carrier, the LAK cells could be clearly induced and cultured at a high expansion fold by stimulation with the beads immobilized with CH-296 and the anti-CD3 antibody, as compared to that of stimulation with the beads immobilized only with the anti-CD3 antibody. In addition, the cells during the culture were in a high concentration and at a high density, and the expansion fold was clearly high by stimulation with CH-296 beads even under the conditions as described above, so that the effectiveness of CH-296 was found.

#### Example 64 Content Ratio of CD8-Positive Cells in LAK Cell Population Cultured Using Low-Serum Medium (AIM V) (Stimulation with Beads Immobilized with FNfr)

##### (1) Induction and Culture of LAK Cells

**[0384]** The induction and the culture of LAK cells were carried out in the same manner as in Example 63.

##### (2) Determination of Content Ratio of CD8-Positive Cell Population in LAK Cells

**[0385]** The content ratio of the CD8-positive cells was determined in the same manner as in item (2) of Example 4. The results are shown in Table 62.

Table 62

	Stimulation on Zeroth Day from Initiation of Culture	Content Ratio of CD8-Positive Cells (%)
CD3 Beads	Anti-CD3	47
CD3 Beads + CH-296 Beads	Anti-CD3 + CH-296	49
CD3 / CH-296 Beads	Anti-CD3 + CH-296	59

10 **[0386]** As shown in Table 62, in the culture of LAK cells stimulated with each of the beads, the content ratio of the CD8-positive cells in LAK cells during the culture could be induced at a high level in the group stimulated in the CD3 beads + CH-296 beads group and the CD3 / CH-296 beads group, as compared to that of the CD3 beads group. In other words, in the culture of LAK cells using beads as a cell culture carrier, it was clarified that the LAK cells could be clearly induced and cultured, while increasing the content ratio of the CD8-positive cells in LAK cells by stimulation with the beads immobilized with CH-296 and the anti-CD3 antibody, as compared to that of stimulation with the beads immobilized only with the anti-CD3 antibody.

#### SEQUENCE LISTING FREE TEXT

#### 20 **[0387]**

SEQ ID NO: 1 ; Partial region of fibronectin named III-8.

25 SEQ ID NO: 2 ; Partial region of fibronectin named III-9.

SEQ ID NO: 3 ; Partial region of fibronectin named III-10.

SEQ ID NO: 4 ; Partial region of fibronectin named III-11.

30 SEQ ID NO: 5 ; Partial region of fibronectin named III-12.

SEQ ID NO: 6 ; Partial region of fibronectin named III-13.

35 SEQ ID NO: 7 ; Partial region of fibronectin named III-14.

SEQ ID NO: 8 ; Partial region of fibronectin named CS-1.

SEQ ID NO: 9 ; Fibronectin fragment named C-274.

40 SEQ ID NO: 10 ; Fibronectin fragment named H-271.

SEQ ID NO: 11 ; Fibronectin fragment named H-296.

45 SEQ ID NO: 12 ; Fibronectin fragment named CH-271.

SEQ ID NO: 13 ; Fibronectin fragment named CH-296.

SEQ ID NO: 14 ; Fibronectin fragment named C-CS1.

50 SEQ ID NO: 15 ; Fibronectin fragment named CHV-89.

SEQ ID NO: 16 ; Fibronectin fragment named CHV-90.

55 SEQ ID NO: 17 ; Fibronectin fragment named CHV-92.

SEQ ID NO: 18 ; Fibronectin fragment named CHV-179.



SEQ ID NO: 19 ; Fibronectin fragment named CHV-181.

SEQ ID NO: 20 ; Fibronectin fragment named H-275-Cys.

5 SEQ ID NO: 21 ; Primer 12S.

SEQ ID NO: 22 ; Primer 14A.

SEQ ID NO: 23 ; Primer Cys-A.

10 SEQ ID NO: 24 ; Primer Cys-S.

SEQ ID NO: 25 ; Fibronectin fragment named CH-296Na.

15 SEQ ID NO: 26 ; Polynucleotide coding Fibronectin fragment named CH-296Na.

SEQ ID NO: 27 ; Primer CH-296Na1.

SEQ ID NO: 28 ; Primer CH-296Na2.

20 SEQ ID NO: 29 ; Primer CH-296Na3.

#### INDUSTRIAL APPLICABILITY

25 **[0388]** According to the process for preparing a cytotoxic lymphocyte of the present invention, there is obtained a cytotoxic lymphocyte in which expansion fold is high even when a serum-free medium or a low-serum concentration medium is used, a high cytotoxic activity is maintained, an expression level of IL-2R is significantly increased, and a ratio of a CD8-positive cell is improved. The lymphocyte is suitably used, for instance, in adoptive immunotherapy. Therefore, there is expected a great contribution of the process of the present invention to the medical field.

30

35

40

45

50

55

SEQUENCE LISTING

5

<110> TAKARA BIO INC.

10

<120> Process for the preparation of lymphocyte having cytotoxic activity

15

<130> 04-058-PCTJP

20

<150> JP 2003-298208

<151> 2003-08-22

25

<150> JP 2004-699

<151> 2004-01-05

30

<150> JP 2004-115648

<151> 2004-04-09

35

<150> JP 2004-222441

40

<151> 2004-07-29

45

<160> 29

50

<210> 1

<211> 87

<212> PRT

55

<213> Artificial Sequence

<220>

<223> partial region of fibronectin named III-8

<400> 1

Pro Thr Asp Leu Arg Phe Thr Asn Ile Gly Pro Asp Thr Met Arg

1 5 10 15

Val Thr Trp Ala Pro Pro Ser Ile Asp Leu Thr Asn Phe Leu

20 25 30

Val Arg Tyr Ser Pro Val Lys Asn Glu Glu Asp Val Ala Glu Leu

35 40 45

Ser Ile Ser Pro Ser Asp Asn Ala Val Val Leu Thr Asn Leu Leu

50 55 60

Pro Gly Thr Glu Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln

65 70 75

His Glu Ser Thr Pro Leu Arg Gly Arg Gln Lys Thr

80 85

<210> 2

<211> 90

<212> PRT

<213> Artificial Sequence

<220>

<223> partial region of fibronectin named III-9

5 <400> 2

Gly Leu Asp Ser Pro Thr Gly Ile Asp Phe Ser Asp Ile Thr Ala

1 5 10 15

10 Asn Ser Phe Thr Val His Trp Ile Ala Pro Arg Ala Thr Ile Thr

20 25 30

15 Gly Tyr Arg Ile Arg His His Pro Glu His Phe Ser Gly Arg Pro

35 40 45

20 Arg Glu Asp Arg Val Pro His Ser Arg Asn Ser Ile Thr Leu Thr

50 55 60

25 Asn Leu Thr Pro Gly Thr Glu Tyr Val Val Ser Ile Val Ala Leu

65 70 75

30 Asn Gly Arg Glu Glu Ser Pro Leu Leu Ile Gly Gln Gln Ser Thr

80 85 90

35 <210> 3

<211> 94

40 <212> PRT

<213> Artificial Sequence

45 <220>

<223> partial region of fibronectin named III-10

50

<400> 3

55 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro

EP 1 666 589 A1

	1	5	10	15
5	Thr Ser Leu Leu Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg			
	20	25	30	
10	Tyr Tyr Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val			
	35	40	45	
15	Gln Glu Phe Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser			
	50	55	60	
20	Gly Leu Lys Pro Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val			
	65	70	75	
25	Thr Gly Arg Gly Asp Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile			
	80	85	90	
30	Asn Tyr Arg Thr			

<210> 4

<211> 84

<212> PRT

<213> Artificial Sequence

<220>

<223> partial region of fibronectin named III-11

<400> 4

Gln Met Gln Val Thr Asp Val Gln Asp Asn Ser Ile Ser Val Lys

1	5	10	15
---	---	----	----

Trp Leu Pro Ser Ser Ser Pro Val Thr Gly Tyr Arg Val Thr Thr

EP 1 666 589 A1

	20	25	30
5	Thr Pro Lys Asn Gly Pro Gly Pro Thr Lys Thr Lys Thr Ala Gly		
	35	40	45
10	Pro Asp Gln Thr Glu Met Thr Ile Glu Gly Leu Gln Pro Thr Val		
	50	55	60
15	Glu Tyr Val Val Ser Val Tyr Ala Gln Asn Pro Ser Gly Glu Ser		
	65	70	75
20	Gln Pro Leu Val Gln Thr Ala Val Thr		

20	80
25	
	<210> 5
	<211> 92
30	<212> PRT
	<213> Artificial Sequence

35	
	<220>
	<223> partial region of fibronectin named III-12

40	
	<400> 5
45	Ala Ile Pro Ala Pro Thr Asp Leu Lys Phe Thr Gln Val Thr Pro
	1                      5                      10                      15
50	Thr Ser Leu Ser Ala Gln Trp Thr Pro Pro Asn Val Gln Leu Thr
	20                      25                      30
	Gly Tyr Arg Val Arg Val Thr Pro Lys Glu Lys Thr Gly Pro Met
55	35                      40                      45

Lys Glu Ile Asn Leu Ala Pro Asp Ser Ser Ser Val Val Val Ser  
 5                                      50                                      55                                      60  
 Gly Leu Met Val Ala Thr Lys Tyr Glu Val Ser Val Tyr Ala Leu  
 10                                      65                                      70                                      75  
 Lys Asp Thr Leu Thr Ser Arg Pro Ala Gln Gly Val Val Thr Thr  
 15                                      80                                      85                                      90  
 Leu Glu

20

&lt;210&gt; 6

25

&lt;211&gt; 89

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

30

&lt;220&gt;

35

&lt;223&gt; partial region of fibronectin named III-13

40

&lt;400&gt; 6

Asn Val Ser Pro Pro Arg Arg Ala Arg Val Thr Asp Ala Thr Glu

1                                      5                                      10                                      15

45

Thr Thr Ile Thr Ile Ser Trp Arg Thr Lys Thr Glu Thr Ile Thr

20                                      25                                      30

50

Gly Phe Gln Val Asp Ala Val Pro Ala Asn Gly Gln Thr Pro Ile

35                                      40                                      45

Gln Arg Thr Ile Lys Pro Asp Val Arg Ser Tyr Thr Ile Thr Gly

55

50                                      55                                      60

Leu Gln Pro Gly Thr Asp Tyr Lys Ile Tyr Leu Tyr Thr Leu Asn

5	65	70	75
---	----	----	----

Asp Asn Ala Arg Ser Ser Pro Val Val Ile Asp Ala Ser Thr

10 80 85

15  $\langle 210 \rangle$  7

**<211> 90**

20 <212> PRT

### <213> Artificial Sequence

25  $\langle 220 \rangle$

<223> partial region of fibronectin named III-14

〈400〉 7

Ala Ile Asp Ala Pro Ser Asn Leu Arg Phe Leu Ala Thr Thr Pro

1 5 10 15

Asn Ser Leu Leu Val Ser Trp Gln Pro Pro Arg Ala Arg Ile Thr

**40**                                      **20**                                      **25**                                      **30**

Gly Tyr Ile Ile Lys Tyr Glu Lys Pro Gly Ser Pro Pro Arg Glu

35 40 45

Val Val Pro Arg Pro Arg Pro Gly Val Thr Glu Ala Thr Ile Thr

50 55 60

Gly Leu Glu Pro Gly Thr Glu Tyr Thr Ile Tyr Val Ile Ala Leu

65 70 75

55 Lys Asn Asn Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys Lys Thr



80

85

90

5

10

<210> 8

<211> 25

<212> PRT

15

<213> Artificial Sequence

20

<220>

<223> partial region of fibronectin named CS-1

25

<400> 8

Asp Glu Leu Pro Gln Leu Val Thr Leu Pro His Pro Asn Leu His

30

1

5

10

15

Gly Pro Glu Ile Leu Asp Val Pro Ser Thr

35

20

25

40

<210> 9

<211> 274

45

<212> PRT

<213> Human

50

<220>

<223> fibronectin fragment named C-274

55

&lt;400&gt; 9

5	Pro Thr Asp Leu Arg Phe Thr Asn Ile Gly Pro Asp Thr Met Arg
	1                      5                      10                      15
10	Val Thr Trp Ala Pro Pro Pro Ser Ile Asp Leu Thr Asn Phe Leu
	20                      25                      30
15	Val Arg Tyr Ser Pro Val Lys Asn Glu Glu Asp Val Ala Glu Leu
	35                      40                      45
20	Ser Ile Ser Pro Ser Asp Asn Ala Val Val Leu Thr Asn Leu Leu
	50                      55                      60
25	Pro Gly Thr Glu Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln
	65                      70                      75
30	His Glu Ser Thr Pro Leu Arg Gly Arg Gln Lys Thr Gly Leu Asp
	80                      85                      90
35	Ser Pro Thr Gly Ile Asp Phe Ser Asp Ile Thr Ala Asn Ser Phe
	95                      100                      105
40	Thr Val His Trp Ile Ala Pro Arg Ala Thr Ile Thr Gly Tyr Arg
	110                      115                      120
45	Ile Arg His His Pro Glu His Phe Ser Gly Arg Pro Arg Glu Asp
	125                      130                      135
50	Arg Val Pro His Ser Arg Asn Ser Ile Thr Leu Thr Asn Leu Thr
	140                      145                      150
55	Pro Gly Thr Glu Tyr Val Val Ser Ile Val Ala Leu Asn Gly Arg
	155                      160                      165
	Glu Glu Ser Pro Leu Leu Ile Gly Gln Gln Ser Thr Val Ser Asp
	170                      175                      180
	Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr Ser Leu

5                   185                   190                   195  
 Leu Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg Tyr Tyr Arg  
                   200                   205                   210  
 10   Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe  
                   215                   220                   225  
 15   Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys  
                   230                   235                   240  
 20   Pro Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg  
                   245                   250                   255  
 25   Gly Asp Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile Asn Tyr Arg  
                   260                   265                   270  
 30   Thr Glu Ile Asp

35   <210> 10

35   <211> 271

40   <212> PRT

40   <213> Human

45   <220>

45   <223> fibronectin fragment named H-271

50   <400> 10

Ala Ile Pro Ala Pro Thr Asp Leu Lys Phe Thr Gln Val Thr Pro

1                   5                   10                   15

55   Thr Ser Leu Ser Ala Gln Trp Thr Pro Pro Asn Val Gln Leu Thr

EP 1 666 589 A1

	20	25	30
5	Gly Tyr Arg Val Arg Val Thr Pro Lys Glu Lys Thr Gly Pro Met		
	35	40	45
10	Lys Glu Ile Asn Leu Ala Pro Asp Ser Ser Ser Val Val Val Ser		
	50	55	60
15	Gly Leu Met Val Ala Thr Lys Tyr Glu Val Ser Val Tyr Ala Leu		
	65	70	75
20	Lys Asp Thr Leu Thr Ser Arg Pro Ala Gln Gly Val Val Thr Thr		
	80	85	90
	Leu Glu Asn Val Ser Pro Pro Arg Arg Ala Arg Val Thr Asp Ala		
25	95	100	105
	Thr Glu Thr Thr Ile Thr Ile Ser Trp Arg Thr Lys Thr Glu Thr		
	110	115	120
30	Ile Thr Gly Phe Gln Val Asp Ala Val Pro Ala Asn Gly Gln Thr		
	125	130	135
35	Pro Ile Gln Arg Thr Ile Lys Pro Asp Val Arg Ser Tyr Thr Ile		
	140	145	150
40	Thr Gly Leu Gln Pro Gly Thr Asp Tyr Lys Ile Tyr Leu Tyr Thr		
	155	160	165
	Leu Asn Asp Asn Ala Arg Ser Ser Pro Val Val Ile Asp Ala Ser		
45	170	175	180
	Thr Ala Ile Asp Ala Pro Ser Asn Leu Arg Phe Leu Ala Thr Thr		
	185	190	195
50	Pro Asn Ser Leu Leu Val Ser Trp Gln Pro Pro Arg Ala Arg Ile		
	200	205	210
55	Thr Gly Tyr Ile Ile Lys Tyr Glu Lys Pro Gly Ser Pro Pro Arg		

EP 1 666 589 A1

	215	220	225
5	Glu Val Val Pro Arg Pro Arg Pro Gly Val Thr Glu Ala Thr Ile		
	230	235	240
10	Thr Gly Leu Glu Pro Gly Thr Glu Tyr Thr Ile Tyr Val Ile Ala		
	245	250	255
15	Leu Lys Asn Asn Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys Lys		
	260	265	270
	Thr		
20			
	<210> 11		
25	<211> 296		
	<212> PRT		
30	<213> Artificial Sequence		
	<220>		
35	<223> fibronectin fragment named H-296		
	<400> 11		
40	Ala Ile Pro Ala Pro Thr Asp Leu Lys Phe Thr Gln Val Thr Pro		
45	1	5	10 15
	Thr Ser Leu Ser Ala Gln Trp Thr Pro Pro Asn Val Gln Leu Thr		
	20	25	30
50	Gly Tyr Arg Val Arg Val Thr Pro Lys Glu Lys Thr Gly Pro Met		
	35	40	45
55	Lys Glu Ile Asn Leu Ala Pro Asp Ser Ser Ser Val Val Val Ser		

EP 1 666 589 A1

	50	55	60
5	Gly Leu Met Val Ala Thr Lys Tyr Glu Val Ser Val Tyr Ala Leu		
	65	70	75
10	Lys Asp Thr Leu Thr Ser Arg Pro Ala Gln Gly Val Val Thr Thr		
	80	85	90
	Leu Glu Asn Val Ser Pro Pro Arg Arg Ala Arg Val Thr Asp Ala		
15		95	100
		105	
	Thr Glu Thr Thr Ile Thr Ile Ser Trp Arg Thr Lys Thr Glu Thr		
20		110	115
		120	
	Ile Thr Gly Phe Gln Val Asp Ala Val Pro Ala Asn Gly Gln Thr		
	125	130	135
25			
	Pro Ile Gln Arg Thr Ile Lys Pro Asp Val Arg Ser Tyr Thr Ile		
	140	145	150
30			
	Thr Gly Leu Gln Pro Gly Thr Asp Tyr Lys Ile Tyr Leu Tyr Thr		
	155	160	165
	Leu Asn Asp Asn Ala Arg Ser Ser Pro Val Val Ile Asp Ala Ser		
35		170	175
		180	
	Thr Ala Ile Asp Ala Pro Ser Asn Leu Arg Phe Leu Ala Thr Thr		
40		185	190
		195	
	Pro Asn Ser Leu Leu Val Ser Trp Gln Pro Pro Arg Ala Arg Ile		
45		200	205
		210	
	Thr Gly Tyr Ile Ile Lys Tyr Glu Lys Pro Gly Ser Pro Pro Arg		
	215	220	225
50			
	Glu Val Val Pro Arg Pro Arg Pro Gly Val Thr Glu Ala Thr Ile		
	230	235	240
55			
	Thr Gly Leu Glu Pro Gly Thr Glu Tyr Thr Ile Tyr Val Ile Ala		

EP 1 666 589 A1

	245	250	255
5	Leu Lys Asn Asn Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys Lys		
	260	265	270
10	Thr Asp Glu Leu Pro Gln Leu Val Thr Leu Pro His Pro Asn Leu		
	275	280	285
	His Gly Pro Glu Ile Leu Asp Val Pro Ser Thr		
15		290	295
20			
	<210> 12		
	<211> 549		
25	<212> PRT		
	<213> Artificial Sequence		
30			
	<220>		
35	<223> fibronectin fragment named CH-271		
	<400> 12		
40	Pro Thr Asp Leu Arg Phe Thr Asn Ile Gly Pro Asp Thr Met Arg		
	1 5 10 15		
45	Val Thr Trp Ala Pro Pro Pro Ser Ile Asp Leu Thr Asn Phe Leu		
	20 25 30		
	Val Arg Tyr Ser Pro Val Lys Asn Glu Glu Asp Val Ala Glu Leu		
50	35 40 45		
	Ser Ile Ser Pro Ser Asp Asn Ala Val Val Leu Thr Asn Leu Leu		
55	50 55 60		

EP 1 666 589 A1

	Pro Gly Thr Glu Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln	
5	65	70 75
	His Glu Ser Thr Pro Leu Arg Gly Arg Gln Lys Thr Gly Leu Asp	
10	80	85 90
	Ser Pro Thr Gly Ile Asp Phe Ser Asp Ile Thr Ala Asn Ser Phe	
15	95	100 105
	Thr Val His Trp Ile Ala Pro Arg Ala Thr Ile Thr Gly Tyr Arg	
20	110	115 120
	Ile Arg His His Pro Glu His Phe Ser Gly Arg Pro Arg Glu Asp	
25	125	130 135
	Arg Val Pro His Ser Arg Asn Ser Ile Thr Leu Thr Asn Leu Thr	
30	140	145 150
	Pro Gly Thr Glu Tyr Val Val Ser Ile Val Ala Leu Asn Gly Arg	
35	155	160 165
	Glu Glu Ser Pro Leu Leu Ile Gly Gln Gln Ser Thr Val Ser Asp	
40	170	175 180
	Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr Ser Leu	
45	185	190 195
	Leu Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg Tyr Tyr Arg	
50	200	205 210
	Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe	
55	215	220 225
	Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys	
	230	235 240
	Pro Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg	
	245	250 255



EP 1 666 589 A1

	Gly Asp Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile Asn Tyr Arg	
5	260	265 270
	Thr Glu Ile Asp Lys Pro Ser Met Ala Ile Pro Ala Pro Thr Asp	
10	275	280 285
	Leu Lys Phe Thr Gln Val Thr Pro Thr Ser Leu Ser Ala Gln Trp	
	290	295 300
15	Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr Arg Val Arg Val Thr	
	305	310 315
20	Pro Lys Glu Lys Thr Gly Pro Met Lys Glu Ile Asn Leu Ala Pro	
	320	325 330
	Asp Ser Ser Ser Val Val Val Ser Gly Leu Met Val Ala Thr Lys	
25	335	340 345
	Tyr Glu Val Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr Ser Arg	
30	350	355 360
	Pro Ala Gln Gly Val Val Thr Thr Leu Glu Asn Val Ser Pro Pro	
	365	370 375
35	Arg Arg Ala Arg Val Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile	
	380	385 390
40	Ser Trp Arg Thr Lys Thr Glu Thr Ile Thr Gly Phe Gln Val Asp	
	395	400 405
45	Ala Val Pro Ala Asn Gly Gln Thr Pro Ile Gln Arg Thr Ile Lys	
	410	415 420
	Pro Asp Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr	
50	425	430 435
	Asp Tyr Lys Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg Ser	
55	440	445 450

EP 1 666 589 A1

5                                      455                                      460                                      465  
 Ser Pro Val Val Ile Asp Ala Ser Thr Ala Ile Asp Ala Pro Ser  
 10                                      470                                      475                                      480  
 Asn Leu Arg Phe Leu Ala Thr Thr Pro Asn Ser Leu Leu Val Ser  
 Trp Gln Pro Pro Arg Ala Arg Ile Thr Gly Tyr Ile Ile Lys Tyr  
 15                                      485                                      490                                      495  
 Glu Lys Pro Gly Ser Pro Pro Arg Glu Val Val Pro Arg Pro Arg  
 20                                      500                                      505                                      510  
 Pro Gly Val Thr Glu Ala Thr Ile Thr Gly Leu Glu Pro Gly Thr  
 25                                      515                                      520                                      525  
 Glu Tyr Thr Ile Tyr Val Ile Ala Leu Lys Asn Asn Gln Lys Ser  
 30                                      530                                      535                                      540  
 Glu Pro Leu Ile Gly Arg Lys Lys Thr  
 35                                      545  
 40                                      550  
 45                                      555  
 50                                      560  
 55                                      565  
 60                                      570  
 65                                      575  
 70                                      580  
 75                                      585  
 80                                      590  
 85                                      595  
 90                                      600  
 95                                      605  
 100                                      610  
 105                                      615  
 110                                      620  
 115                                      625  
 120                                      630  
 125                                      635  
 130                                      640  
 135                                      645  
 140                                      650  
 145                                      655  
 150                                      660  
 155                                      665  
 160                                      670  
 165                                      675  
 170                                      680  
 175                                      685  
 180                                      690  
 185                                      695  
 190                                      700  
 195                                      705  
 200                                      710  
 205                                      715  
 210                                      720  
 215                                      725  
 220                                      730  
 225                                      735  
 230                                      740  
 235                                      745  
 240                                      750  
 245                                      755  
 250                                      760  
 255                                      765  
 260                                      770  
 265                                      775  
 270                                      780  
 275                                      785  
 280                                      790  
 285                                      795  
 290                                      800  
 295                                      805  
 300                                      810  
 305                                      815  
 310                                      820  
 315                                      825  
 320                                      830  
 325                                      835  
 330                                      840  
 335                                      845  
 340                                      850  
 345                                      855  
 350                                      860  
 355                                      865  
 360                                      870  
 365                                      875  
 370                                      880  
 375                                      885  
 380                                      890  
 385                                      895  
 390                                      900  
 395                                      905  
 400                                      910  
 405                                      915  
 410                                      920  
 415                                      925  
 420                                      930  
 425                                      935  
 430                                      940  
 435                                      945  
 440                                      950  
 445                                      955  
 450                                      960  
 455                                      965  
 460                                      970  
 465                                      975  
 470                                      980  
 475                                      985  
 480                                      990  
 485                                      995  
 490                                      1000  
 495                                      1005  
 500                                      1010  
 505                                      1015  
 510                                      1020  
 515                                      1025  
 520                                      1030  
 525                                      1035  
 530                                      1040  
 535                                      1045  
 540                                      1050  
 545                                      1055  
 550                                      1060  
 555                                      1065  
 560                                      1070  
 565                                      1075  
 570                                      1080  
 575                                      1085  
 580                                      1090  
 585                                      1095  
 590                                      1100  
 595                                      1105  
 600                                      1110  
 605                                      1115  
 610                                      1120  
 615                                      1125  
 620                                      1130  
 625                                      1135  
 630                                      1140  
 635                                      1145  
 640                                      1150  
 645                                      1155  
 650                                      1160  
 655                                      1165  
 660                                      1170  
 665                                      1175  
 670                                      1180  
 675                                      1185  
 680                                      1190  
 685                                      1195  
 690                                      1200  
 695                                      1205  
 700                                      1210  
 705                                      1215  
 710                                      1220  
 715                                      1225  
 720                                      1230  
 725                                      1235  
 730                                      1240  
 735                                      1245  
 740                                      1250  
 745                                      1255  
 750                                      1260  
 755                                      1265  
 760                                      1270  
 765                                      1275  
 770                                      1280  
 775                                      1285  
 780                                      1290  
 785                                      1295  
 790                                      1300  
 795                                      1305  
 800                                      1310  
 805                                      1315  
 810                                      1320  
 815                                      1325  
 820                                      1330  
 825                                      1335  
 830                                      1340  
 835                                      1345  
 840                                      1350  
 845                                      1355  
 850                                      1360  
 855                                      1365  
 860                                      1370  
 865                                      1375  
 870                                      1380  
 875                                      1385  
 880                                      1390  
 885                                      1395  
 890                                      1400  
 895                                      1405  
 900                                      1410  
 905                                      1415  
 910                                      1420  
 915                                      1425  
 920                                      1430  
 925                                      1435  
 930                                      1440  
 935                                      1445  
 940                                      1450  
 945                                      1455  
 950                                      1460  
 955                                      1465  
 960                                      1470  
 965                                      1475  
 970                                      1480  
 975                                      1485  
 980                                      1490  
 985                                      1495  
 990                                      1500  
 995                                      1505  
 1000                                      1510  
 1005                                      1515  
 1010                                      1520  
 1015                                      1525  
 1020                                      1530  
 1025                                      1535  
 1030                                      1540  
 1035                                      1545  
 1040                                      1550  
 1045                                      1555  
 1050                                      1560  
 1055                                      1565  
 1060                                      1570  
 1065                                      1575  
 1070                                      1580  
 1075                                      1585  
 1080                                      1590  
 1085                                      1595  
 1090                                      1600  
 1095                                      1605  
 1100                                      1610  
 1105                                      1615  
 1110                                      1620  
 1115                                      1625  
 1120                                      1630  
 1125                                      1635  
 1130                                      1640  
 1135                                      1645  
 1140                                      1650  
 1145                                      1655  
 1150                                      1660  
 1155                                      1665  
 1160                                      1670  
 1165                                      1675  
 1170                                      1680  
 1175                                      1685  
 1180                                      1690  
 1185                                      1695  
 1190                                      1700  
 1195                                      1705  
 1200                                      1710  
 1205                                      1715  
 1210                                      1720  
 1215                                      1725  
 1220                                      1730  
 1225                                      1735  
 1230                                      1740  
 1235                                      1745  
 1240                                      1750  
 1245                                      1755  
 1250                                      1760  
 1255                                      1765  
 1260                                      1770  
 1265                                      1775  
 1270                                      1780  
 1275                                      1785  
 1280                                      1790  
 1285                                      1795  
 1290                                      1800  
 1295                                      1805  
 1300                                      1810  
 1305                                      1815  
 1310                                      1820  
 1315                                      1825  
 1320                                      1830  
 1325                                      1835  
 1330                                      1840  
 1335                                      1845  
 1340                                      1850  
 1345                                      1855  
 1350                                      1860  
 1355                                      1865  
 1360                                      1870  
 1365                                      1875  
 1370                                      1880  
 1375                                      1885  
 1380                                      1890  
 1385                                      1895  
 1390                                      1900  
 1395                                      1905  
 1400                                      1910  
 1405                                      1915  
 1410                                      1920  
 1415                                      1925  
 1420                                      1930  
 1425                                      1935  
 1430                                      1940  
 1435                                      1945  
 1440                                      1950  
 1445                                      1955  
 1450                                      1960  
 1455                                      1965  
 1460                                      1970  
 1465                                      1975  
 1470                                      1980  
 1475                                      1985  
 1480                                      1990  
 1485                                      1995  
 1490                                      2000  
 1495                                      2005  
 1500                                      2010  
 1505                                      2015  
 1510                                      2020  
 1515                                      2025  
 1520                                      2030  
 1525                                      2035  
 1530                                      2040  
 1535                                      2045  
 1540                                      2050  
 1545                                      2055  
 1550                                      2060  
 1555                                      2065  
 1560                                      2070  
 1565                                      2075  
 1570                                      2080  
 1575                                      2085  
 1580                                      2090  
 1585                                      2095  
 1590                                      2100  
 1595                                      2105  
 1600                                      2110  
 1605                                      2115  
 1610                                      2120  
 1615                                      2125  
 1620                                      2130  
 1625                                      2135  
 1630                                      2140  
 1635                                      2145  
 1640                                      2150  
 1645                                      2155  
 1650                                      2160  
 1655                                      2165  
 1660                                      2170  
 1665                                      2175  
 1670                                      2180  
 1675                                      2185  
 1680                                      2190  
 1685                                      2195  
 1690                                      2200  
 1695                                      2205  
 1700                                      2210  
 1705                                      2215  
 1710                                      2220  
 1715                                      2225  
 1720                                      2230  
 1725                                      2235  
 1730                                      2240  
 1735                                      2245  
 1740                                      2250  
 1745                                      2255  
 1750                                      2260  
 1755                                      2265  
 1760                                      2270  
 1765                                      2275  
 1770                                      2280  
 1775                                      2285  
 1780                                      2290  
 1785                                      2295  
 1790                                      2300  
 1795                                      2305  
 1800                                      2310  
 1805                                      2315  
 1810                                      2320  
 1815                                      2325  
 1820                                      2330  
 1825                                      2335  
 1830                                      2340  
 1835                                      2345  
 1840                                      2350  
 1845                                      2355  
 1850                                      2360  
 1855                                      2365  
 1860                                      2370  
 1865                                      2375  
 1870                                      2380  
 1875                                      2385  
 1880                                      2390  
 1885                                      2395  
 1890                                      2400  
 1895                                      2405  
 1900                                      2410  
 1905                                      2415  
 1910                                      2420  
 1915                                      2425  
 1920                                      2430  
 1925                                      2435  
 1930                                      2440  
 1935                                      2445  
 1940                                      2450  
 1945                                      2455  
 1950                                      2460  
 1955                                      2465  
 1960                                      2470  
 1965                                      2475  
 1970                                      2480  
 1975                                      2485  
 1980                                      2490  
 1985                                      2495  
 1990                                      2500  
 1995                                      2505  
 2000                                      2510  
 2005                                      2515  
 2010                                      2520  
 2015                                      2525  
 2020                                      2530  
 2025                                      2535  
 2030                                      2540  
 2035                                      2545  
 2040                                      2550  
 2045                                      2555  
 2050                                      2560  
 2055                                      2565  
 2060                                      2570  
 2065                                      2575  
 2070                                      2580  
 2075                                      2585  
 2080                                      2590  
 2085                                      2595  
 2090                                      2600  
 2095                                      2605  
 2100                                      2610  
 2105                                      2615  
 2110                                      2620  
 2115                                      2625  
 2120                                      2630  
 2125                                      2635  
 2130                                      2640  
 2135                                      2645  
 2140                                      2650  
 2145                                      2655  
 2150                                      2660  
 2155                                      2665  
 2160                                      2670  
 2165                                      2675  
 2170                                      2680  
 2175                                      2685  
 2180                                      2690  
 2185                                      2695  
 2190                                      2700  
 2195                                      2705  
 2200                                      2710  
 2205                                      2715  
 2210                                      2720  
 2215                                      2725  
 2220                                      2730  
 2225                                      2735  
 2230                                      2740  
 2235                                      2745  
 2240                                      2750  
 2245                                      2755  
 2250                                      2760  
 2255                                      2765  
 2260                                      2770  
 2265                                      2775  
 2270                                      2780  
 2275                                      2785  
 2280                                      2790  
 2285                                      2795  
 2290                                      2800  
 2295                                      2805  
 2300                                      2810  
 2305                                      2815  
 2310                                      2820  
 2315                                      2825  
 2320                                      2830  
 2325                                      2835  
 2330                                      2840  
 2335                                      2845  
 2340                                      2850  
 2345                                      2855  
 2350                                      2860  
 2355                                      2865  
 2360                                      2870  
 2365                                      2875  
 2370                                      2880  
 2375                                      2885  
 2380                                      2890  
 2385                                      2895  
 2390                                      2900  
 2395                                      2905  
 2400                                      2910  
 2405                                      2915  
 2410                                      2920  
 2415                                      2925  
 2420                                      2930  
 2425                                      2935  
 2430                                      2940  
 2435                                      2945  
 2440                                      2950  
 2445                                      2955  
 2450                                      2960  
 2455                                      2965  
 2460                                      2970  
 2465                                      2975  
 2470                                      2980  
 2475                                      2985  
 2480                                      2990  
 2485                                      2995  
 2490                                      3000  
 2495                                      3005  
 2500                                      3010  
 2505                                      3015  
 2510                                      3020  
 2515                                      3025  
 2520                                      3030  
 2525                                      3035  
 2530                                      3040  
 2535                                      3045  
 2540                                      3050  
 2545                                      3055  
 2550                                      3060  
 2555                                      3065  
 2560                                      3070  
 2565                                      3075  
 2570                                      3080  
 2575                                      3085  
 2580                                      3090  
 2585                                      3095  
 2590                                      3100  
 2595                                      3105  
 2600                                      3110  
 2605                                      3115  
 2610                                      3120  
 2615                                      3125  
 2620                                      3130  
 2625                                      3135  
 2630                                      3140  
 2635                                      3145  
 2640                                      3150  
 2645                                      3155  
 2650                                      3160  
 2655                                      3165  
 2660                                      3170  
 2665                                      3175  
 2670                                      3180  
 2675                                      3185  
 2680                                      3190  
 2685                                      3195  
 2690                                      3200  
 2695                                      3205  
 2700                                      3210  
 2705                                      3215  
 2710                                      3220  
 2715                                      3225  
 2720                                      3230  
 2725                                      3235  
 2730                                      3240  
 2735                                      3245  
 2740                                      3250  
 2745                                      3255  
 2750                                      3260  
 2755                                      3265  
 2760                                      3270  
 2765                                      3275  
 2770                                      3280  
 2775                                      3285  
 2780                                      3290  
 2785                                      3295  
 2790                                      3300  
 2795                                      3305  
 2800                                      3310  
 2805                                      3315  
 2810                                      3320  
 2815                                      3325  
 2820                                      3330  
 2825                                      3335  
 2830                                      3340  
 2835                                      3345  
 2840                                      3350  
 2845                                      3355  
 2850                                      3360  
 2855                                      3365  
 2860                                      3370  
 2865                                      3375  
 2870                                      3380  
 2875                                      3385  
 2880                                      3390  
 2885                                      3395  
 2890                                      3400  
 2895                                      3405  
 2900                                      3410  
 2905                                      3415  
 2910                                      3420  
 2915                                      3425  
 2920                                      3430  
 2925                                      3435  
 2930                                      3440  
 2935                                      3445  
 2940                                      3450  
 2945                                      3455  
 2950                                      3460  
 2955                                      3465  
 2960                                      3470  
 2965                                      3475  
 2970                                      3480  
 2975                                      3485  
 2980                                      3490  
 2985                                      3495  
 2990                                      3500  
 2995                                      3505  
 3000                                      3510  
 3005                                      3515  
 3010                                      3520  
 3015                                      3525  
 3020                                      3530  
 3025                                      3535  
 3030                                      3540  
 3035                                      3545  
 3040                                      3550  
 3045                                      3555  
 3050                                      3560  
 3055                                      3565  
 3060                                      3570  
 3065                                      3575  
 3070                                      3580  
 3075                                      3585  
 3080                                      3590  
 3085                                      3595  
 3090

EP 1 666 589 A1

	1	5	10	15
5	Val Thr Trp Ala Pro Pro Pro Ser Ile Asp Leu Thr Asn Phe Leu			
		20	25	30
10	Val Arg Tyr Ser Pro Val Lys Asn Glu Glu Asp Val Ala Glu Leu			
		35	40	45
	Ser Ile Ser Pro Ser Asp Asn Ala Val Val Leu Thr Asn Leu Leu			
15		50	55	60
	Pro Gly Thr Glu Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln			
20		65	70	75
	His Glu Ser Thr Pro Leu Arg Gly Arg Gln Lys Thr Gly Leu Asp			
		80	85	90
25	Ser Pro Thr Gly Ile Asp Phe Ser Asp Ile Thr Ala Asn Ser Phe			
		95	100	105
30	Thr Val His Trp Ile Ala Pro Arg Ala Thr Ile Thr Gly Tyr Arg			
		110	115	120
	Ile Arg His His Pro Glu His Phe Ser Gly Arg Pro Arg Glu Asp			
35		125	130	135
	Arg Val Pro His Ser Arg Asn Ser Ile Thr Leu Thr Asn Leu Thr			
40		140	145	150
	Pro Gly Thr Glu Tyr Val Val Ser Ile Val Ala Leu Asn Gly Arg			
45		155	160	165
	Glu Glu Ser Pro Leu Leu Ile Gly Gln Gln Ser Thr Val Ser Asp			
		170	175	180
50	Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr Ser Leu			
		185	190	195
55	Leu Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg Tyr Tyr Arg			

EP 1 666 589 A1

	200	205	210
5	Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe		
	215	220	225
10	Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys		
	230	235	240
15	Pro Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg		
	245	250	255
20	Gly Asp Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile Asn Tyr Arg		
	260	265	270
	Thr Glu Ile Asp Lys Pro Ser Met Ala Ile Pro Ala Pro Thr Asp		
25	275	280	285
	Leu Lys Phe Thr Gln Val Thr Pro Thr Ser Leu Ser Ala Gln Trp		
	290	295	300
30	Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr Arg Val Arg Val Thr		
	305	310	315
35	Pro Lys Glu Lys Thr Gly Pro Met Lys Glu Ile Asn Leu Ala Pro		
	320	325	330
40	Asp Ser Ser Ser Val Val Val Ser Gly Leu Met Val Ala Thr Lys		
	335	340	345
45	Tyr Glu Val Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr Ser Arg		
	350	355	360
	Pro Ala Gln Gly Val Val Thr Thr Leu Glu Asn Val Ser Pro Pro		
50	365	370	375
	Arg Arg Ala Arg Val Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile		
	380	385	390
55	Ser Trp Arg Thr Lys Thr Glu Thr Ile Thr Gly Phe Gln Val Asp		

EP 1 666 589 A1

	395	400	405
5	Ala Val Pro Ala Asn Gly Gln Thr Pro Ile Gln Arg Thr Ile Lys		
	410	415	420
10	Pro Asp Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr		
	425	430	435
15	Asp Tyr Lys Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg Ser		
	440	445	450
20	Ser Pro Val Val Ile Asp Ala Ser Thr Ala Ile Asp Ala Pro Ser		
	455	460	465
25	Asn Leu Arg Phe Leu Ala Thr Thr Pro Asn Ser Leu Leu Val Ser		
	470	475	480
30	Trp Gln Pro Pro Arg Ala Arg Ile Thr Gly Tyr Ile Ile Lys Tyr		
	485	490	495
35	Glu Lys Pro Gly Ser Pro Pro Arg Glu Val Val Pro Arg Pro Arg		
	500	505	510
40	Pro Gly Val Thr Glu Ala Thr Ile Thr Gly Leu Glu Pro Gly Thr		
	515	520	525
45	Glu Tyr Thr Ile Tyr Val Ile Ala Leu Lys Asn Asn Gln Lys Ser		
	530	535	540
50	Glu Pro Leu Ile Gly Arg Lys Lys Thr Asp Glu Leu Pro Gln Leu		
	545	550	555
55	Val Thr Leu Pro His Pro Asn Leu His Gly Pro Glu Ile Leu Asp		
	560	565	570
	Val Pro Ser Thr		

<210> 14

<211> 302

<212> PRT

<213> Artificial Sequence

<220>

<223> fibronectin fragment named C-CS1

<400> 14

Pro Thr Asp Leu Arg Phe Thr Asn Ile Gly Pro Asp Thr Met Arg

1 5 10 15

Val Thr Trp Ala Pro Pro Pro Ser Ile Asp Leu Thr Asn Phe Leu

20 25 30

Val Arg Tyr Ser Pro Val Lys Asn Glu Glu Asp Val Ala Glu Leu

35 40 45

Ser Ile Ser Pro Ser Asp Asn Ala Val Val Leu Thr Asn Leu Leu

50 55 60

Pro Gly Thr Glu Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln

65 70 75

His Glu Ser Thr Pro Leu Arg Gly Arg Gln Lys Thr Gly Leu Asp

80 85 90

Ser Pro Thr Gly Ile Asp Phe Ser Asp Ile Thr Ala Asn Ser Phe

95 100 105

Thr Val His Trp Ile Ala Pro Arg Ala Thr Ile Thr Gly Tyr Arg

110 115 120

Ile Arg His His Pro Glu His Phe Ser Gly Arg Pro Arg Glu Asp

EP 1 666 589 A1

	125	130	135
5	Arg Val Pro His Ser Arg Asn Ser Ile Thr Leu Thr Asn Leu Thr		
	140	145	150
10	Pro Gly Thr Glu Tyr Val Val Ser Ile Val Ala Leu Asn Gly Arg		
	155	160	165
15	Glu Glu Ser Pro Leu Leu Ile Gly Gln Gln Ser Thr Val Ser Asp		
	170	175	180
20	Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr Ser Leu		
	185	190	195
25	Leu Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg Tyr Tyr Arg		
	200	205	210
30	Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe		
	215	220	225
35	Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys		
	230	235	240
40	Pro Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg		
	245	250	255
45	Gly Asp Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile Asn Tyr Arg		
	260	265	270
50	Thr Glu Ile Asp Lys Pro Ser Asp Glu Leu Pro Gln Leu Val Thr		
	275	280	285
55	Leu Pro His Pro Asn Leu His Gly Pro Glu Ile Leu Asp Val Pro		
	290	295	300
	Ser Thr		

<210> 15

<211> 367

<212> PRT

<213> Artificial Sequence

<220>

<223> fibronectin fragment named CHV-89

<400> 15

Pro Thr Asp Leu Arg Phe Thr Asn Ile Gly Pro Asp Thr Met Arg

1 5 10 15

Val Thr Trp Ala Pro Pro Pro Ser Ile Asp Leu Thr Asn Phe Leu

20 25 30

Val Arg Tyr Ser Pro Val Lys Asn Glu Glu Asp Val Ala Glu Leu

35 40 45

Ser Ile Ser Pro Ser Asp Asn Ala Val Val Leu Thr Asn Leu Leu

50 55 60

Pro Gly Thr Glu Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln

65 70 75

His Glu Ser Thr Pro Leu Arg Gly Arg Gln Lys Thr Gly Leu Asp

80 85 90

Ser Pro Thr Gly Ile Asp Phe Ser Asp Ile Thr Ala Asn Ser Phe

95 100 105

Thr Val His Trp Ile Ala Pro Arg Ala Thr Ile Thr Gly Tyr Arg

110 115 120

Ile Arg His His Pro Glu His Phe Ser Gly Arg Pro Arg Glu Asp



EP 1 666 589 A1

	125	130	135
5	Arg Val Pro His Ser Arg Asn Ser Ile Thr Leu Thr Asn Leu Thr		
	140	145	150
10	Pro Gly Thr Glu Tyr Val Val Ser Ile Val Ala Leu Asn Gly Arg		
	155	160	165
15	Glu Glu Ser Pro Leu Leu Ile Gly Gln Gln Ser Thr Val Ser Asp		
	170	175	180
20	Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr Ser Leu		
	185	190	195
25	Leu Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg Tyr Tyr Arg		
	200	205	210
30	Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe		
	215	220	225
35	Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys		
	230	235	240
40	Pro Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg		
	245	250	255
45	Gly Asp Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile Asn Tyr Arg		
	260	265	270
50	Thr Glu Ile Asp Lys Pro Ser Met Asn Val Ser Pro Pro Arg Arg		
	275	280	285
55	Ala Arg Val Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile Ser Trp		
	290	295	300
	Arg Thr Lys Thr Glu Thr Ile Thr Gly Phe Gln Val Asp Ala Val		
	305	310	315
	Pro Ala Asn Gly Gln Thr Pro Ile Gln Arg Thr Ile Lys Pro Asp		

EP 1 666 589 A1

	320	325	330
5	Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr Asp Tyr		
	335	340	345
10	Lys Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg Ser Ser Pro		
	350	355	360
	Val Val Ile Asp Ala Ser Thr		
15		365	
20			
	<210> 16		
25	<211> 368		
	<212> PRT		
	<213> Artificial Sequence		
30			
	<220>		
35	<223> fibronectin fragment named CHV-90		
40			
	<400> 16		
	Pro Thr Asp Leu Arg Phe Thr Asn Ile Gly Pro Asp Thr Met Arg		
	1	5	10 15
45	Val Thr Trp Ala Pro Pro Pro Ser Ile Asp Leu Thr Asn Phe Leu		
	20	25	30
	Val Arg Tyr Ser Pro Val Lys Asn Glu Glu Asp Val Ala Glu Leu		
50		35	40 45
	Ser Ile Ser Pro Ser Asp Asn Ala Val Val Leu Thr Asn Leu Leu		
55	50	55	60

	Pro Gly Thr Glu Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln	
5	65	70 75
	His Glu Ser Thr Pro Leu Arg Gly Arg Gln Lys Thr Gly Leu Asp	
10	80	85 90
	Ser Pro Thr Gly Ile Asp Phe Ser Asp Ile Thr Ala Asn Ser Phe	
	95	100 105
15	Thr Val His Trp Ile Ala Pro Arg Ala Thr Ile Thr Gly Tyr Arg	
	110	115 120
20	Ile Arg His His Pro Glu His Phe Ser Gly Arg Pro Arg Glu Asp	
	125	130 135
	Arg Val Pro His Ser Arg Asn Ser Ile Thr Leu Thr Asn Leu Thr	
25	140	145 150
	Pro Gly Thr Glu Tyr Val Val Ser Ile Val Ala Leu Asn Gly Arg	
30	155	160 165
	Glu Glu Ser Pro Leu Leu Ile Gly Gln Gln Ser Thr Val Ser Asp	
35	170	175 180
	Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr Ser Leu	
	185	190 195
40	Leu Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg Tyr Tyr Arg	
	200	205 210
45	Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe	
	215	220 225
	Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys	
50	230	235 240
	Pro Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg	
55	245	250 255

Gly Asp Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile Asn Tyr Arg

5	260	265	270
---	-----	-----	-----

Thr Glu Ile Asp Lys Pro Ser Met Ala Ile Asp Ala Pro Ser Asn

10	275	280	285
----	-----	-----	-----

Leu Arg Phe Leu Ala Thr Thr Pro Asn Ser Leu Leu Val Ser Trp

290 295 300

Gln Pro Pro Arg Ala Arg Ile Thr Gly Tyr Ile Ile Lys Tyr Glu

**305**

20 Lys Pro Gly Ser Pro Pro Arg Glu Val Val Pro Arg Pro Arg Pro

**320**

Gly Val Thr Glu Ala Thr Ile Thr Gly Leu Glu Pro Gly Thr Glu

335 340 345

Tyr Thr Ile Tyr Val Ile Ala Leu Lys Asn Asn Gln Lys Ser Glu

30 350 355 360

Pro Leu Ile Gly Arg Lys Lys Thr

35 365

40 〈210〉 17

<211> 370

45 &lt;212&gt; PRT

### <213> Artificial Sequence

50  $\langle 220 \rangle$

<223> fibronectin fragment named CHV-92

55

&lt;400&gt; 17

5	Pro Thr Asp Leu Arg Phe Thr Asn Ile Gly Pro Asp Thr Met Arg
	1                      5                      10                      15
10	Val Thr Trp Ala Pro Pro Pro Ser Ile Asp Leu Thr Asn Phe Leu
	20                      25                      30
	Val Arg Tyr Ser Pro Val Lys Asn Glu Glu Asp Val Ala Glu Leu
15	35                      40                      45
	Ser Ile Ser Pro Ser Asp Asn Ala Val Val Leu Thr Asn Leu Leu
20	50                      55                      60
	Pro Gly Thr Glu Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln
	65                      70                      75
25	His Glu Ser Thr Pro Leu Arg Gly Arg Gln Lys Thr Gly Leu Asp
	80                      85                      90
30	Ser Pro Thr Gly Ile Asp Phe Ser Asp Ile Thr Ala Asn Ser Phe
	95                      100                      105
35	Thr Val His Trp Ile Ala Pro Arg Ala Thr Ile Thr Gly Tyr Arg
	110                      115                      120
	Ile Arg His His Pro Glu His Phe Ser Gly Arg Pro Arg Glu Asp
40	125                      130                      135
	Arg Val Pro His Ser Arg Asn Ser Ile Thr Leu Thr Asn Leu Thr
45	140                      145                      150
	Pro Gly Thr Glu Tyr Val Val Ser Ile Val Ala Leu Asn Gly Arg
	155                      160                      165
50	Glu Glu Ser Pro Leu Leu Ile Gly Gln Gln Ser Thr Val Ser Asp
	170                      175                      180
55	Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr Ser Leu

EP 1 666 589 A1

	185	190	195
5	Leu Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg Tyr Tyr Arg		
	200	205	210
10	Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe		
	215	220	225
15	Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys		
	230	235	240
20	Pro Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg		
	245	250	255
25	Gly Asp Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile Asn Tyr Arg		
	260	265	270
30	Thr Glu Ile Asp Lys Pro Ser Met Ala Ile Pro Ala Pro Thr Asp		
	275	280	285
35	Leu Lys Phe Thr Gln Val Thr Pro Thr Ser Leu Ser Ala Gln Trp		
	290	295	300
40	Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr Arg Val Arg Val Thr		
	305	310	315
45	Pro Lys Glu Lys Thr Gly Pro Met Lys Glu Ile Asn Leu Ala Pro		
	320	325	330
50	Asp Ser Ser Ser Val Val Val Ser Gly Leu Met Val Ala Thr Lys		
	335	340	345
55	Tyr Glu Val Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr Ser Arg		
	350	355	360
	Pro Ala Gln Gly Val Val Thr Thr Leu Glu		
	365	370	

5           <210> 18  
           <211> 457  
 10          <212> PRT  
           <213> Artificial Sequence

15           <220>  
           <223> fibronectin fragment named CHV-179

20           <400> 18  
 Pro Thr Asp Leu Arg Phe Thr Asn Ile Gly Pro Asp Thr Met Arg  
 25           1                   5                   10                   15  
 Val Thr Trp Ala Pro Pro Pro Ser Ile Asp Leu Thr Asn Phe Leu  
 30                   20                   25                   30  
 Val Arg Tyr Ser Pro Val Lys Asn Glu Glu Asp Val Ala Glu Leu  
 35                   35                   40                   45  
 Ser Ile Ser Pro Ser Asp Asn Ala Val Val Leu Thr Asn Leu Leu  
                   50                   55                   60  
 40          Pro Gly Thr Glu Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln  
                   65                   70                   75  
 45          His Glu Ser Thr Pro Leu Arg Gly Arg Gln Lys Thr Gly Leu Asp  
                   80                   85                   90  
 Ser Pro Thr Gly Ile Asp Phe Ser Asp Ile Thr Ala Asn Ser Phe  
 50                   95                   100                   105  
 Thr Val His Trp Ile Ala Pro Arg Ala Thr Ile Thr Gly Tyr Arg  
 55                   110                   115                   120

EP 1 666 589 A1

	Ile Arg His His Pro Glu His Phe Ser Gly Arg Pro Arg Glu Asp	
5	125	130 135
	Arg Val Pro His Ser Arg Asn Ser Ile Thr Leu Thr Asn Leu Thr	
10	140	145 150
	Pro Gly Thr Glu Tyr Val Val Ser Ile Val Ala Leu Asn Gly Arg	
	155	160 165
15	Glu Glu Ser Pro Leu Leu Ile Gly Gln Gln Ser Thr Val Ser Asp	
	170	175 180
20	Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr Ser Leu	
	185	190 195
	Leu Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg Tyr Tyr Arg	
25	200	205 210
	Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe	
30	215	220 225
	Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys	
35	230	235 240
	Pro Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg	
	245	250 255
40	Gly Asp Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile Asn Tyr Arg	
	260	265 270
45	Thr Glu Ile Asp Lys Pro Ser Met Asn Val Ser Pro Pro Arg Arg	
	275	280 285
	Ala Arg Val Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile Ser Trp	
50	290	295 300
	Arg Thr Lys Thr Glu Thr Ile Thr Gly Phe Gln Val Asp Ala Val	
55	305	310 315



EP 1 666 589 A1

Pro Ala Asn Gly Gln Thr Pro Ile Gln Arg Thr Ile Lys Pro Asp  
5 320 325 330  
Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr Asp Tyr  
10 335 340 345  
Lys Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg Ser Ser Pro  
15 350 355 360  
Val Val Ile Asp Ala Ser Thr Ala Ile Asp Ala Pro Ser Asn Leu  
20 365 370 375  
Arg Phe Leu Ala Thr Thr Pro Asn Ser Leu Leu Val Ser Trp Gln  
380 385 390  
Pro Pro Arg Ala Arg Ile Thr Gly Tyr Ile Ile Lys Tyr Glu Lys  
25 395 400 405  
Pro Gly Ser Pro Pro Arg Glu Val Val Pro Arg Pro Arg Pro Gly  
30 410 415 420  
Val Thr Glu Ala Thr Ile Thr Gly Leu Glu Pro Gly Thr Glu Tyr  
35 425 430 435  
Thr Ile Tyr Val Ile Ala Leu Lys Asn Asn Gln Lys Ser Glu Pro  
40 440 445 450  
Leu Ile Gly Arg Lys Lys Thr  
45 455

<210> 19

<211> 459

<212> PRT

<213> Artificial Sequence

5 <220>

<223> fibronectin fragment named CHV-181

10 <400> 19

Pro Thr Asp Leu Arg Phe Thr Asn Ile Gly Pro Asp Thr Met Arg

15 1 5 10 15

Val Thr Trp Ala Pro Pro Pro Ser Ile Asp Leu Thr Asn Phe Leu

20 20 25 30

Val Arg Tyr Ser Pro Val Lys Asn Glu Glu Asp Val Ala Glu Leu

25 35 40 45

Ser Ile Ser Pro Ser Asp Asn Ala Val Val Leu Thr Asn Leu Leu

50 55 60

30 Pro Gly Thr Glu Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln

65 70 75

35 His Glu Ser Thr Pro Leu Arg Gly Arg Gln Lys Thr Gly Leu Asp

80 85 90

Ser Pro Thr Gly Ile Asp Phe Ser Asp Ile Thr Ala Asn Ser Phe

40 95 100 105

Thr Val His Trp Ile Ala Pro Arg Ala Thr Ile Thr Gly Tyr Arg

45 110 115 120

Ile Arg His His Pro Glu His Phe Ser Gly Arg Pro Arg Glu Asp

125 130 135

50 Arg Val Pro His Ser Arg Asn Ser Ile Thr Leu Thr Asn Leu Thr

140 145 150

55 Pro Gly Thr Glu Tyr Val Val Ser Ile Val Ala Leu Asn Gly Arg

EP 1 666 589 A1

	155	160	165
5	Glu Glu Ser Pro Leu Leu Ile Gly Gln Gln Ser Thr Val Ser Asp		
	170	175	180
10	Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr Ser Leu		
	185	190	195
15	Leu Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg Tyr Tyr Arg		
	200	205	210
	Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe		
20	215	220	225
	Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys		
	230	235	240
25	Pro Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg		
	245	250	255
30	Gly Asp Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile Asn Tyr Arg		
	260	265	270
35	Thr Glu Ile Asp Lys Pro Ser Met Ala Ile Pro Ala Pro Thr Asp		
	275	280	285
	Leu Lys Phe Thr Gln Val Thr Pro Thr Ser Leu Ser Ala Gln Trp		
40	290	295	300
	Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr Arg Val Arg Val Thr		
	305	310	315
45	Pro Lys Glu Lys Thr Gly Pro Met Lys Glu Ile Asn Leu Ala Pro		
	320	325	330
50	Asp Ser Ser Ser Val Val Val Ser Gly Leu Met Val Ala Thr Lys		
	335	340	345
55	Tyr Glu Val Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr Ser Arg		

EP 1 666 589 A1

5                   350                   355                   360  
 Pro Ala Gln Gly Val Val Thr Thr Leu Glu Asn Val Ser Pro Pro  
                   365                   370                   375  
 10 Arg Arg Ala Arg Val Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile  
                   380                   385                   390  
 Ser Trp Arg Thr Lys Thr Glu Thr Ile Thr Gly Phe Gln Val Asp  
 15                   395                   400                   405  
 Ala Val Pro Ala Asn Gly Gln Thr Pro Ile Gln Arg Thr Ile Lys  
 20                   410                   415                   420  
 Pro Asp Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr  
                   425                   430                   435  
 25 Asp Tyr Lys Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg Ser  
                   440                   445                   450  
 30 Ser Pro Val Val Ile Asp Ala Ser Thr  
                   455

35

40 <210> 20

<211> 276

<212> PRT

45 <213> Artificial Sequence

50 <220>

<223> fibronectin fragment named H-275-Cys

55 <400> 20

EP 1 666 589 A1

	Met	Ala	Ala	Ser	Ala	Ile	Pro	Ala	Pro	Thr	Asp	Leu	Lys	Phe	Thr
5	1				5					10					15
	Gln	Val	Thr	Pro	Thr	Ser	Leu	Ser	Ala	Gln	Trp	Thr	Pro	Pro	Asn
					20					25					30
10	Val	Gln	Leu	Thr	Gly	Tyr	Arg	Val	Arg	Val	Thr	Pro	Lys	Glu	Lys
					35					40					45
15	Thr	Gly	Pro	Met	Lys	Glu	Ile	Asn	Leu	Ala	Pro	Asp	Ser	Ser	Ser
					50					55					60
20	Val	Val	Val	Ser	Gly	Leu	Met	Val	Ala	Thr	Lys	Tyr	Glu	Val	Ser
					65					70					75
	Val	Tyr	Ala	Leu	Lys	Asp	Thr	Leu	Thr	Ser	Arg	Pro	Ala	Gln	Gly
25					80					85					90
	Val	Val	Thr	Thr	Leu	Glu	Asn	Val	Ser	Pro	Pro	Arg	Arg	Ala	Arg
30					95					100					105
	Val	Thr	Asp	Ala	Thr	Glu	Thr	Thr	Ile	Thr	Ile	Ser	Trp	Arg	Thr
					110					115					120
35	Lys	Thr	Glu	Thr	Ile	Thr	Gly	Phe	Gln	Val	Asp	Ala	Val	Pro	Ala
					125					130					135
40	Asn	Gly	Gln	Thr	Pro	Ile	Gln	Arg	Thr	Ile	Lys	Pro	Asp	Val	Arg
					140					145					150
45	Ser	Tyr	Thr	Ile	Thr	Gly	Leu	Gln	Pro	Gly	Thr	Asp	Tyr	Lys	Ile
					155					160					165
	Tyr	Leu	Tyr	Thr	Leu	Asn	Asp	Asn	Ala	Arg	Ser	Ser	Pro	Val	Val
50					170					175					180
	Ile	Asp	Ala	Ser	Thr	Ala	Ile	Asp	Ala	Pro	Ser	Asn	Leu	Arg	Phe
55					185					190					195

5                   Leu Ala Thr Thr Pro Asn Ser Leu Leu Val Ser Trp Gln Pro Pro  
                                   200                                   205                                   210  
                  Arg Ala Arg Ile Thr Gly Tyr Ile Ile Lys Tyr Glu Lys Pro Gly  
 10                                   215                                   220                                   225  
                  Ser Pro Pro Arg Glu Val Val Pro Arg Pro Arg Pro Gly Val Thr  
                                   230                                   235                                   240  
 15                   Glu Ala Thr Ile Thr Gly Leu Glu Pro Gly Thr Glu Tyr Thr Ile  
                                   245                                   250                                   255  
 20                   Tyr Val Ile Ala Leu Lys Asn Asn Gln Lys Ser Glu Pro Leu Ile  
                                   260                                   265                                   270  
 25                   Gly Arg Lys Lys Thr Cys  
                                   275

30

<210> 21

35

<211> 38

<212> DNA

40

<213> Artificial Sequence

<220>

45

<223> primer 12S

50

<400> 21

aaaccatggc agctagcgct attcctgcac caactgac

38

55

5                   <210> 22  
                   <211> 36  
                   <212> DNA  
 10                  <213> Artificial Sequence  
  
 15                  <220>  
                   <223> primer 14A  
  
 20                  <400> 22  
                   aaaggatccc taactagtct ttctccttcc aatcag                   36  
 25  
  
 30                  <210> 23  
                   <211> 40  
                   <212> DNA  
 35                  <213> Artificial Sequence  
  
 40                  <220>  
                   <223> primer Cys-A  
  
 45                  <400> 23  
                   aaaagcggcc gctagcgcaa gccatgggtct gtttcctgtg                   40  
 50  
  
 55                  <210> 24  
                   <211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> primer Cys-S

<400> 24

aaaagcggcc gcactagtgc atagggatcc ggctgagcaa c 41

<210> 25

<211> 658

<212> PRT

<213> Artificial Sequence

<220>

<223> fibronectin fragment named CH-296Na

<400> 25

Met Pro Thr Asp Leu Arg Phe Thr Asn Ile Gly Pro Asp Thr Met Arg

1 5 10 15

Val Thr Trp Ala Pro Pro Pro Ser Ile Asp Leu Thr Asn Phe Leu Val

20 25 30

Arg Tyr Ser Pro Val Lys Asn Glu Glu Asp Val Ala Glu Leu Ser Ile

35 40 45

Ser Pro Ser Asp Asn Ala Val Val Leu Thr Asn Leu Leu Pro Gly Thr



EP 1 666 589 A1

	50	55	60	
5	Glu Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln His Glu Ser Thr			
	65	70	75	80
10	Pro Leu Arg Gly Arg Gln Lys Thr Gly Leu Asp Ser Pro Thr Gly Ile			
	85	90	95	
15	Asp Phe Ser Asp Ile Thr Ala Asn Ser Phe Thr Val His Trp Ile Ala			
	100	105	110	
20	Pro Arg Ala Thr Ile Thr Gly Tyr Arg Ile Arg His His Pro Glu His			
	115	120	125	
25	Phe Ser Gly Arg Pro Arg Glu Asp Arg Val Pro His Ser Arg Asn Ser			
	130	135	140	
30	Ile Thr Leu Thr Asn Leu Thr Pro Gly Thr Glu Tyr Val Val Ser Ile			
	145	150	155	160
35	Val Ala Leu Asn Gly Arg Glu Glu Ser Pro Leu Leu Ile Gly Gln Gln			
	165	170	175	
40	Ser Thr Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr			
	180	185	190	
45	Pro Thr Ser Leu Leu Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg			
	195	200	205	
50	Tyr Tyr Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln			
	210	215	220	
55	Glu Phe Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu			
	225	230	235	240
	Lys Pro Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg			
	245	250	255	
	Gly Asp Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile Asn Tyr Arg Thr			

EP 1 666 589 A1

	260	265	270
5	Glu Ile Asp Lys Pro Ser Gln Met Gln Val Thr Asp Val Gln Asp Asn		
	275	280	285
10	Ser Ile Ser Val Lys Trp Leu Pro Ser Ser Ser Pro Val Thr Gly Tyr		
	290	295	300
15	Arg Val Thr Thr Thr Pro Lys Asn Gly Pro Gly Pro Thr Lys Thr Lys		
	305	310	315
	320		
	Thr Ala Gly Pro Asp Gln Thr Glu Met Thr Ile Glu Gly Leu Gln Pro		
20		325	330
		335	
	Thr Val Glu Tyr Val Val Ser Val Tyr Ala Gln Asn Pro Ser Gly Glu		
25		340	345
		350	
	Ser Gln Pro Leu Val Gln Thr Ala Val Thr Ala Ile Pro Ala Pro Thr		
	355	360	365
30	Asp Leu Lys Phe Thr Gln Val Thr Pro Thr Ser Leu Ser Ala Gln Trp		
	370	375	380
35	Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr Arg Val Arg Val Thr Pro		
	385	390	395
	400		
	Lys Glu Lys Thr Gly Pro Met Lys Glu Ile Asn Leu Ala Pro Asp Ser		
40		405	410
		415	
	Ser Ser Val Val Val Ser Gly Leu Met Val Ala Thr Lys Tyr Glu Val		
45		420	425
		430	
	Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr Ser Arg Pro Ala Gln Gly		
50		435	440
		445	
	Val Val Thr Thr Leu Glu Asn Val Ser Pro Pro Arg Arg Ala Arg Val		
	450	455	460
55	Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile Ser Trp Arg Thr Lys Thr		

EP 1 666 589 A1

465                      470                      475                      480  
 5    Glu Thr Ile Thr Gly Phe Gln Val Asp Ala Val Pro Ala Asn Gly Gln  
                          485                      490                      495  
 10   Thr Pro Ile Gln Arg Thr Ile Lys Pro Asp Val Arg Ser Tyr Thr Ile  
                          500                      505                      510  
 15   Thr Gly Leu Gln Pro Gly Thr Asp Tyr Lys Ile Tyr Leu Tyr Thr Leu  
                          515                      520                      525  
   Asn Asp Asn Ala Arg Ser Ser Pro Val Val Ile Asp Ala Ser Thr Ala  
 20                      530                      535                      540  
   Ile Asp Ala Pro Ser Asn Leu Arg Phe Leu Ala Thr Thr Pro Asn Ser  
 25   545                      550                      555                      560  
   Leu Leu Val Ser Trp Gln Pro Pro Arg Ala Arg Ile Thr Gly Tyr Ile  
                          565                      570                      575  
 30   Ile Lys Tyr Glu Lys Pro Gly Ser Pro Pro Arg Glu Val Val Pro Arg  
                          580                      585                      590  
 35   Pro Arg Pro Gly Val Thr Glu Ala Thr Ile Thr Gly Leu Glu Pro Gly  
                          595                      600                      605  
   Thr Glu Tyr Thr Ile Tyr Val Ile Ala Leu Lys Asn Asn Gln Lys Ser  
 40                      610                      615                      620  
   Glu Pro Leu Ile Gly Arg Lys Lys Thr Asp Glu Leu Pro Gln Leu Val  
 45   625                      630                      635                      640  
   Thr Leu Pro His Pro Asn Leu His Gly Pro Glu Ile Leu Asp Val Pro  
                          645                      650                      655  
 50   Ser Thr  
 55

5       <210> 26  
       <211> 1989  
 10       <212> DNA  
       <213> Artificial Sequence

15       <220>  
       <223> polynucleotide coding CH-296Na

20       <400> 26

25       catatgccca ctgacctgcg attcaccaac attgggtccag acaccatgcg tgtcacctgg       60  
       gctccacccc catccattga tttaaccaac ttcctgggtgc gttactcgcc tgtgaaaaat       120  
       gaggaagaig ttgcagagtt gtcaatttct ctttcagaca atgcagtggg ctttaacaaat       180  
 30       ctcctgcctg gtacagaata ttagtgagt gtctccagtg tctacgaaca acatgagagc       240  
       acacctctta gaggaagaca gaaaacaggt cttgattccc caactggcat tgacttttct       300  
 35       gatattactg ccaactcttt tactgtgcac tggattgctc ctcgagccac catcactggc       360  
       tacaggatcc gccatcatcc cgagcacttc agtgggagac ctcgagaaga tcgggtgccc       420  
       cactctcgga attccatcac cctcaccaac ctactccag gcacagagta tgtggtcagc       480  
 40       atcgttgctc ttaatggcag agaggaaagt cctttattga ttggccaaca atcaacagtt       540  
       tcigatgttc cgagggacct ggaagtgtt gtgctgaccc ccaccagcct actgatcagc       600  
 45       tgggatgctc ctgctgtcac agtgagatat tacaggatca cttacggaga aacaggagga       660  
       aatagccctg tccaggagtt cactgtgcct gggagcaagt ctacagctac catcagcggc       720  
       cttaaacctg gagttgatta taccatcact gtgtatgctg tcaactggccg tggagacagc       780  
 50       cccgaagca gcaagccaat ttccattaat taccgaacag aaattgaaa accatcccag       840  
       atgcaagtga ccgatgttca ggacaacagc attagtgtca agtggctgcc ttcaagttcc       900  
 55       cctgttactg gttacagagt aaccaccact cccaaaaatg gaccaggacc aacaaaaact       960

5      aaaactgcag gtccagatca aacagaaatg actattgaag gcttgcagcc cacagtggag 1020  
 tatgtgggta gtgtctatgc tcagaatcca agcggagaga gtcagcctct gggttcagact 1080  
 gcagtaaccg ctattcctgc accaactgac ctgaagtcca ctcagggtcac acccacaagc 1140  
 10      ctgagcgcgc agtggacacc acccaatggt cagctcactg gataatcgagt gcgggtgacc 1200  
 cccaaggaga agaccggacc aatgaaagaa atcaaccttg ctcttgacag ctcatccgtg 1260  
 gttgtatcag gacttatggt ggccaccaa taatgaagta gtgtctatgc tcttaaggac 1320  
 15      actttgacaa gcagaccagc tcagggtgtt gtcaccactc tggagaatgt cagcccacca 1380  
 agaagggtc gigtgacaga tgctactgag accacatca ccattagctg gagaaccaag 1440  
 20      actgagacga tcactggctt ccaagtigat gccgttccag ccaatggcca gactccaatc 1500  
 cagagaacca tcaagccaga tgcagaagc tacaccatta caggtttaca accaggcact 1560  
 gactacaaga tctacctgta caccttgaat gacaatgtc ggagctcccc tgtggtcac 1620  
 25      gacgcctcca ctgccattga tgcaccatcc aacctgcgtt tctggccac cacacccaat 1680  
 tccttgctgg tatcatggca gccgccacgt gccaggatta ccggctacat catcaagtat 1740  
 30      gagaagcctg ggtctcctcc cagagaagtg gtccctcggc cccgccctgg tgcacagag 1800  
 gctactatta ctggcctgga accgggaacc gaatatataa ttlatgtcat tgccctgaag 1860  
 35      aataatcaga agagcgagcc ctgatgtgga aggaaaaaga cagacgagct tccccaactg 1920  
 gtaacccttc cacaccccaa tcttcatgga ccagagatct tggatgttcc tccacataa 1980  
 tagaagctt 1989  
 40

45      <210> 27

<211> 22

<212> DNA

50      <213> Artificial Sequence

55      <220>

<223> Primer CH-296Na1

5

<400> 27

10

atcatatgcc cactgacctg cg

22

15

<210> 28

<211> 23

20

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Primer CH-296Na2

30

<400> 28

35

ataagcttct attatgtgga agg

23

40

<210> 29

<211> 22

45

<212> DNA

<213> Artificial Sequence

50

<220>

<223> Primer CH-296Na3

55

&lt;400&gt; 29

accatcactg gctacaggat cc

22

## Claims

1. A method for preparing a cytotoxic lymphocyte **characterized in that** the method comprises the step of carrying out at least one step selected from induction, maintenance and expansion of a cytotoxic lymphocyte using a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 5% by volume, in the presence of fibronectin, a fragment thereof or a mixture thereof.
2. The method according to claim 1, wherein the cytotoxic lymphocyte highly expresses an interleukin-2 receptor as compared to a cytotoxic lymphocyte prepared in the absence of fibronectin, a fragment thereof or a mixture thereof.
3. The method according to claim 1, wherein the cytotoxic lymphocyte contains CD8-positive cell in a higher ratio as compared to a cytotoxic lymphocyte prepared in the absence of fibronectin, a fragment thereof or a mixture thereof.
4. The method according to claim 1, wherein an expansion fold is higher as compared to that of a method for preparing a cytotoxic lymphocyte in the absence of fibronectin, a fragment thereof or a mixture thereof.
5. The method according to any one of claims 1 to 4, wherein a cytotoxic activity is enhanced or high cytotoxic activity is maintained as compared to a cytotoxic activity of a cytotoxic lymphocyte prepared in the absence of fibronectin, a fragment thereof or a mixture thereof.
6. The method according to any one of claims 1 to 5, wherein fibronectin, a fragment thereof or a mixture thereof is immobilized on a solid phase.
7. The method according to claim 6, wherein the solid phase is a cell culture equipment or a cell culture carrier.
8. The method according to claim 7, wherein the cell culture equipment is a petri dish, a flask or a bag, and the cell culture carrier is beads, a membrane or a slide glass.
9. The method according to any one of claims 1 to 8, wherein the cytotoxic lymphocyte is a lymphokine-activated killer cell.
10. The method according to any one of claims 1 to 9, wherein the fibronectin fragment is a polypeptide (m) comprising at least any one of the amino acid sequences shown in SEQ ID NOs: 1 to 8 of Sequence Listing, or a polypeptide (n) comprising at least one amino acid sequence having substitution, deletion, insertion or addition of one or the plural number of amino acids in any one of said amino acid sequences, wherein the polypeptide (n) has a function equivalent to that of said polypeptide (m).
11. The method according to claim 10, wherein the fibronectin fragment has a cell adhesion activity and/or a heparin binding activity.
12. The method according to claim 10, wherein the fibronectin fragment is at least one polypeptide selected from the group consisting of polypeptides having any one of the amino acid sequences shown in SEQ ID NOs: 9 to 20 and 25 of Sequence Listing.
13. The method according to claim 1 which is carried out in a cell culture equipment, wherein the method satisfies the conditions of:

- (a) a ratio of the number of cells to a culture area in the cell culture equipment at initiation of culture being 1 cell/cm<sup>2</sup> to  $5 \times 10^5$  cells/cm<sup>2</sup>; and/or
- (b) a concentration of cells in a medium at initiation of culture being 1 cell/mL to  $5 \times 10^5$  cells/mL.

14. The method according to claim 13, wherein the method does not require a step of diluting a cell culture solution.

15. The method according to claim 1, wherein the method comprises carrying out at least any one of induction, maintenance and expansion of a cytotoxic lymphocyte in the presence of fibronectin, a fragment thereof or a mixture thereof in a cell culture equipment containing a medium, wherein the method comprises at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment, and wherein the culture conditions immediately after at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment satisfy the conditions of:

- (c) a concentration of cells in the cell culture solution being  $2 \times 10^5$  cells/mL to  $1 \times 10^8$  cells/mL; or
- (d) a ratio of the number of cells in the cell culture solution to a culture area in the cell culture equipment being  $1 \times 10^5$  cells/cm<sup>2</sup> to  $1 \times 10^8$  cells/cm<sup>2</sup>.

16. The method according to claim 1, wherein the method comprises carrying out at least any one of induction, maintenance and expansion of a cytotoxic lymphocyte in the presence of fibronectin, a fragment thereof or a mixture thereof in a cell culture equipment containing a medium, wherein the method comprises at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment, and wherein a total concentration of serum and plasma in the medium immediately after at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment is same as that at initiation of the culture or lowered as compared to that at initiation of the culture.

17. A cytotoxic lymphocyte obtained by the method as defined in any one of claims 1 to 16.

18. A medicament comprising as an effective ingredient the cytotoxic lymphocyte obtained by the method as defined in any one of claims 1 to 16.

19. A medium for culturing a cytotoxic lymphocyte, **characterized in that** the medium comprises as an effective ingredient fibronectin, a fragment thereof or a mixture thereof, and that a total concentration of serum and plasma in the medium is 0% by volume or more and less than 5% by volume.

20. The method according to any one of claims 1 to 16, further comprising a step of transducing a foreign gene into a cytotoxic lymphocyte.

21. The method according to claim 20, wherein the foreign gene is transduced using retrovirus, adenovirus, adeno-associated virus or simian virus.

22. A polypeptide having the amino acid sequence (x) shown in SEQ ID NO: 25 of Sequence Listing or an amino acid sequence (y) having deletion, insertion, addition or substitution of one or the plural number of amino acids in the amino acid sequence (x), wherein the polypeptide having the amino acid sequence (y) has a function equivalent to that of the amino acid sequence (x).

23. A nucleic acid encoding the polypeptide of claim 22.

24. The nucleic acid according to claim 23, wherein the nucleic acid comprises (1) a DNA comprising the nucleotide sequence shown in SEQ ID NO: 26; (2) a DNA comprising a nucleotide sequence having deletion, substitution, insertion or addition of one or the plural number of nucleotides in the nucleotide sequence shown in SEQ ID NO: 26, wherein the DNA encodes a polypeptide having a function equivalent to that of the polypeptide encoded by the DNA (1); or (3) a DNA which hybridizes to a DNA comprising the nucleotide sequence shown in SEQ ID NO: 26 under stringent conditions, wherein the DNA encodes a polypeptide having a function equivalent to that of the polypeptide encoded by the DNA (1).






FIG. 1

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/012238

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int.Cl <sup>7</sup> C12N15/09, C07K14/47, C12N5/08, A61K35/26, A61P35/00, A61P37/04  According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Int.Cl <sup>7</sup> C12N15/09, C07K14/47, C12N5/08, A61K35/26, A61P35/00, A61P37/04  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) SwissProt/PIR/Geneseq, GenBank/EMBL/DDBJ/Geneseq, WPI (DIALOG), BIOSIS (DIALOG), JSTPlus (JOIS), MEDLINE (STN)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/016511 A1 (Takara Bio Inc.), 27 February, 2003 (27.02.03), & EP 1424387 A1	1-21
X	Proc.Natl.Acad.Sci., USA, Vol.80, No.16, pages 3218 to 3222 (1983)	22-25
A	Eur.J.Immunol., Vol.21, pages 1559 to 1562, (1991)	1-21
A	Cell Immunol., Vol.135, No.1, pages 105 to 117, (1991)	1-21
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 01 October, 2004 (01.10.04)		Date of mailing of the international search report 26 October, 2004 (26.10.04)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (January 2004)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/012238

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:

a. type of material



a sequence listing



table(s) related to the sequence listing

b. format of material



in written format



in computer readable form

c. time of filing/furnishing



contained in the international application as filed



filed together with the international application in computer readable form



furnished subsequently to this Authority for the purposes of search

2. ☒ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/012238

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

As reported in the following document 1, a technique of inducing cytotoxic T lymphocytes by using fibronectin and its fragment (for example, VLA-4 binding domain, VLA-5 binding domain, heparin binding domain or the like) had been publicly known before the application of the present case. Thus, this point cannot be regarded as a special technical feature in the meaning within PCT Rule 13.3.

According to PCT Rule 13.3, unity of inventions should be judged without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim.

Thus, the inventions relating to (continued to extra sheet)

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/012238

Continuation of Box No.III of continuation of first sheet(2)

the represented by SEQ ID NOS:1 to 20 and 25 as claimed are considered not as a group of inventions so linked as to form a single general inventive concept but as 21 invention groups respectively relating to 21 polypeptides differing from each other.

Document 1: WO 03/016511 A1 (Takara Bio Inc.) 27 February, 2003 (27.02.03)